ARTICLES OF MANUFACTURE AND METHODS FOR MODELING CHINESE HAMSTER OVARY (CHO) CELL METABOLISM

Information

  • Patent Application
  • 20120191434
  • Publication Number
    20120191434
  • Date Filed
    August 24, 2011
    12 years ago
  • Date Published
    July 26, 2012
    11 years ago
Abstract
The invention provides a Chinese Hamster Ovary (CHO) cell model and methods of using such a model. The invention provides methods and computer readable medium or media containing such models and methods.
Description

Tables 1-3 and 5-7 associated with this application are provided via EFS-Web in lieu of a paper copy, and are hereby incorporated by reference into the specification. The files containing Tables 1-3 and 5-7 are entitled 448164-999008_Table1.txt; 448164-999008_Table2.txt; 448164-999008_Table3.txt; 448164-999008_Table5.txt; 448164-999008_Table6.txt; and 448164-999008_Table7.txt, which are 97.3 KB, 14.8 KB, 3.2 KB, 89.7 KB, 14.7 KB, and 66.7 KB, in size, respectively, and were created on Aug. 24, 2011.









LENGTHY TABLES




The patent application contains a lengthy table section. A copy of the table is available in electronic form from the USPTO web site (). An electronic copy of the table will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).






BACKGROUND OF THE INVENTION

The present invention relates generally analysis of the activity of chemical reaction networks and, more specifically, to computational methods for simulating and predicting the activity of CHO cell metabolism.


Protein-based therapeutic products have contributed immensely to healthcare and constitute a large and growing percentage of the total pharmaceutical market. Therapeutic proteins first entered the market less than 20 years ago and have already grown to encompass 10-30% of the total US market for pharmaceuticals. The trend towards therapeutic proteins is accelerating. In recent years, more than half of the new molecular entities to receive FDA approval were biologics produced mostly in mammalian cell systems, and an estimated 700 or more protein-based therapeutics are at various stages of clinical development, with 150 to 200 in late-stage trials.


Over the past two decades, substantial progress has been made to overcome some of the key barriers to large-scale mammalian cell culture, including improvements in vector design, host cell engineering, medium development, screening methods and process engineering, resulting in yield improvements of up to 100-fold over titers seen in the mid 1980's. Despite these improvements, developing new biopharmaceutical products remains an expensive and lengthy process, typically taking six years from pre-clinical process development to product launch, where 20-30% of the total cost is associated with process development and clinical manufacturing. Production costs by mammalian cell culture remain high, and new methods to provide a more effective approach to optimize overall process development are of highest interest to the industry, particularly as regulatory constraints on development timelines remain stringent and production demands for new therapeutics are rapidly rising, especially for the quantities required for treatment of chronic diseases. Production costs are a major concern for management planning, especially with intense product competition, patent expirations, introduction of second-generation therapeutics and accompanying price pressure, and pricing constraints imposed by regulators and reimbursement agencies. Reducing the cost of therapeutic protein development and manufacturing would do much to ensure that the next generation of medicines can be created in amounts large enough to meet patients' needs, and at a price low enough that patients can afford.


Thus, there exists a need for a model that describes Chinese Hamster Ovary (CHO) cells metabolic network, which can be used for bioproduction of desired products such as biologics. The present invention satisfies this need and provides related advantages as well.


SUMMARY OF INVENTION

The invention provides models and methods useful for modeling a CHO cell. The invention provides methods and computer readable medium or media containing such methods. Such a computer readable medium or media can comprise commands for carrying out a method of the invention. The methods of the invention can be utilized to model characteristics of a CHO cell line, for example, product production, growth, culture characteristics, and the like. The invention provides models and methods useful for optimizing CHO cell lines. The invention provides computer readable medium or media. Such a computer readable medium or media can comprise a data structure relating a plurality of reactants to a plurality of reactions from a CHO cell and in some aspects of the invention the data structure further comprises relating a plurality of reactants to a plurality of reactions from a CHO cell transcriptome, each of the reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product; a constraint set for said plurality of reactions for said data structures, and commands for determining at least one flux distribution that minimizes or maximizes an objective function when the constraint set is applied to the data structure, wherein the at least one flux distribution is predictive of a physiological function of the CHO cell. The invention additionally provides methods for predicting a physiological function of a CHO cell, such as, growth, energy production, redox equivalent production, biomass production, production of biomass precursors, production of a protein, production of an amino acid, production of a purine, production of a pyrimidine, production of a lipid, production of a fatty acid, production of a cofactor, transport of a metabolite, and consumption of carbon, nitrogen, sulfur, phosphate, hydrogen or oxygen.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows a model-driven media optimization in CHO cell culture. Reported is the % increase over baseline (control) performance that model-based media formulations to reduce byproducts and increase growth and product titer achieved (Designs 1, 2, and 3), as well as an industry standard depletion analysis (Depletion).





DETAILED DESCRIPTION OF THE INVENTION

The invention provides in silico models of Chinese Hamster Ovary (CHO) cells that describe the interconnections between genes in a cell genome and their associated reactions and reactants. As disclosed herein, protein-based therapeutic products have contributed immensely to healthcare and constitute a large and growing percentage of the total pharmaceutical drugs. The majority of these FDA approved products are manufactured using mammalian cell culture systems. Over the past 10-20 years substantial progress has been made to overcome some of the key barriers to large-scale mammalian cell culture. Despite these improvements, the development of new biopharmaceutical products remains an expensive and lengthy process, where 20-30% of the total cost is associated with process development and clinical manufacturing. Production of therapeutic protein in mammalian cell lines is hampered by a number of standing issues. For example, selection of high-producing mammalian cell lines represents a bottleneck in process development for the production of biopharmaceuticals. Production of therapeutic proteins in mammalian cell lines has been dominated by the use of selection markers that have metabolic origin. However, the current selection methods are hampered by a number of disadvantages, including extensive development timelines and cost. In addition, most process optimization strategies are currently performed using a trial and error approach where cells are treated as a ‘black box’ and process outputs are improved over several months by laborious experimentation. These empirical optimization techniques are widely used because in most cases little is known about the underlying physiological interactions that impact growth and protein production in the host cell lines. A fundamental understanding of cell line physiology and metabolism, enabled by computational modeling and simulation technologies, can greatly improve and accelerate media and process development in mammalian cell line systems.


The invention provides a computer readable medium or media having stored thereon computer executable commands for performing the steps of providing a data structure relating a plurality of reactants to a plurality of reactions, wherein the plurality of reactants and the plurality of reactions are a selection of reactants and reactions as shown in Tables 1, 3 and 4 for a Chinese hamster ovary (CHO) cell, and wherein the data structure relates a plurality of reactants and a plurality of reactions selected from the reactants and reactions as shown in Tables 1 and 2 for a CHO cell transcriptome; providing a constraint set for the plurality of reactions for the data structure; and determining at least one flux distribution that minimizes or maximizes an objective function when the constraint set is applied to the data structure, wherein the at least one flux distribution is predictive of a physiological function of the CHO cell or a culture condition for the CHO cell.


The invention provides a computer readable medium or media having stored thereon computer executable commands for performing the steps of providing a data structure relating a plurality of reactants to a plurality of reactions, wherein the plurality of reactants and the plurality of reactions are a selection of reactants and reactions as shown in Tables 5, 8, and 9 for a Chinese hamster ovary (CHO) cell, and wherein the data structure relates a plurality of reactants and a plurality of reactions selected from the reactants and reactions as shown in Tables 5, 6 and 7 for a CHO cell transcriptome; providing a constraint set for the plurality of reactions for the data structure; and determining at least one flux distribution that minimizes or maximizes an objective function when the constraint set is applied to the data structure, wherein the at least one flux distribution is predictive of a physiological function of the CHO cell or a culture condition for the CHO cell.


The objective function can be, for example, uptake rate of two or more nutrients, wherein the two or more nutrients are carbon sources, product formation, energy synthesis, biomass production, or a combination thereof, decreasing byproduct formation. In the computer readable medium or media of the invention, the culture condition can be selected from the group consisting of optimized culture medium for the cell, optimized cell culture process, optimized cell productivity, and metabolic engineering of the cell. In a particular embodiment, the optimized cell productivity can be increased biomass production or increased product yield. Additionally, the culture condition can be reduced scale up variability, reduced batch to batch variability, reduced clonal variability, improved cell growth, or viable cell density or cell productivity in exponential growth phase or stationary phase.


In a computer readable medium or media of the invention, the physiological function can be selected from the group consisting of growth, energy production, redox equivalent production, biomass production, production of biomass precursors, production of a protein, production of an amino acid, production of a purine, production of a pyrimidine, production of a lipid, production of a fatty acid, production of a cofactor, transport of a metabolite, and consumption of carbon, nitrogen, sulfur, phosphate, hydrogen or oxygen.


In another embodiment, the computer readable medium or media of the invention can include a plurality of reactions comprising at least one reaction from peripheral metabolic pathway. A peripheral metabolic pathway can be, for example, amino acid biosynthesis, amino acid degradation, purine biosynthesis, pyrimidine biosynthesis, lipid biosynthesis, fatty acid metabolism, cofactor biosynthesis or transport processes. In still another embodiment, computer readable medium or media of the invention can include a data structure comprising a reaction network, including a plurality of reaction networks. In a particular embodiment, the cell of the computer readable medium or media produces a product selected from an exogenous growth factor, monoclonal antibody, hormone, cytokine, fusion protein, enzyme, vaccine, virus, anticoagulant, and nucleic acid.


In yet another embodiment, the computer readable medium or media of the invention contains a data structure comprising a set of linear algebraic equations. In another embodiment of the computer readable medium or media of the invention, at least one reactant in the plurality of reactants or at least one reaction in the plurality of reactions is annotated with an assignment to a subsystem or compartment. In still another embodiment, at least a first substrate or product in the plurality of reactions is assigned to a first compartment and at least a second substrate or product in the plurality of reactions is assigned to a second compartment.


The invention additionally provides a method for predicting a culture condition for a CHO cell. Such a method can include the steps of providing a data structure relating a plurality of reactants to a plurality of reactions from a CHO cell, wherein the plurality of reactants and the plurality of reactions are a selection of reactants and reactions as shown in Table 1, 3 and 4 for a Chinese hamster ovary (CHO) cell, and wherein the data structure relates a plurality of reactants and a plurality of reactions selected from the reactants and reactions as shown in Tables 1 and 2 for a CHO cell transcriptome, each of the reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product, wherein the plurality of reactions comprises one or more extracellular exchange reactions; providing a constraint set for the plurality of reactions for the data structure; providing an objective function, wherein the objective function is uptake rate of two or more nutrients, wherein the two or more nutrients are carbon sources; and determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the data structure, wherein the at least one flux distribution is predictive of a culture condition for the eukaryotic cell.


The invention additionally provides a method for predicting a culture condition for a CHO cell. Such a method can include the steps of providing a data structure relating a plurality of reactants to a plurality of reactions from a CHO cell, wherein the plurality of reactants and the plurality of reactions are a selection of reactants and reactions as shown in Tables 5, 8 and 9 for a Chinese hamster ovary (CHO) cell, and wherein the data structure relates a plurality of reactants and a plurality of reactions selected from the reactants and reactions as shown in Tables 5, 6 and 7 for a CHO cell transcriptome, each of the reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product, wherein the plurality of reactions comprises one or more extracellular exchange reactions; providing a constraint set for the plurality of reactions for the data structure; providing an objective function, wherein the objective function is uptake rate of two or more nutrients, wherein the two or more nutrients are carbon sources; and determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the data structure, wherein the at least one flux distribution is predictive of a culture condition for the eukaryotic cell.


In such a method, the objective function can further comprise product formation, energy synthesis, biomass production, or a combination thereof or decreasing byproduct formation. In such a method, the culture condition can be selected from optimized culture medium for the cell, optimized cell culture process, optimized cell productivity, including increased biomass production or increased product yield, metabolic engineering of the cell, reduced scale up variability, reduced batch to batch variability, reduced clonal variability, or improved cell growth, viable cell density or cell productivity in exponential growth phase or stationary phase.


The data structure can comprise, for example, a reaction network, including a plurality of reaction networks. In a particular embodiment, the cell produces a product selected from the group consisting of an exogenous growth factor, monoclonal antibody, hormone, cytokine, fusion protein, enzyme, vaccine, virus, anticoagulant, and nucleic acid. Further, the data structure c of a method of the invention can comprise a set of linear algebraic equations. In one embodiment, at least one reactant in the plurality of reactants or at least one reaction in the plurality of reactions is annotated with an assignment to a subsystem or compartment. In still another embodiment, at least a first substrate or product in the plurality of reactions is assigned to a first compartment and at least a second substrate or product in the plurality of reactions is assigned to a second compartment.


The invention further provides method for optimizing a Chinese hamster ovary (CHO) cell to produce a product. The method can include the steps of providing a data structure relating a plurality of reactants to a plurality of reactions, wherein the plurality of reactants and the plurality of reactions are a selection of reactants and reactions as shown in Tables 1, 3, and 4 for a CHO cell, and wherein the data structure relates a plurality of reactants and a plurality of reactions selected from the reactants and reactions as shown in Tables 1 and 2 for a CHO cell transcriptome; providing a constraint set for the plurality of reactions for the data structure; determining at least one flux distribution that minimizes or maximizes an objective function when the constraint set is applied to the data structure, wherein the at least one flux distribution is predictive of producing a product in the CHO cell; and modifying the CHO cell as determined above. In a particular embodiment, the product can be selected from the group consisting of an exogenous growth factor, monoclonal antibody, hormone, cytokine, fusion protein, enzyme, vaccine, virus, anticoagulant, and nucleic acid.


The invention further provides method for optimizing a Chinese hamster ovary (CHO) cell to produce a product. The method can include the steps of providing a data structure relating a plurality of reactants to a plurality of reactions, wherein the plurality of reactants and the plurality of reactions are a selection of reactants and reactions as shown in Tables 5, 8 and 9 for a CHO cell, and wherein the data structure relates a plurality of reactants and a plurality of reactions selected from the reactants and reactions as shown in Tables 5, 6 and 7 for a CHO cell transcriptome; providing a constraint set for the plurality of reactions for the data structure; determining at least one flux distribution that minimizes or maximizes an objective function when the constraint set is applied to the data structure, wherein the at least one flux distribution is predictive of producing a product in the CHO cell; and modifying the CHO cell as determined above. In a particular embodiment, the product can be selected from the group consisting of an exogenous growth factor, monoclonal antibody, hormone, cytokine, fusion protein, enzyme, vaccine, virus, anticoagulant, and nucleic acid.


In a particular embodiment of such a method of the invention, the objective function can further comprise product formation, energy synthesis, biomass production, or a combination thereof or decreasing byproduct formation. In a method of the invention, a culture condition is selected from the group consisting of optimized culture medium for the cell, optimized cell culture process, optimized cell productivity, and metabolic engineering of the cell. In a particular embodiment, the objective function can be production of the product. In a further embodiment, the two or more nutrients can be carbon sources.


In one embodiment, the present invention provides cell line metabolic models of CHO cells. Using a computational platform, a number of metabolic network reconstructions have been generated for production mammalian cell lines, in particular CHO. The integrated computational and experimental modeling platform allows for the development of metabolic models of mammalian cells, media and process optimization and development, understanding metabolism under different genetic and environmental conditions, engineering cell lines, and developing novel selection systems. Thus, the invention provides methods and in silico models to simulate cell line metabolism, improve and optimize cell culture media and cell culture processes, improve and increase protein production, identify new selection systems, identify biomarkers for cell culture contamination, for example, with viruses or bacteria, and improving metabolic characteristics of a cell line.


In another embodiment, the invention provides media and/or process optimization and development. A computational modeling platform and expertise can be used in metabolic modeling and mammalian cell culture to reduce byproduct formation in CHO cells. As disclosed herein, the model can be used to develop nutritional modifications to the basal media to reduce byproduct formation and improve growth and productivity. This media and process optimization platform can significantly improve the existing timelines associated with therapeutic protein production in mammalian cell lines. The media and process optimization platform can be used by: (1) reconstructing, refining, and expanding metabolic models of CHO cell lines, (2) integrating a transient flux balance approach for quantitative implementation of media designs, and (3) validating the final framework using case studies for antibody production in production cell lines. This platform can be used to reduce the timelines to develop an optimized media that results in lower byproduct formation and higher productivity in cell culture through rational selection of nutrient supplementation and process optimization strategies.


In another embodiment, the invention models allow understanding of metabolism in mammalian cell lines and cell line engineering. Using an integrated computational and experimental approach, the invention also allows characterization of metabolism in production cell lines. For example, the effect of sodium butyrate supplementation, commonly used to enhance protein expression, on CHO cell metabolism can be studied using its metabolic network reconstruction and predicted alternative strategies that result in similar metabolic characteristics without the addition of sodium butyrate. The reconstructed networks can be used to develop a rational approach for recombinant protein production in CHO cell lines to: (a) generate fundamental understanding for cell line response to environmental and genetic changes, and (b) develop novel metabolic interventions for improved protein production.


In yet another embodiment, the invention provides cell line engineering and novel selection system design. In addition, the methods and models of the invention can utilize the knowledge of a whole cell metabolism and is capable to provide rational designs for identifying new selection systems. An integrated computational and experimental approach can be used to identify novel selection systems in CHO cell line and experimentally implement the most promising and advantageous candidate to validate the approach. This approach can be implemented in three stages: (1) identify essential metabolic reactions that are candidate targets for designing novel and superior selection systems using a reconstructed metabolic model of a cell line such as CHO, rank-order and prioritize the candidate targets based on a number of criteria including the predicted stringent specificity of the new selection system and improved cell physiology, (2) experimentally implement the top candidate selection system in a cell line using experimental techniques such as by first creating an auxotrophic clone, transiently transfecting cells with a selection vector that includes an antibody-expressing gene, and selecting protein producing cell lines based on their auxotrophy, and (3) evaluate the development and implementation of a model-based selection system in CHO cells by comparing experimentally generated cell culture data with those calculated by the reconstructed model. This integrated computational and experimental platform allows for design of new and superior metabolic selection systems in mammalian based protein production by computationally identifying and experimentally developing novel selection systems.


As disclosed herein, in one embodiment, a computational modeling approach is used for the design of mammalian cell culture media to reduce byproduct formation and increase protein production. The computational modeling and experimental implementation are applicable to any cell lines such as mammalian cell line, in particular Chinese Hamster Ovary (CHO), including modified versions of such cell lines, such as CHO DHFR. It is understood that such cell lines are merely exemplary and that the methods are applicable to any cell line for which sufficient information on metabolic reactions is known or can be deduced from other cells or related organisms, as disclosed herein. The methods of the invention can additionally be applied to other cell lines such as plant or insect cells and to design or modify media, process and cell lines. Such cell lines are useful for production of biologics, including but not limited to growth factors, monoclonal antibodies, hormones, cytokines, fusion proteins, recombinant enzymes, recombinant vaccines, viruses, anticoagulants, and nucleic acids. In one embodiment, the cell lines are derived from a multicellular organism such as an animal, for example, a human, a plant or an insect.


As disclosed herein, the methods of the invention are useful in applying computational metabolic models for a cell line, in particular a mammalian cell line, such as Chinese Hamster Ovary (CHO), and any variation of those, for example, CHO DHFR cell lines, that are used for production of biologics such as protein products. Exemplary biologics include, but are not limited to, growth factors, monoclonal antibodies, hormones, cytokines, fusion proteins, recombinant enzymes, recombinant vaccines, viruses, anticoagulants, and nucleic acids. In addition, the methods of the invention can be used to develop a computational metabolic model for engineering and optimizing cell culture media, that is, media optimization, designing cell culture process, that is, process design, and engineering the cell, that is, cell line engineering, to improve biomass production, product yield, and/or product titers, that is, to improve the overall cell culture productivity, reduce byproduct formation, or improve any desired metabolic characteristic in a cell culture. In an embodiment, maximization of the nutrient uptake rates or energy maintenance can be used as the objective function for simulating mammalian cell line physiology and cell culture.


The models of the invention are based on a data structure relating a plurality of reactants to a plurality of reactions, wherein each of the reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product. The reactions included in the data structure can be those that are common to all or most cells or to a particular type or species of cell, for example a particular cell line, such as core metabolic reactions, or reactions specific for one or more given cell type.


As used herein, the term “reaction” is intended to mean a conversion that consumes a substrate or forms a product that occurs in or by a cell. The term can include a conversion that occurs due to the activity of one or more enzymes that are genetically encoded by a genome of the cell. The term can also include a conversion that occurs spontaneously in a cell. Conversions included in the term include, for example, changes in chemical composition such as those due to nucleophilic or electrophilic addition, nucleophilic or electrophilic substitution, elimination, isomerization, deamination, phosphorylation, methylation, reduction, oxidation or changes in location such as those that occur due to a transport reaction that moves a reactant from one cellular compartment to another. In the case of a transport reaction, the substrate and product of the reaction can be chemically the same and the substrate and product can be differentiated according to location in a particular cellular compartment. Thus, a reaction that transports a chemically unchanged reactant from a first compartment to a second compartment has as its substrate the reactant in the first compartment and as its product the reactant in the second compartment. It will be understood that when used in reference to an in silico model or data structure, a reaction is intended to be a representation of a chemical conversion that consumes a substrate or produces a product.


As used herein, the term “reactant” is intended to mean a chemical that is a substrate or a product of a reaction that occurs in or by a cell. The term can include substrates or products of reactions performed by one or more enzymes encoded by a genome, reactions occurring in cells or organisms that are performed by one or more non-genetically encoded macromolecule, protein or enzyme, or reactions that occur spontaneously in a cell. Metabolites are understood to be reactants within the meaning of the term. It will be understood that when used in reference to an in silico model or data structure, a reactant is intended to be a representation of a chemical that is a substrate or a product of a reaction that occurs in or by a cell.


As used herein the term “substrate” is intended to mean a reactant that can be converted to one or more products by a reaction. The term can include, for example, a reactant that is to be chemically changed due to nucleophilic or electrophilic addition, nucleophilic or electrophilic substitution, elimination, isomerization, deamination, phosphorylation, methylation, reduction, oxidation or that is to change location such as by being transported across a membrane or to a different compartment.


As used herein, the term “product” is intended to mean a reactant that results from a reaction with one or more substrates. The term can include, for example, a reactant that has been chemically changed due to nucleophilic or electrophilic addition, nucleophilic or electrophilic substitution, elimination, isomerization, deamination, phosphorylation, methylation, reduction or oxidation or that has changed location such as by being transported across a membrane or to a different compartment.


As used herein, the term “product formation” or “formation of a product,” when used in reference to a cell or cell model, either an actual cell or an in silico model, refers to the production of a desired product by the cell or cell model. One skilled in the art would readily understand the meaning of these terms as referring to the production or formation of a product by a cell or cell model.


As used herein, the term “stoichiometric coefficient” is intended to mean a numerical constant correlating the number of one or more reactants and the number of one or more products in a chemical reaction. Typically, the numbers are integers as they denote the number of molecules of each reactant in an elementally balanced chemical equation that describes the corresponding conversion. However, in some cases the numbers can take on non-integer values, for example, when used in a lumped reaction or to reflect empirical data.


As used herein, the term “plurality,” when used in reference to reactions or reactants is intended to mean at least 2 reactions or reactants. The term can include any number of reactions or reactants in the range from 2 to the number of naturally occurring reactants or reactions for a particular of cell or cells. Thus, the term can include, for example, at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 33, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000 or more reactions or reactants. The number of reactions or reactants can be expressed as a portion of the total number of naturally occurring reactions for a particular cell or cells including a CHO cell or cells, such as at least 20%, 30%, 50%, 60%, 75%, 90%, 95%, 98% or 99% of the total number of naturally occurring reactions that occur in a CHO cell.


As used herein, the term “data structure” is intended to mean a physical or logical relationship among data elements, designed to support specific data manipulation functions. The term can include, for example, a list of data elements that can be added combined or otherwise manipulated such as a list of representations for reactions from which reactants can be related in a matrix or network. The term can also include a matrix that correlates data elements from two or more lists of information such as a matrix that correlates reactants to reactions. Information included in the term can represent, for example, a substrate or product of a chemical reaction, a chemical reaction relating one or more substrates to one or more products, a constraint placed on a reaction, or a stoichiometric coefficient.


As used herein, the term “constraint” is intended to mean an upper or lower boundary for a reaction. A boundary can specify a minimum or maximum flow of mass, electrons or energy through a reaction. A boundary can further specify directionality of a reaction. A boundary can be a constant value such as zero, infinity, or a numerical value such as an integer. Alternatively, a boundary can be a variable boundary value as set forth below.


As used herein, the term “variable,” when used in reference to a constraint is intended to mean capable of assuming any of a set of values in response to being acted upon by a constraint function. The term “function,” when used in the context of a constraint, is intended to be consistent with the meaning of the term as it is understood in the computer and mathematical arts. A function can be binary such that changes correspond to a reaction being off or on. Alternatively, continuous functions can be used such that changes in boundary values correspond to increases or decreases in activity. Such increases or decreases can also be binned or effectively digitized by a function capable of converting sets of values to discreet integer values. A function included in the term can correlate a boundary value with the presence, absence or amount of a biochemical reaction network participant such as a reactant, reaction, enzyme or gene. A function included in the term can correlate a boundary value with an outcome of at least one reaction in a reaction network that includes the reaction that is constrained by the boundary limit. A function included in the term can also correlate a boundary value with an environmental condition such as time, pH, temperature or redox potential.


As used herein, the term “activity,” when used in reference to a reaction, is intended to mean the amount of product produced by the reaction, the amount of substrate consumed by the reaction or the rate at which a product is produced or a substrate is consumed. The amount of product produced by the reaction, the amount of substrate consumed by the reaction or the rate at which a product is produced or a substrate is consumed can also be referred to as the flux for the reaction.


As used herein, the term “activity,” when used in reference to a cell, is intended to mean the magnitude or rate of a change from an initial state to a final state. The term can include, for example, the amount of a chemical consumed or produced by a cell, the rate at which a chemical is consumed or produced by a cell, the amount or rate of growth of a cell or the amount of or rate at which energy, mass or electrons flow through a particular subset of reactions.


Depending on the application, the plurality of reactions for a cell model or method of the invention, can include reactions selected from core metabolic reactions or peripheral metabolic reactions. As used herein, the term “core,” when used in reference to a metabolic pathway, is intended to mean a metabolic pathway selected from glycolysis/gluconeogenesis, the pentose phosphate pathway (PPP), the tricarboxylic acid (TCA) cycle, glycogen storage, electron transfer system (ETS), the malate/aspartate shuttle, the glycerol phosphate shuttle, and plasma and mitochondrial membrane transporters. As used herein, the term “peripheral,” when used in reference to a metabolic pathway, is intended to mean a metabolic pathway that includes one or more reactions that are not a part of a core metabolic pathway.


As used herein, the term “transcriptome” refers the set of all RNA molecules transcribed in a cell, including mRNA, rRNA, tRNA, and non-coding RNA produced in a cell. The term can be applied to the total set of transcripts in a given organism, or to the specific subset of transcripts present in a particular cell type. When used herein in reference to a CHO model, the transcriptome refers to the transcripts present in a CHO cell or a representation of transcripts from a single CHO cell, which are derived from a plurality of CHO cells. It is understood that a CHO cell transcriptome can also include less than the total transcripts present in a single CHO cell. For example, the CHO model described herein can, in some aspects, include all of the transcriptome reactions identified or fewer than the total number of transcriptome reactions identified in Tables 1, 2, 5, 6 or 7. It is also understood that the transcriptome in a CHO cell will depend on the conditions in which the cell is placed. Unlike the genome, which is roughly fixed for a given cell line (excluding mutations), the transcriptome can vary with external environmental conditions. For example, changes in media, nutrients, temperature or other culture conditions, and the like, can alter gene expression such that a transcriptome can change under a different set of conditions. Because it includes all mRNA transcripts in the cell, the transcriptome reflects the genes that are being actively expressed at any given time, with the exception of mRNA degradation phenomena such as transcriptional attenuation. Transcriptome analysis can be performed with well known expression profiling techniques, including nucleic acid microarray methods, PCR methods, and the like.


A plurality of reactants can be related to a plurality of reactions in any data structure that represents, for each reactant, the reactions by which it is consumed or produced. Thus, the data structure, which is referred to herein as a “reaction network data structure,” serves as a representation of a biological reaction network or system. An example of a reaction network that can be represented in a reaction network data structure of the invention is the collection of reactions that constitute the metabolic reactions of cell lines, as described in the Examples. The choice of reactions to include in a particular reaction network data structure, from among all the possible reactions that can occur in a cell being modeled depends on the cell type and the physiological condition being modeled, and can be determined experimentally or from the literature, as described further below. Thus, the choice of reactions to include in a particular reaction network data structure can be selected depending on whether media optimization, cell line optimization, process development, or other methods and desired results disclosed herein are selected.


The reactions to be included in a particular network data structure can be determined experimentally using, for example, gene or protein expression profiles, where the molecular characteristics of the cell can be correlated to the expression levels. The expression or lack of expression of genes or proteins in a cell type can be used in determining whether a reaction is included in the model by association to the expressed gene(s) and or protein(s). Thus, it is possible to use experimental technologies to determine which genes and/or proteins are expressed in a specific cell type, and to further use this information to determine which reactions are present in the cell type of interest. In this way a subset of reactions from all of those reactions that can occur in cells in generally, for example, mammalian cells, are selected to comprise the set of reactions that represent a specific cell type. cDNA expression profiles have been demonstrated to be useful, for example, for classification of breast cancer cells (Sorlie et al., Proc. Natl. Acad. Sci. U.S.A. 98(19):10869-10874 (2001)).


Media composition plays an important role in mammalian cell line protein production. The composition of the feed medium can affect cell growth, protein production, protein quality, and downstream protein purification (Rose et al., Handbook of Industrial Cell Culture (Humana Press, Totowa), pp. 69-103 (2003)). Inadequate medium formulation can lead to cell death and reduced productivity or posttranslational processing. On the other hand, a medium with too high a concentration of nutrients can shift metabolism, causing toxic accumulation of byproducts such as lactate and ammonia (Rose et al., supra, 2003). Most large-scale processes are operated using animal serum free media. Excluding serum from the cell culture media minimizes the risk of viral contamination and adventitious agents transmission. Added benefits in using serum free media include increased consistency in growth and productivity, a more simplified downstream purification process, and reduced medium formulation costs (Rose et al., supra, 2003).


Low biomass concentration in standard mammalian cell culture reduces productivity and product titers in mammalian cell cultures compared to microbial systems (Sheikh et al., Biotechnol Prog. 21:112-121 (2005)). Byproduct formation of lactate, alanine, and ammonia in mammalian cell culture can reduce biomass yield and protein production, cause toxic accumulation, and inhibit cell growth (Rose et al., supra, 2003; Namjoshi et al., Biotechnol Bioeng 81:80-91 (2003)). Although byproduct formation in mammalian cell lines is similar to what is observed in E. coli and yeast, its underlying mechanism remains unclear (Sheikh et al., supra, 2005). In microbial systems, this metabolic overflow is reduced by maintaining glucose at low levels. In mammalian cell culture however, low substrate concentrations induce apoptosis and cell death, which limits the use of this strategy in large-scale protein production processes (Cotter and al Rubeai, Trends Biotechnol 13:150-155 (1995)). Cell line engineering strategies to knockout lactate dehyrogenase in hybridoma and express yeast pyruvate carboxylase in baby hamster kidney (BHK) cell lines have also shown moderate improvements in biomass and product titer (Chen et al., Biotechnol Bioeng 72:55-61 (2001); Irani et al., J Biotechnol 93:269-282 (2002)). In addition, generating a stable engineered cell line can be time consuming and laborious. Alternative strategies are needed to reduce byproduct formation with minimum or no cell line engineering approaches.


Currently, most process optimization strategies are performed using a trial and error approach, where process outputs are improved laboriously by experimentation. In general, nutrient components in the cell culture media are determined using one or a combination of the following strategies (Rose et al., supra, 2003): borrowing—adopting a medium composition from the published literature; component swapping—swapping one media component for another at the same usage level; depletion analysis—continuously supplying the media with the depleting nutrients; one-at-a-time—adjusting one component at a time and maintaining the others the same; statistical approaches, including but not limited to full factorial design, partial factorial design, and Plackett-Burman design; optimization techniques, including but not limited to response surface methodology, simplex search and multiple linear regression; computational methods, including but not limited to evolutionary algorithm, genetic algorithm, particle swarm optimization, neural networks and fuzzy logic.


Computational strategies listed above require large sets of experimental data for algorithmic training and in general do not provide a complete solution for media development and optimization in mammalian cell culture. An optimized medium using a laboratory scale cell culture is often not robust to scale-up changes at the manufacturing stage, and requires re-optimization. The lot-to-lot variability in serum-based media components generates inconsistency in growth and protein productivity in mammalian cell cultures. Repeated runs on a media formula can show different nutrient depletion patterns that are in general unexplainable by the existing media design strategies. Overall, media optimization is often performed with little knowledge about how, why, or where the nutrients are used and whether the depleted components are catabolized by the cell or simply degraded without any metabolic benefits to the cell culture. In essence, the cell is treated as a black box. Opening this black box and understanding the fundamental physiological interaction of the cell can lead to more informed and rational approaches for media optimization and cell line engineering and can greatly improve the protein production in mammalian cell lines.


Recent efforts in stoichiometric modeling of mammalian cell lines has been made. Unlike the trial and error strategies that are commonly used in therapeutic protein production, metabolic modeling provides a clear definition for metabolism in the host cell lines and offers a rational approach for designing and optimizing protein production. Computational metabolic modeling can serve as a design and diagnostic tool to: identify what pathways are being used under specified genetic and environmental conditions; determine the fate of nutrients in the cell; identify the source of waste products; examine the effect of eliminating existing reactions or adding new pathways to the host cell line, analyze the effect of adding nutrients to the media, interpret process changes, for example, scale-up, at the metabolic level, and generate rational design strategies for media optimization, process development, and cell engineering.


Computational models have been developed to study protein production in mammalian cell lines using a variety of modeling approaches including metabolic flux analysis (MFA) or flux balance analysis (FBA) (Sheikh et al., supra, 2005; Xie and Wang, Biotechnol Bioeng 52:579-590 (1996); Xie and Wang, Biotechnol Bioeng 52:591-601 (1996); Savinell and Palsson, J. Theor. Biol 154:421-454 (1992a); Savinell and Palsson, J. Theor. Biol 154:455-473 (1992b)). MFA-based models have been used to develop strategies for media design in batch and fed-batch hybridoma cell culture using a lumped “black box” model containing simplified stoichiometric equations (Xie and Wang, Cytotechnology 15:17-29 (1994); Xie and Wang, Biotechnol Bioeng 95:270-284 (2006); Xie and Wang, Biotechnol Bioeng 43:1164-1174 (1994)). FBA-based models have also been used to study hybridoma cell culture (Sheikh et al., supra, 2005; Savinell and Paulsson, supra, 1992a; Savinell and Palsson, supra, 1992b). As described previously, four objective functions were used to study metabolism in a hybridoma: (1) minimizing ATP production, (2) minimizing moles of nutrient uptake, (3) minimizing mass nutrient uptake, and (4) minimizing NADH production (Savinell and Palsson, supra, 1992a). Although no single objective was found to govern cell behavior, minimizing redox production gave results that were most similar to hybridoma cell behavior. Also described previously, three alternative objective functions were examined, including maximizing growth, minimizing substrate uptake rate, and production of monoclonal antibody (Sheikh et al., supra, 2005). The model correctly predicted growth, lactate, and ammonia production when glucose, oxygen, and glutamine uptake was constrained to experimentally measured values. However, the model did not predict the production of alanine and did not provide any explanation for why animal cells oxidize glutamine partially. Neither of the FBA-based models described previously (Savinell and Palsson, supra, 1992a; Sheikh et al., supra, 2005) were utilized to design or optimize cell culture media.


Metabolic models can be used for rational bioprocess design. Any attempt to improve protein production by overcoming fundamental metabolic limitations requires a platform for the comprehensive analysis of cellular metabolic systems. Genome-scale models of metabolism offer the most effective way to achieve a high-level characterization and representation of metabolism. These models reconcile all of the existing genetic, biochemical, and physiological data into a metabolic reconstruction encompassing all of the metabolic capabilities and fitness of an organism. These in silico models serve as the most concise representation of collective biological knowledge on the metabolism of a microorganism. As such they become the focal point for the integrative analysis of vast amounts of experimental data and a central resource to design experiments, interpret experimental data, and drive research programs. It is recognized that the construction of genome-scale in silico models is important to integrate large amounts of diverse high-throughput datasets and to prospectively design experiments to systematically fill in gaps in the knowledge base of particular organisms (Ideker et al., Science 292:929-934 (2001)).


Constructing and demonstrating the use of genome-scale models of metabolism has been described. Previously published in silico representations of metabolism include those for Escherichia coli MG1655 (Edwards and Palsson, Proc. Natl. Acad. Sci. USA 97:5528-5533 (2000)), H. influenzae Rd (Edwards and Palsson, J. Biol. Chem. 274:17410-17416 (1999); Schilling and Palsson, J. Theor. Biol. 203:249-283 (2000)), H. pylori (Schilling et al., J. Bacteriol. 184:4582-4593 (2002)), and S. cerevisiae (Forster et al., Genome Res 13:244-253 (2003)). The general process has been previously published along with various applications of the in silico models (Schilling et al., Biotechnol. Prog. 15:288-295 (1999)); Covert et al., Trends Biochem. Sci. 26:179-186 (2001)).


In combination with appropriate simulation methods, these models can also be used to generate hypotheses to guide experimental design efforts and to improve the efficiency of bioprocess design and optimization. When properly integrated with experimental technologies, an extremely powerful combined platform for metabolic engineering can be implemented for a wide range of applications within industrial pharmaceutical and biotechnology for production and development of healthcare products, therapeutic proteins, and biologics.


In one embodiment, the invention provides a computer readable medium or media, comprising a data structure relating a plurality of reactants to a plurality of reactions from a cell based on the CHO models described herein, each of the reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product; a constraint set for said plurality of reactions for said data structures, and commands for determining at least one flux distribution that minimizes or maximizes an objective function when the constraint set is applied to the data structure, wherein the at least one flux distribution is predictive of a physiological function of the cell. For example, the data structure can comprise a reaction network. In addition, the data structure can comprise a plurality of reaction networks.


In a particular embodiment, the computer readable medium or media can comprise at least one reaction that is annotated to indicate an associated gene or protein. In addition, the computer readable medium or media can further comprise a gene database having information characterizing the associated gene. At least one of the reactions in the data structure can be a regulated reaction. In addition, the constraint set can include a variable constraint for the regulated reaction.


In another embodiment, the cell can be optimized to increase product yield, to minimize scale up variability, to minimize batch to batch variability or optimized to minimize clonal variability. Additionally, the cell can be optimized to improve cell productivity in stationary phase.


In another embodiment, the cell is derived from an animal, plant or insect. As used herein, a “derived from an animal, plant or insect” refers to a cell that is of animal, plant or insect origin that has been obtained from an animal, plant or insect. Such a cell can be an established cell line or a primary culture. Cell lines are commercially available and can be obtained, for example, from sources such as the American Type American Type Culture Collection (ATCC)(Manassas Va.) or other commercial sources. In a particular embodiment, the cell can be a mammalian cell, such as a Chinese Hamster Ovary (CHO). It is understood that cell variants, such as CHO DHFR-cells, and the like, which can be used with non-selection systems, as disclosed herein. Generally the cells of the invention are obtained from a multicellular organism, in particular a eukaryotic cell from a multicellular organism, in contrast to a cell that exists as a single celled organism such as yeast. Thus, a eukaryotic cell from a multicellular organism as used herein specifically excludes yeast cells.


The invention provides a method for predicting a culture condition for a eukaryotic cell from the CHO cell model described herein. The method can include the steps of providing a data structure relating a plurality of reactants to a plurality of reactions from a cell, each of the reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product, wherein the plurality of reactions comprises one or more extracellular exchange reactions; providing a constraint set for the plurality of reactions for the data structure; providing an objective function, wherein the objective function is uptake rate of two or more nutrients, wherein the two or more nutrients are carbon sources; and determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the data structure, wherein the at least one flux distribution is predictive of a culture condition for the eukaryotic cell. In such a method, the objective function can further comprise product formation, energy synthesis, biomass production, or a combination thereof. Alternatively, the objective function can further comprise decreasing byproduct formation.


Additionally in such a method of the invention, the culture condition can be optimized culture medium for the cell, optimized cell culture process, optimized cell productivity, and metabolic engineering of the cell. The optimized cell productivity can be, for example, increased biomass production or increased product yield. The culture condition can be reduced scale up variability, reduced batch to batch variability, reduced clonal variability, improved cell growth, viable cell density or cell productivity in exponential growth phase or stationary phase or other desired culture conditions.


It is understood that the methods of the invention disclosed herein are generally performed on a computer. Thus, the methods of the invention can be performed, for example, with appropriate computer executable commands stored on a computer readable medium or media that carry out the steps of any of the methods disclosed herein. For example, if desired, a data structure can be stored on a computer readable medium or media and accessed to provide the data structure for use with a method of the invention. Additionally, if desired, any and up to all commands for performing the steps of a method of the invention can be stored on a computer readable medium or media and utilized to perform the steps of a method of the invention. Thus, the invention provides a computer readable medium or media having stored thereon computer executable commands for performing the steps of any method of the invention.


In one embodiment, the invention provides a computer readable medium or media having stored thereon commands for performing the computer executable steps of providing a data structure relating a plurality of reactants to a plurality of reactions from a cell based on the CHO cell model disclosed herein, each of the reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product, wherein the plurality of reactions comprises one or more extracellular exchange reactions; providing a constraint set for the plurality of reactions for the data structure; providing an objective function, wherein the objective function is uptake rate of two or more nutrients, wherein the two or more nutrients are carbon sources; and determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the data structure, wherein the at least one flux distribution is predictive of a culture condition for the eukaryotic cell. The computer readable medium or media can include additional steps of such a method of the invention, as disclosed herein.


As used herein, a “culture condition” when used in reference to a cell refers to the state of a cell under a given set of conditions in a cell culture. Such a culture condition can be a condition of a cell culture or an in silico model of a cell in culture. A cell culture or tissue culture is understood by those skilled in the art to include an in vitro culture of a cell, in particular a cell culture of a eukarotic cell from a multicellular organism. Such an in vitro culture refers to the well known meaning of occurring outside an organism, although it is understood that such cells in culture are living cells. A culture condition can refer to the base state or steady state of a cell under a set of conditions or the state of a cell when such conditions are altered, either in an actual cell culture or in an in silico model of a cell culture. For example, a culture condition can refer to the state of a cell, in culture, as calculated based on the cell modeling methods, as disclosed herein. In addition, a culture condition can refer to the state of a cell under an altered set of conditions, for example, the state of a cell as calculated under the conditions of an optimized cell culture medium, optimized cell culture process, optimized cell productivity or after metabolic engineering, including any or all of these conditions as calculated using the in silico models as disclosed herein. Additional exemplary culture conditions include, but are not limited to, reduced scale up variability, reduced batch to batch variability, reduced clonal variability, improved cell growth, viable cell density or cell productivity in exponential growth phase or stationary phase. Such altered conditions can be included in a model of the invention or methods of producing such a model by applying an appropriate constraint set and objective function to achieve the desired result, as disclosed herein and as understood by those skilled in the art.


The methods of the invention as disclosed herein can be used to produce an in silico model of a CHO cell culture. Such an in silico model is generally produced to obtain a culture condition that is the base state of a cell. Once a base model is established, the model can be further refined or altered by selecting a different constraint set or objective function than used in the base state model to achieve a desired outcome. The selection of appropriate constraint sets and/or objective functions to achieve a desired outcome are well known to those skilled in the art.


In embodiments of the invention, an objective function can be the uptake rate of two or more nutrients. In a cell culture, it is understood that a nutrient is provided from the extracellular environment, generally in the culture media, although a nutrient can also be provided from a second cell in a co-culture if such a cell secretes a product that functions as a nutrient for the other cell in the co-culture. The components of a culture medium for providing nutrients to a cell in culture, either to maintain cell viability or cell growth, are well known to those skilled in the art. Such nutrients include, but are not limited to, carbon source, inorganic salts, metals, vitamins, amino acids, fatty acids, and the like (see, for example, Harrison and Rae, General Techniques of Cell Culture, chapter 3, pp. 31-59, Cambridge University Press, Cambridge United Kingdom (1997)). Such nutrients can be provided as a defined medium or supplemented with nutrient sources such as serum, as is well known to those skilled in the art. The culture medium generally includes carbohydrate as a source of carbon. Exemplary carbohydrates that can be used as a carbon source include, but are not limited to, sugars such as glucose, galactose, fructose, sucrose, and the like. It is understood that any nutrient that contains carbon and can be utilized by the cell in culture as a carbon source can be considered a nutrient that is a carbon source. Nutrients in the extracellular environment available to a cell include those substrates or products of an extracellular exchange reaction, including transport or transformation reactions. Thus, any reaction that allows transport or transformation of a nutrient in the extracellular environment, including but not limited to those shown in Tables 1-4 as exemplary reactions, for utilization inside the cell where the nutrient contains carbon is considered to be a nutrient that is a carbon source. Numerous commercial sources are available for various culture media. In particular embodiments of the invention, the methods of the invention utilize an objective function that includes the uptake rate of two or more nutrients that are carbon sources, although it is understood that the uptake of other nutrients can additionally or alternatively be used in the methods of the invention as a parameter of an objective function. As disclosed herein, cells from a multicellular organism have evolved to be bathed in nutrients. A cell from a multicellular organism therefore generally has an inefficient uptake of nutrients. Previously, it was considered that a cell in culture would generally uptake one carbon source. The present invention is based, in part, on the observation and unexpected results obtained by modeling the uptake of two or more nutrients, in particular two or more carbon sources.


As disclosed herein, the invention can be used to generate models of a cultured CHO cell that allow various culture conditions to be tested and, if desired, optimized, by selecting appropriate constraint sets and/or objective functions that achieve a desired culture condition. Exemplary culture conditions are disclosed herein and include, but are not limited to, product formation, energy synthesis, biomass production, byproduct formation, optimizing cell culture medium for a cell, optimizing a cell culture process, optimizing cell productivity, metabolically engineering a cell, reducing scale up variability, reducing batch to batch variability, reducing clonal variability, and the like. In some cases, a desired culture condition includes increasing or improving on a condition, for example, increasing product yield, biomass, cell growth, viable cell density, cell productivity, and the like. In other cases, a desired culture condition includes decreasing, reducing or minimizing an effect, for example, decreasing byproduct formation, reducing scale up variability, reducing batch to batch variability, reducing clonal variability, and the like. It is further understood that any number of desirable culture conditions can be combined, either simultaneously or sequentially, for calculation by a method of the invention to achieve a desired outcome. For example, it can be desirable to increase cell productivity by increasing biomass and/or increasing the yield or titer of a product. Therefore, increased biomass and increased product yield can be included, for example, as an objective function or as a component of an objective function combined with another component, for example, uptake rate of a nutrient. Additionally, it can be desirable to both increase product yield and decrease byproduct formation, so these could similarly be combined, for example, as an objective function. It is understood that any combination of desired culture conditions can be utilized to achieve an improved or optimized culture condition. One skilled in the art, based on the methods disclosed herein and those well known to those skilled in the art, can select an appropriate constraint set and/or objective function to achieve a desired outcome of a culture condition. As used herein, when used in the context of a culture condition, an optimized culture condition such as optimized growth medium, optimized cell culture process, or optimized cell productivity is intended to mean an improvement relative to another condition. The use of the term optimized or improved culture condition is distinct from an optimization problem as known to those skilled in the mathematical arts.


The methods of the invention can be used to optimize or improve a culture medium to increase growth or viability of a cell in culture, for example, growth rate, cell density in suspension culture, product production in exponential growth or stationary phase, and the like. Additionally, the methods of the invention can be used to optimize or increase a cell culture process, also referred to herein as process design. Process design as used herein generally refers to the design and engineering of scale up from small to large scale processes, in particular as they are used in an industrial and commercial scale for culture of cells. Process design is well known to those skilled in the art and can include, for example, the size and type of culture vessels, oxygenation, replenishment of media and nutrients, removal of media containing growth inhibitory byproducts, harvesting of a desired product, and the like. The methods disclosed herein can be used to model culture conditions relating to process design to improve or optimize a cell culture process. The methods of the invention can further be used to optimize or improve cell productivity, for example, increasing biomass production or increasing product yield or titer, or a combination thereof. The methods of the invention can also be used to identify the distinct and significant difference between, for example, (a) laboratory and large scale cell cultures (to reduce scale-up variability), (b) different bioreactor and/or shake flask culture conditions performed with the same cells, media, and cell culture parameters (to reduce batch-to-batch variability), and (c) different clones (to reduce clonal variability).


To optimize a culture condition, the model generated by a method of the invention is used to simulate flux distribution for each condition using the maximization of uptake of nutrients, alone or in combination with maximization or minimization of energy production, byproduct formation, growth, and/or product formation. As disclosed herein, Flux Variability Analysis (FVA) or other suitable analytical methods can be performed for each cultivation conditions. For example, in the case of reducing scale up variability, that is laboratory scale versus large scale conditions, FVA can be performed for each condition to identify a range of flux values for each reaction in the metabolic model. Next, significantly reduced or significantly elevated fluxes in the different cultivation conditions are compared for each reaction. From this comparison, significant metabolic changes can be identified that are indicative of the observed differences. The knowledge obtained by analyzing the data in the context of the reconstructed model is used to identify design parameters that should be monitored or controlled in cell culture to prevent variability in cell culture condition that would result in scale up variability or batch to batch variability. In addition, by determining the variability under different culture conditions and optimizing or improving the conditions of a cell culture, for example by determining limiting nutrient(s) and providing increased amounts of such nutrients in the media, clonal variability can be reduced by reducing selective pressures that could result in the selection of clones with a phenotype that differs from a desired parental cell line. One skilled in the art will readily know appropriate selection of a constraint set or objective function to achieve a desired outcome of a culture condition using the methods and models of the invention.


The models and methods of the invention are particularly useful to optimize cells, culture medium or production of a desired product, as disclosed herein. Exemplary desired products include, but are not limited to, growth factors, monoclonal antibodies, hormones, cytokines, fusion proteins, enzymes, vaccines, viruses, anticoagulants, and nucleic acids. It is understood that, with respect to a cell producing a desired product, the product is produced at an increased level relative to a native parental cell and therefore is considered to be an exogenous product. The models and methods of the invention are based on selecting a desired objective function and generating a model based on the methods disclosed herein. For example, the methods and models can be used to optimize uptake rate of one or more nutrients, energy synthesis, biomass production, or a combination thereof. In addition, the methods and models of the invention can be used to optimize a culture medium for the cell, optimize a cell culture process, optimize cell productivity, or metabolic engineering of said cell. For example, optimized cell productivity can include increased biomass production, increased product yield, or increased product titers.


“Exogenous” as it is used herein is intended to mean that the referenced molecule or the referenced activity is introduced into the host organism. The molecule can be introduced, for example, by introduction of an encoding nucleic acid into the host genetic material such as by integration into a host chromosome or as non-chromosomal genetic material such as a plasmid. Therefore, the term as it is used in reference to expression of an encoding nucleic acid refers to introduction of the encoding nucleic acid in an expressible form into the host organism. When used in reference to a biosynthetic activity, the term refers to an activity that is introduced into the host reference organism. The source can be, for example, a homologous or heterologous encoding nucleic acid that expresses the referenced activity following introduction into the host organism. Therefore, the term “endogenous” refers to a referenced molecule or activity that is present in the host. Similarly, the term when used in reference to expression of an encoding nucleic acid refers to expression of an encoding nucleic acid contained within the organism. The term “heterologous” refers to a molecule or activity derived from a source other than the referenced species whereas “homologous” refers to a molecule or activity derived from the host organism. Accordingly, exogenous expression of an encoding nucleic acid of the invention can utilize either or both a heterologous or homologous encoding nucleic acid. Thus, it is understood that a desired product produced by a cell of the invention is an exogenous product, that is, a product introduced that is not normally expressed by the cell or having an increased level of expression relative to a native parental cell. Therefore, such a cell line has been engineered, either recombinantly or by selection, to have increased expression of a desired product, including but not limited to growth factors, monoclonal antibodies, hormones, cytokines, fusion proteins, enzymes, vaccines, viruses, anticoagulants, and nucleic acids. Such an increased expression can occur by recombinantly expressing a nucleic acid that is a desired product or a nucleic acid encoding a desired product. Alternatively, increased expression can occur by genetically modifying the cell to increase expression of a promoter and/or enhancer, either constitutively or by introducing an inducible promoter and/or enhancer.


As disclosed herein, the data structure can comprise a set of linear algebraic equations. In addition, the commands can comprise an optimization problem. In another embodiment, at least one reactant in the plurality of reactants or at least one reaction in the plurality of reactions can be annotated with an assignment to a subsystem or compartment. For example, a first substrate or product in the plurality of reactions can be assigned to a first compartment and a second substrate or product in the plurality of reactions can be assigned to a second compartment. Furthermore, at least a first substrate or product, or more substrates or products, in the plurality of reactions can be assigned to a first compartment and at least a second substrate or product, or more substrates or products, in the plurality of reactions can be assigned to a second compartment. In addition, a plurality of reactions can be annotated to indicate a plurality of associated genes and the gene database can comprise information characterizing the plurality of associated genes.


In another embodiment, the invention provides a method for predicting a physiological function of a CHO cell. The method can include the steps of providing a data structure relating a plurality of reactants to a plurality of reactions from a cell, each of the reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product; providing a constraint set for said plurality of reactions for said data structures; providing an objective function, and determining at least one flux distribution that minimizes or maximizes an objective function when the constraint set is applied to the data structure, wherein the at least one flux distribution is predictive of a physiological function of the cell. In methods of the invention, the data structure can comprise a reaction network. In addition, the data structure can comprise a plurality of reaction networks.


If desired, at least one of the reactions can be annotated to indicate an associated gene. In addition, the method can further comprise a gene database having information characterizing the associated gene. In another embodiment, at least one of the reactions can be a regulated reaction. In yet another embodiment, the constraint set can include a variable constraint for the regulated reaction.


As disclosed herein, the methods and models of the invention provide computational metabolic models for cells, such as a mammalian cell line, that can be used for production of a desired product or biologic, including but not limited to growth factors, monoclonal antibodies, hormones, cytokines, fusion proteins, recombinant enzymes, recombinant vaccines, viruses, anticoagulants, and nucleic acids. The use of a computational metabolic model can be used for engineering and optimizing cell culture media (media optimization), designing cell culture process (process design), and engineering the cell (cell line engineering) to improve biomass production, product yield, and/or product titers, that is, to improve the overall cell culture productivity. For example, maximization of the nutrient uptake rates can be used as the objective function in methods of the invention for simulating a cell's physiology and or growth and/or productivity in cell culture.


As disclosed herein, the methods and models of the invention can be used for media optimization, process optimization and/or development, cell line engineering, selection system design, cell line models, including models as disclosed herein such as Hybridoma, NS0, CHO. The invention additional provides models of cell lines based on reactions as found, for example, in Tables 1-4, including deletion designs and metabolic models. The methods and models can be used, for example, to improve yield of desired products; to address and optimize scale-up variability, for example, using the model to understand scale-up variability; to address and optimize batch-to-batch variability, for example, using the models to better understand batch to batch variability; to address and optimize clonal differences, for example, using the models to study the metabolic differences in clones following transfection; to improved productivity in stationary phase, for example, using the models to better understand the impact of changes to media when cells are growing in the stationary phase; and to develop novel selection systems, for example, to identify novel selection systems using the model and develop experimentally additional selection systems for engineering a host organism.


The methods and models of the invention can additionally be used, for example, to identify biofluid-based biomarkers for human inborn errors of metabolism; to identify biomarkers for the progression, development, and onset of diseases such as cancer; to identify biomarkers for assessing toxicology and clinical safety of therapeutic compounds; and to identify biomarkers for use in drug discovery to determine the effect(s) of a therapeutic agent through an analysis and comparison to an untreated individual. Such methods and models are based on selecting a suitable system and applying the methods disclosed herein to achieve a desired outcome, for example, selecting a suitable individual or group of individuals having inborn errors of metabolism, having a disease diagnosis such as cancer diagnosis or a predisposition to develop a disease, exposure to toxic chemicals, treatment with a therapeutic agent, and the like. The identified biomarkers can be used in various applications, including, but not limited to, diagnostics, therapy selection, and monitoring of therapeutic effectiveness.


The invention additionally provides computer readable medium or media, comprising a data structure relating a plurality of reactants to a plurality of reactions from a CHO cell, each of the reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product; a constraint set for the plurality of reactions for the data structures, and commands for determining at least one flux distribution that minimizes or maximizes an objective function when the constraint set is applied to the data structure, wherein the objective function identifies a target selectable marker reaction or reactant and wherein the at least one flux distribution is predictive of a physiological function of the cell. Thus, as disclosed herein, the invention provides a method to identify novel target pathways, reactions or reactants that can be used as new selectable markers for engineering a recombinant cell line.


The invention additionally provides a method for identifying a target selectable marker for a cell. The method can include the steps of providing a first data structure relating a plurality of reactants to a plurality of reactions from a cell, each of the reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product, wherein the plurality of reactions comprises one or more extracellular exchange reactions; providing a constraint set for the plurality of reactions for the first data structure; providing an objective function, wherein the objective function is uptake rate of two or more nutrients, wherein the two or more nutrients are carbon sources; determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the data structure; deleting a reaction from the data structure to generate a second data structure and repeating steps of providing a constraint set, providing an objective function and determining at least one flux distribution as discussed above; optionally repeating the deleting step by deleting a different reaction, wherein the at least one flux distribution determined with the second data structure is predictive of a reaction required for cell growth or cell viability, thereby identifying a target selectable marker reaction or reactant. Such a method can further comprise providing the second data structure; providing one or more extracellular substrates or products corresponding to one or more reactions of the one or more extracellular exchange reactions to the second data structure to generate a third data structure; providing a constraint set for the plurality of reactions for the third data structure; providing an objective function, wherein the objective function is cell viability or growth; and determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the third data structure, wherein the at least one flux distribution determined with the third data structure is predictive of an extracellular substrate or product that complements the target selectable marker reaction or reactant, thereby identifying a selectable marker reaction or reactant. In such a method, the objective function can further comprise uptake rate of the one or more extracellular substrates or products.


The invention additionally provides a computer readable medium or media having stored thereon computer executable commands for performing the steps of providing a first data structure relating a plurality of reactants to a plurality of reactions from a cell, each of the reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product, wherein the plurality of reactions comprises one or more extracellular exchange reactions; providing a constraint set for the plurality of reactions for the first data structure; providing an objective function, wherein the objective function is uptake rate of two or more nutrients, wherein the two or more nutrients are carbon sources; determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the data structure; deleting a reaction from the data structure to generate a second data structure and repeating steps of providing a constraint set, providing an objective function and determining at least one flux distribution as discussed above; optionally repeating the deleting step by deleting a different reaction, wherein the at least one flux distribution determined with the second data structure is predictive of a reaction required for cell growth or cell viability, thereby identifying a target selectable marker reaction or reactant. A computer readable medium or media can further comprise commands for performing the steps of providing the second data structure; providing one or more extracellular substrates or products corresponding to one or more reactions of the one or more extracellular exchange reactions to the second data structure to generate a third data structure; providing a constraint set for the plurality of reactions for the third data structure; providing an objective function, wherein the objective function is cell viability or growth; and determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the third data structure, wherein the at least one flux distribution determined with the third data structure is predictive of an extracellular substrate or product that complements the target selectable marker reaction or reactant, thereby identifying a selectable marker reaction or reactant.


As used herein, a “selectable marker” is well known to those skilled in molecular biology and refers to a gene whose expression allows the identification of cells that have been transformed or transfected with a vector containing the marker gene, that is, the presence or absence of the gene (selectable marker) can be selected for, generally based on an altered growth or cell viability characteristic of the cell. Well known exemplary selectable markers used routinely in cell culture include, for example, the dihydrofolate reductase (DHFR) and glutamine synthetase (GS) selection systems. The methods of the invention allow the identification of target selectable markers by using in silico models of a cell to identify a reaction that is required for cell viability or cell growth, that is, an essential reaction. Generally, selectable markers are utilized such that a cell will either die in the absence of a product produced by the selectable marker or will not grow, either case of which will prevent a cell lacking a complementary product from growing. The methods of the invention are based on deleting a reaction from a data structure containing a plurality of reactions and determining whether the deletion has an effect on cell viability or growth. If the deletion results in no cell growth or in cell death, then the deleted reaction is a target selectable marker. The method can be used to determine any of a number of target selectable markers by optionally repeating deleting different reactions. In a method of the invention, a single reaction is deleted to test for the effect on cell growth or viability, although multiple reactions can be deleted, if desired. In general, if a reaction is deleted from a data structure and the deletion has no effect on cell growth or viability, then a different reaction is deleted from the data structure and tested for its effect on cell growth or viability. Accordingly, in such a method, the data structure generally has only one reaction deleted at a time to test for the effect on cell growth or viability. As used herein, inhibiting cell growth generally includes preventing cell division or slowing the rate of cell division so that the doubling time of the cell is substantially reduced, for example, at least 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or even further reduction in doubling time, so long as the difference in growth rate from a cell containing the selectable marker is sufficient to differentiate the presence or absence of the selectable marker.


After identifying a target selectable marker reaction or reactant, the deleted data structure that identifies a reaction or reactant required for cell growth or viability can be tested for the ability to support cell growth or viability by the addition of an extracellular reaction to the data structure that complements the deleted reaction. For example, if a reaction is deleted and the deletion results in cell death or no cell growth, the product of that reaction can be used to complement the missing reaction and cause the cell to resume cell growth or viability. To be particularly useful as a selectable marker and selection system, it is desirable to be able to complement the missing reaction by addition of a component to the cell culture medium. Therefore, for a deleted reaction to be useful as a selectable marker, the deleted product must either be provided in the culture medium and transported into the cell or a precursor of the product transported into the cell and either transformed or converted to the missing product. To test for this possibility, one or more extracellular exchange reactions, which could potentially result in transport of the deleted product or a precursor of the product, is added to the data structure with the deleted reaction, and the cell is tested for whether cell growth or viability is recovered or resumed. If cell growth and viability is recovered with the addition of the extracellular substrate or product that can be transported, transformed or converted into the product intracellularly, then the deleted reaction and the complementary extracellular product or substrate can function as a selectable marker system. As used herein, a substrate or product that “complements” a target selectable marker refers to a substrate or product that, when added to a cell culture (in vitro or in silico), allows a cell having a deleted reaction (target selectable marker) required for cell growth or cell viability to restore cell growth or viability to the cell. Thus, the methods of the invention can be used to identify target selectable marker reactions or reactants and a selectable marker reaction or reactant with a complementary substrate or product that restores cell growth or viability.


The invention also provides a method for predicting a physiological function of a cell, comprising providing a data structure relating a plurality of reactants to a plurality of reactions from a cell, each of the reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product; providing a constraint set for the plurality of reactions for the data structures; providing an objective function, and determining at least one flux distribution that minimizes or maximizes an objective function when the constraint set is applied to the data structure, wherein the objective function identifies a target selectable marker reaction or reactant and wherein the at least one flux distribution is predictive of a physiological function of the cell.


The invention additionally provides a method for predicting a biomarker for a contaminant of a cell culture of a eukaryotic cell from a CHO cell. The method can include the steps of providing a first data structure relating a plurality of reactants to a plurality of reactions from a non-contaminated cell, each of the reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product, wherein the plurality of reactions comprises one or more extracellular exchange reactions; providing a second data structure relating a plurality of reactants to a plurality of reactions from a contaminated cell, each of the reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product, wherein the plurality of reactions comprises one or more extracellular exchange reactions; providing a constraint set for the plurality of reactions for the first and second data structures; providing an objective function, wherein the objective function is uptake rate of one or more nutrients, wherein the two or more nutrients are carbon sources; determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the first data structure; determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the second data structure; comparing the at least one flux distribution determined for the first data structure with the at least one flux distribution determined for the second data structure, wherein a difference in the at least one flux distribution for the first and second data structures is predictive of a biomarker for a contaminant of the cell culture. In such a method, the objective function can further comprise secretion rate of one or more products.


The invention additionally provides a computer readable medium or media having stored thereon computer executable commands for performing the steps of providing a first data structure relating a plurality of reactants to a plurality of reactions from a non-contaminated CHO cell, each of the reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product, wherein the plurality of reactions comprises one or more extracellular exchange reactions; providing a second data structure relating a plurality of reactants to a plurality of reactions from a contaminated cell, each of the reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product, wherein the plurality of reactions comprises one or more extracellular exchange reactions; providing a constraint set for the plurality of reactions for the first and second data structures; providing an objective function, wherein the objective function is uptake rate of one or more nutrients, wherein the two or more nutrients are carbon sources; determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the first data structure; determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the second data structure; comparing the at least one flux distribution determined for the first data structure with the at least one flux distribution determined for the second data structure, wherein a difference in the at least one flux distribution for the first and second data structures is predictive of a biomarker for a contaminant of the cell culture.


As disclosed herein, a biomarker for a cell culture contaminant such as a viral or bacterial contaminant can be identified using methods of the invention. The differences between a contaminated versus non-contaminated cell culture allow the identification of biomarker, that is, a marker produced by the cell that differentiates between a contaminated versus non-contaminated cell culture, useful for monitoring for potential contamination of a cell culture.


As disclosed herein, the methods of the invention can be used to generate models of an organism in culture. For example, exemplary models have been generated using methods of the invention. In particular, exemplary models have been generated for a CHO cell line (Table 1-9). The invention additionally provides a model comprising a selection of reactions of any of those shown in Tables 1-9, including up to all of the reactions in Tables 1-9 for the respective models.


The invention also provides a computer readable medium or media having stored thereon computer executable commands for performing methods utilizing any of the models of Tables 1-9. In one embodiment, the invention provides a computer readable medium or media containing commands to perform the steps of providing a data structure relating a plurality of reactants to a plurality of reactions, wherein the plurality of reactants and plurality of reactions are a selection of reactants and reactions as shown in Table 1-9 for a Chinese hamster ovary (CHO) cell; providing a constraint set for the plurality of reactions for the data structure; and determining at least one flux distribution that minimizes or maximizes an objective function when the constraint set is applied to the data structure, wherein the at least one flux distribution is predictive of a physiological function of the CHO cell.


As used herein, a “selection of reactants and reactions” when used with reference to a model of the invention means that a suitable number of the reactions and reactants, including up to all the reactions and reactants, can be selected from a list of reactions for use of the model. For example, any and up to all the reactions as shown in Tables 1-9 can be a selection of reactants and reactions, so long as the selected reactions are sufficient to provide an in silico model suitable for a desired purpose, such as those disclosed herein. It is understood that, if desired, a selection of reactions can include a net reaction between more than one of the individual reactions shown in Tables 1-9. For example, if reaction 1 converts substrate A to product B, and reaction 2 converts substrate B to product C, a net reaction of the conversion of substrate A to product C can be used in the selection of reactions and reactants for use of a model of the invention. One skilled in the art will recognize that such a net reaction conserves stoichiometry between the conversion of A to B to C or A to C and will therefore satisfy the requirements for utilizing the model. In a particular embodiment, the invention provides a model of a CHO cell with all the reactions of Table 1-9, either individually as shown in Tables 1-9 or with one or more net reactions, as discussed above.


The reactants to be used in a reaction network data structure of the invention can be obtained from or stored in a compound database. As used herein, the term “compound database” is intended to mean a computer readable medium or media containing a plurality of molecules that includes substrates and products of biological reactions. The plurality of molecules can include molecules found in multiple organisms or cell types, thereby constituting a universal compound database. Alternatively, the plurality of molecules can be limited to those that occur in a particular organism or cell type, thereby constituting an organism-specific or cell type-specific compound database. Each reactant in a compound database can be identified according to the chemical species and the cellular compartment in which it is present. Thus, for example, a distinction can be made between glucose in the extracellular compartment versus glucose in the cytosol. Additionally each of the reactants can be specified as a metabolite of a primary or secondary metabolic pathway. Although identification of a reactant as a metabolite of a primary or secondary metabolic pathway does not indicate any chemical distinction between the reactants in a reaction, such a designation can assist in visual representations of large networks of reactions.


As used herein, the term “compartment” is intended to mean a subdivided region containing at least one reactant, such that the reactant is separated from at least one other reactant in a second region. A subdivided region included in the term can be correlated with a subdivided region of a cell. Thus, a subdivided region included in the term can be, for example, the intracellular space of a cell; the extracellular space around a cell; the interior space of an organelle such as a mitochondrium, endoplasmic reticulum, Golgi apparatus, vacuole or nucleus; or any subcellular space that is separated from another by a membrane or other physical barrier. For example, a mitochondrial compartment is a subdivided region of the intracellular space of a cell, which in turn, is a subdivided region of a cell or tissue. A subdivided region also can include, for example, different regions or systems of a tissue, organ or physiological system of an organism. Subdivided regions can also be made in order to create virtual boundaries in a reaction network that are not correlated with physical barriers. Virtual boundaries can be made for the purpose of segmenting the reactions in a network into different compartments or substructures.


As used herein, the term “substructure” is intended to mean a portion of the information in a data structure that is separated from other information in the data structure such that the portion of information can be separately manipulated or analyzed. The term can include portions subdivided according to a biological function including, for example, information relevant to a particular metabolic pathway such as an internal flux pathway, exchange flux pathway, central metabolic pathway, peripheral metabolic pathway, or secondary metabolic pathway. The term can include portions subdivided according to computational or mathematical principles that allow for a particular type of analysis or manipulation of the data structure.


The reactions included in a reaction network data structure can be obtained from a metabolic reaction database that includes the substrates, products, and stoichiometry of a plurality of metabolic reactions of a cell line that exhibit biochemical or physiological interactions. The reactants in a reaction network data structure can be designated as either substrates or products of a particular reaction, each with a stoichiometric coefficient assigned to it to describe the chemical conversion taking place in the reaction. Each reaction is also described as occurring in either a reversible or irreversible direction. Reversible reactions can either be represented as one reaction that operates in both the forward and reverse direction or be decomposed into two irreversible reactions, one corresponding to the forward reaction and the other corresponding to the backward reaction.


Reactions included in a reaction network data structure can include intra-system or exchange reactions. Intra-system reactions are the chemically and electrically balanced interconversions of chemical species and transport processes, which serve to replenish or drain the relative amounts of certain metabolites. These intra-system reactions can be classified as either being transformations or translocations. A transformation is a reaction that contains distinct sets of compounds as substrates and products, while a translocation contains reactants located in different compartments. Thus a reaction that simply transports a metabolite from the extracellular environment to the cytosol, without changing its chemical composition is solely classified as a translocation, while a reaction that takes an extracellular substrate and converts it into a cytosolic product is both a translocation and a transformation. Further, intra-system reactions can include reactions representing one or more biochemical or physiological functions of an independent cell, tissue, organ or physiological system. An “extracellular exchange reaction” as used herein refers in particular to those reactions that traverse the cell membrane and exchange substrates and products between the extracellular environment and intracellular environment of a cell. Such extracellular exchange reactions include, for example, translocation and transformation reactions between the extracellular environment and intracellular environment of a cell.


Exchange reactions are those which constitute sources and sinks, allowing the passage of metabolites into and out of a compartment or across a hypothetical system boundary. These reactions are included in a model for simulation purposes and represent the metabolic demands placed a cell. While they may be chemically balanced in certain cases, they are typically not balanced and can often have only a single substrate or product. As a matter of convention the exchange reactions are further classified into demand exchange and input/output exchange reactions.


The metabolic demands placed on a cell metabolic reaction network can be readily determined from the dry weight composition of the cell, which is available in the published literature or which can be determined experimentally. The uptake rates and maintenance requirements for a cell line can also be obtained from the published literature or determined experimentally.


Input/output exchange reactions are used to allow extracellular reactants to enter or exit the reaction network represented by a model of the invention. For each of the extracellular metabolites a corresponding input/output exchange reaction can be created. These reactions are always reversible with the metabolite indicated as a substrate with a stoichiometric coefficient of one and no products produced by the reaction. This particular convention is adopted to allow the reaction to take on a positive flux value (activity level) when the metabolite is being produced or removed from the reaction network and a negative flux value when the metabolite is being consumed or introduced into the reaction network. These reactions will be further constrained during the course of a simulation to specify exactly which metabolites are available to the cell and which can be excreted by the cell.


A demand exchange reaction is always specified as an irreversible reaction containing at least one substrate. These reactions are typically formulated to represent the production of an intracellular metabolite by the metabolic network or the aggregate production of many reactants in balanced ratios such as in the representation of a reaction that leads to biomass formation, also referred to as growth.


A demand exchange reactions can be introduced for any metabolite in a model of the invention. Most commonly these reactions are introduced for metabolites that are required to be produced by the cell for the purposes of creating a new cell such as amino acids, nucleotides, phospholipids, and other biomass constituents, or metabolites that are to be produced for alternative purposes. Once these metabolites are identified, a demand exchange reaction that is irreversible and specifies the metabolite as a substrate with a stoichiometric coefficient of unity can be created. With these specifications, if the reaction is active it leads to the net production of the metabolite by the system meeting potential production demands. Examples of processes that can be represented as a demand exchange reaction in a reaction network data structure and analyzed by the methods of the invention include, for example, production or secretion of an individual protein; production or secretion of an individual metabolite such as an amino acid, vitamin, nucleoside, antibiotic or surfactant; production of ATP for extraneous energy requiring processes such as locomotion or muscle contraction; or formation of biomass constituents.


In addition to these demand exchange reactions that are placed on individual metabolites, demand exchange reactions that utilize multiple metabolites in defined stoichiometric ratios can be introduced. These reactions are referred to as aggregate demand exchange reactions. An example of an aggregate demand reaction is a reaction used to simulate the concurrent growth demands or production requirements associated with cell growth that are placed on a cell, for example, by simulating the formation of multiple biomass constituents simultaneously at a particular cellular growth rate.


Constraint-based modeling can be used to model and predict cellular behavior in reconstructed networks. In order to analyze, interpret, and predict cellular behavior using approaches other than the constraint-based modeling approach, each individual step in a biochemical network is described, normally with a rate equation that requires a number of kinetic constants. However, it is currently not possible to formulate this level of description of cellular processes on a genome scale. The kinetic parameters cannot be estimated from the genome sequence, and these parameters are not available in the literature in the abundance required for accurate modeling. In the absence of kinetic information, it is still possible to assess the capabilities and performance of integrated cellular processes and incorporate data that can be used to constrain these capabilities.


To accomplish suitable modeling, a constraint-based approach for modeling can be implemented. Rather than attempting to calculate and predict exactly what a metabolic network does, the range of possible phenotypes that a metabolic system can display is narrowed based on the successive imposition of governing physico-chemical constraints (Palsson, Nat. Biotechnol. 18:1147-1150 (2000)). Thus, instead of calculating an exact phenotypic solution, that is, exactly how the cell behaves under given genetic and environmental conditions, the feasible set of phenotypic solutions in which the cell can operate is determined (FIG. 1).


Such a constraint-based approach provides a basis for understanding the structure and function of biochemical networks through an incremental process. This incremental refinement presently occurs in the following four steps, each of which involves consideration of fundamentally different constraints: (1) the imposition of stoichiometric constraints that represent flux balances; (2) the utilization of limited thermodynamic constraints to restrict the directional flow through enzymatic reactions; (3) the addition of capacity constraints to account for the maximum flux through individual reactions; and (4) the imposition of regulatory constraints, where available.


Each step provides increasing amounts of information that can be used to further reduce the range of feasible flux distributions and phenotypes that a metabolic network can display. Each of these constraints can be described mathematically, offering a concise geometric interpretation of the effects that each successive constraint places on metabolic function (FIG. 1). In combination with linear programming, constraint-based modeling has been used to represent probable physiological functions such as biomass and ATP production. Constraint-based modeling approaches have been reviewed in detail (Schilling et al., Biotechnol. Prog. 15:288-295 (1999); Varma and Palsson, Bio/Technology 12:994-998 (1994); Edwards et al., Environ. Microbiol. 4:133-140 (2002); Price et al., Nat. Rev. Microbiol. 2:886-897 (2004)).


Transient flux balance analysis can also be used. A number of computational modeling methods have been developed based on the basic premise of the constraint-based approach, including the transient flux balance analysis (Varma and Palsson, Appl. Environ. Microbiol. 60:3724-3731 (1994); Price et al., Nat. Rev. Microbiol. 2:886-897 (2004)). Transient flux balance analysis is a well-established approach for computing the time profile of consumed and secreted metabolites in a bioreactor, predicted based on the computed values from a steady state constraint-based metabolic model (Covert et al., J. Theor. Biol. 213:73-88 (2001)); Varma and Palsson, Appl. Environ. Microbiol. 60:3724-3731 (1994); Covert and Palsson, J. Biol. Chem. 277:28058-28064 (2002)). This approach has been successfully used to predict growth and metabolic byproduct secretion in wild-type E. coli in aerobic and anaerobic batch and fed-batch bioreactors (FIG. 2), and to improve the predictability of the metabolic models using transcriptional regulatory constraints (Varma and Palsson, supra, 2004; Covert and Palsson, supra, 2002).


Briefly, a time profile of metabolite concentrations is calculated by the transient flux balance analysis in an iterative two-step process, where: (1) uptake and secretion rate of metabolites are determined using a metabolic network and linear optimization, and (2) the metabolite concentrations in the bioreactor are calculated using the dynamic mass balance equation (FIG. 3). A set of uptake rates of nutrients can be used to constrain the flux balance calculation in the metabolic network. Using linear optimization, an intracellular flux distribution is calculated and metabolite secretion rates are determined in the metabolic network. The calculated secretion rates are then used to determine the concentration of metabolites in the bioreactor media using the standard dynamic mass balance equations,






S−S
o
=q
s
∫X
v
dt  Equation (1),


where S is a consumed nutrient or produced metabolite concentration, So is the initial or previous time point metabolite concentration, and Xv is the viable cell concentration. Cell specific growth rate is computed using standard growth equation,






X
v
=X
v,o
e
μt  Equation (2),


where Xv,o is the initial cell concentration and μ is cell specific growth rate. This procedure is repeated in small arbitrary time intervals for the duration of bioreactor or cell culture experiment from which a time profile of metabolite and cell concentration can be graphically displayed (see, for example, FIG. 2). Transient analysis can thus estimate the time profile of the metabolite concentrations and determine the duration of the cell culture, that is, when the cells run out of nutrients and growth of the cell culture ceases.


The SimPheny™ method or similar modeling method can also be used (see U.S. publication 20030233218). Exemplary modeling methods are also described in U.S. publications 2004/0029149 and 2006/0147899. Improving the efficiency of biological discovery and delivering on the potential of model-driven systems biology requires the development of a computational infrastructure to support collaborative model development, simulation, and data integration/management. In addition, such a high performance-computing platform should embrace the iterative nature of modeling and simulation to allow the value of a model to increase in time as more information is incorporated. One such modeling method is called SimPheny™, short for Simulating Phenotypes, which allows the integration of simulation based systems biology for solving complex biological problems (FIG. 4). SimPheny™ was developed to support multi-user research in concentrated or distributed environments to allow effective collaboration. It serves as the basis for a model-centric approach to biological discovery. The SimPheny™ method has been described previously (see U.S. publication 2003/0233218; WO03106998).


The SimPheny™ method allows the modeling of biochemical reaction networks and metabolism in organism-specific models. The platform supports the development of metabolic models, all of the necessary simulation activities, and the capability to integrate various experimental data. The system is divided into a number of discrete modules to support various activities associated with modeling and simulation. The modules include: (1) universal data, (2) model development, (3) atlas design, (4) simulation, (5) content mining, (6) experimental data analysis, and (7) pathway predictor.


Each of these modules encapsulates activities that are crucial to supporting the iterative model development process. They are all fully integrated with each other so that information created in one module can be utilized where appropriate in other modules. Within the universal data module, all of the data concerning chemical compounds, reactions, and organisms is maintained, providing the underlying information required for constructing cellular models. The model-development module is used to create a model and assign all the appropriate reactions to a model along with specifying any related information such as the genetic associations (FIG. 5) and reference information related to the reaction in the model and the model in general. The atlas design module is used to design metabolic maps and organize them into collections or maps (an atlas). Models are used to simulate the phenotypic behavior of an organism under changing genetic circumstances and environmental conditions. These simulations are performed within the simulation module that enables the use of optimization strategies to calculate cellular behavior. In addition to calculated simulation results, this module allows for the viewing of results in a wide variety of contexts. In order to browse and mine the biological content of all the models and associated genomics for the model organisms, a separate module for data mining can be used. Thus, SimPheny™ represents an exemplary tool that provides the power of modeling and simulation within a systems biology research strategy.


The representation of a reaction network with a set of linear algebraic equations presented as a stoichiometric matrix has been described (U.S. publication 2006/0147899). A reaction network can be represented as a set of linear algebraic equations which can be presented as a stoichiometric matrix S, with S being an m×n matrix where m corresponds to the number of reactants or metabolites and n corresponds to the number of reactions taking place in the network. Each column in the matrix corresponds to a particular reaction n, each row corresponds to a particular reactant m, and each Smn element corresponds to the stoichiometric coefficient of the reactant m in the reaction denoted n. The stoichiometric matrix can include intra-system reactions which are related to reactants that participate in the respective reactions according to a stoichiometric coefficient having a sign indicative of whether the reactant is a substrate or product of the reaction and a value correlated with the number of equivalents of the reactant consumed or produced by the reaction. Exchange reactions are similarly correlated with a stoichiometric coefficient. The same compound can be treated separately as an internal reactant and an external reactant such that an exchange reaction exporting the compound is correlated by stoichiometric coefficients of −1 and 1, respectively. However, because the compound is treated as a separate reactant by virtue of its compartmental location, a reaction which produces the internal reactant but does not act on the external reactant is correlated by stoichiometric coefficients of 1 and 0, respectively. Demand reactions such as growth can also be included in the stoichiometric matrix being correlated with substrates by an appropriate stoichiometric coefficient.


As disclosed herein, a stoichiometric matrix provides a convenient format for representing and analyzing a reaction network because it can be readily manipulated and used to compute network properties, for example, by using linear programming or general convex analysis. A reaction network data structure can take on a variety of formats so long as it is capable of relating reactants and reactions in the manner exemplified herein for a stoichiometric matrix and in a manner that can be manipulated to determine an activity of one or more reactions using methods such as those exemplified herein. Other examples of reaction network data structures that are useful in the invention include a connected graph, list of chemical reactions or a table of reaction equations.


A reaction network data structure can be constructed to include all reactions that are involved in metabolism occurring in a cell line or any portion thereof. A portion of an cell's metabolic reactions that can be included in a reaction network data structure of the invention includes, for example, a central metabolic pathway such as glycolysis, the TCA cycle, the PPP or ETS; or a peripheral metabolic pathway such as amino acid biosynthesis, amino acid degradation, purine biosynthesis, pyrimidine biosynthesis, lipid biosynthesis, fatty acid metabolism, vitamin or cofactor biosynthesis, transport processes and alternative carbon source catabolism. Examples of individual pathways are described in the Examples. Other examples of portions of metabolic reactions that can be included in a reaction network data structure of the invention include, for example, TAG biosynthesis, muscle contraction requirements, bicarbonate buffer system and/or ammonia buffer system. Specific examples of these and other reactions are described further below and in the Examples. Depending upon a particular application, a reaction network data structure can include a plurality of reactions including any or all of the reactions known in a cell or organism.


For some applications, it can be advantageous to use a reaction network data structure that includes a minimal number of reactions to achieve a particular activity under a particular set of environmental conditions. A reaction network data structure having a minimal number of reactions can be identified by performing the simulation methods described below in an iterative fashion where different reactions or sets of reactions are systematically removed and the effects observed. Accordingly, the invention provides a computer readable medium, containing a data structure relating a plurality of reactants to a plurality of reactions.


Depending upon the particular cell type, the physiological conditions being tested, and the desired activity of a model or method of the invention, a reaction network data structure can contain smaller numbers of reactions such as at least 200, 150, 100 or 50 reactions. A reaction network data structure having relatively few reactions can provide the advantage of reducing computation time and resources required to perform a simulation. When desired, a reaction network data structure having a particular subset of reactions can be made or used in which reactions that are not relevant to the particular simulation are omitted. Alternatively, larger numbers of reactions can be included in order to increase the accuracy or molecular detail of the methods of the invention or to suit a particular application. Thus, a reaction network data structure can contain at least 300, 350, 400, 450, 500, 550, 600 or more reactions up to the number of reactions that occur in a cell or organism or that are desired to simulate the activity of the full set of reactions occurring in a cell or organism. A reaction network data structure that is substantially complete with respect to the metabolic reactions of a cell or organism provides an advantage of being relevant to a wide range of conditions to be simulated, whereas those with smaller numbers of metabolic reactions are specific to a particular subset of conditions to be simulated.


A reaction network data structure can include one or more reactions that occur in or by a cell or organism and that do not occur, either naturally or following manipulation, in or by another organism, such as CHO cells. It is understood that a reaction network data structure of a particular cell type can also include one or more reactions that occur in another cell type. Addition of such heterologous reactions to a reaction network data structure of the invention can be used in methods to predict the consequences of heterologous gene transfer and protein expression.


The reactions included in a reaction network data structure of the invention can be metabolic reactions. A reaction network data structure can also be constructed to include other types of reactions such as regulatory reactions, signal transduction reactions, cell cycle reactions, reactions involved in apoptosis, reactions involved in responses to hypoxia, reactions involved in responses to cell-cell or cell-substrate interactions, reactions involved in protein synthesis and regulation thereof, reactions involved in gene transcription and translation, and regulation thereof, and reactions involved in assembly of a cell and its subcellular components.


A reaction network data structure or index of reactions used in the data structure such as that available in a metabolic reaction database, as described above, can be annotated to include information about a particular reaction. A reaction can be annotated to indicate, for example, assignment of the reaction to a protein, macromolecule or enzyme that performs the reaction, assignment of a gene(s) that codes for the protein, macromolecule or enzyme, the Enzyme Commission (EC) number of the particular metabolic reaction, a subset of reactions to which the reaction belongs, citations to references from which information was obtained, or a level of confidence with which a reaction is believed to occur in a cell or organism. A computer readable medium or media of the invention can include a gene database containing annotated reactions. Such information can be obtained during the course of building a metabolic reaction database or model of the invention as described below.


As used herein, the term “gene database” is intended to mean a computer readable medium or media that contains at least one reaction that is annotated to assign a reaction to one or more macromolecules that perform the reaction or to assign one or more nucleic acid that encodes the one or more macromolecules that perform the reaction. A gene database can contain a plurality of reactions, some or all of which are annotated. An annotation can include, for example, a name for a macromolecule; assignment of a function to a macromolecule; assignment of an organism that contains the macromolecule or produces the macromolecule; assignment of a subcellular location for the macromolecule; assignment of conditions under which a macromolecule is regulated with respect to performing a reaction, being expressed or being degraded; assignment of a cellular component that regulates a macromolecule; an amino acid or nucleotide sequence for the macromolecule; an mRNA isoform, enzyme isoform, or any other desirable annotation or annotation found for a macromolecule in a genome database such as those that can be found in Genbank, a site maintained by the NCBI (ncbi.nlm.gov), the Kyoto Encyclopedia of Genes and Genomes (KEGG) (www.genome.ad.jp/kegg/), the protein database SWISS-PROT (ca.expasy.org/sprot/), the LocusLink database maintained by the NCBI (www.ncbi.nlm.nih.gov/LocusLink/), the Enzyme Nomenclature database maintained by G. P. Moss of Queen Mary and Westfield College in the United Kingdom (www.chem.qmw.ac.uk/iubmb/enzyme/).


A gene database of the invention can include a substantially complete collection of genes or open reading frames in a cell or organism, substantially complete collection of the macromolecules encoded by the cell's or organism's genome. Alternatively, a gene database can include a portion of genes or open reading frames in an organism or a portion of the macromolecules encoded by the organism's genome, such as the portion that includes substantially all metabolic genes or macromolecules. The portion can be at least 10%, 15%, 20%, 25%, 50%, 75%, 90% or 95% of the genes or open reading frames encoded by the organism's genome, or the macromolecules encoded therein. A gene database can also include macromolecules encoded by at least a portion of the nucleotide sequence for the organism's genome such as at least 10%, 15%, 20%, 25%, 50%, 75%, 90% or 95% of the organism's genome. Accordingly, a computer readable medium or media of the invention can include at least one reaction for each macromolecule encoded by a portion of a cell or organism's genome.


An in silico model of cell of the invention can be built by an iterative process which includes gathering information regarding particular reactions to be added to a model, representing the reactions in a reaction network data structure, and performing preliminary simulations wherein a set of constraints is placed on the reaction network and the output evaluated to identify errors in the network. Errors in the network such as gaps that lead to non-natural accumulation or consumption of a particular metabolite can be identified as described below and simulations repeated until a desired performance of the model is attained. Combination of the central metabolism and the cell specific reaction networks into a single model produces, for example, a cell specific reaction network.


Information to be included in a data structure of the invention can be gathered from a variety of sources including, for example, annotated genome sequence information and biochemical literature. Sources of annotated human genome sequence information include, for example, KEGG, SWISS-PROT, LocusLink, the Enzyme Nomenclature database, the International Human Genome Sequencing Consortium and commercial databases. KEGG contains a broad range of information, including a substantial amount of metabolic reconstruction. The genomes of 304 organisms can be accessed here, with gene products grouped by coordinated functions, often represented by a map (e.g., the enzymes involved in glycolysis would be grouped together). The maps are biochemical pathway templates which show enzymes connecting metabolites for various parts of metabolism. These general pathway templates are customized for a given organism by highlighting enzymes on a given template which have been identified in the genome of the organism. Enzymes and metabolites are active and yield useful information about stoichiometry, structure, alternative names and the like, when accessed.


SWISS-PROT contains detailed information about protein function. Accessible information includes alternate gene and gene product names, function, structure and sequence information, relevant literature references, and the like. LocusLink contains general information about the locus where the gene is located and, of relevance, tissue specificity, cellular location, and implication of the gene product in various disease states.


The Enzyme Nomenclature database can be used to compare the gene products of two organisms. Often the gene names for genes with similar functions in two or more organisms are unrelated. When this is the case, the E.C. (Enzyme Commission) numbers can be used as unambiguous indicators of gene product function. The information in the Enzyme Nomenclature database is also published in Enzyme Nomenclature (Academic Press, San Diego, Calif., 1992) with 5 supplements to date, all found in the European Journal of Biochemistry (Blackwell Science, Malden, Mass.).


Sources of biochemical information include, for example, general resources relating to metabolism, resources relating specifically to a particular cell's or organism's metabolism, and resources relating to the biochemistry, physiology and pathology of specific cell types.


Sources of general information relating to metabolism, which can be used to generate human reaction databases and models, include J. G. Salway, Metabolism at a Glance, 2nd ed., Blackwell Science, Malden, Mass. (1999) and T. M. Devlin, ed., Textbook of Biochemistry with Clinical Correlations, 4th ed., John Wiley and Sons, New York, N.Y. (1997). Human metabolism-specific resources include J. R. Bronk, Human Metabolism: Functional Diversity and Integration, Addison Wesley Longman, Essex, England (1999).


In the course of developing an in silico model of metabolism, the types of data that can be considered include, for example, biochemical information which is information related to the experimental characterization of a chemical reaction, often directly indicating a protein(s) associated with a reaction and the stoichiometry of the reaction or indirectly demonstrating the existence of a reaction occurring within a cellular extract; genetic information, which is information related to the experimental identification and genetic characterization of a gene(s) shown to code for a particular protein(s) implicated in carrying out a biochemical event; genomic information, which is information related to the identification of an open reading frame and functional assignment, through computational sequence analysis, that is then linked to a protein performing a biochemical event; physiological information, which is information related to overall cellular physiology, fitness characteristics, substrate utilization, and phenotyping results, which provide evidence of the assimilation or dissimilation of a compound used to infer the presence of specific biochemical event (in particular translocations); and modeling information, which is information generated through the course of simulating activity of cells, tissues or physiological systems using methods such as those described herein which lead to predictions regarding the status of a reaction such as whether or not the reaction is required to fulfill certain demands placed on a metabolic network. Additional information that can be considered includes, for example, cell type-specific or condition-specific gene expression information, which can be determined experimentally, such as by gene array analysis or from expressed sequence tag (EST) analysis, or obtained from the biochemical and physiological literature.


The majority of the reactions occurring in a cell's or organism's reaction networks are catalyzed by enzymes/proteins, which are created through the transcription and translation of the genes found within the chromosome in the cell. The remaining reactions occur either spontaneously or through non-enzymatic processes. Furthermore, a reaction network data structure can contain reactions that add or delete steps to or from a particular reaction pathway. For example, reactions can be added to optimize or improve performance of a model for multicellular interactions in view of empirically observed activity. Alternatively, reactions can be deleted to remove intermediate steps in a pathway when the intermediate steps are not necessary to model flux through the pathway. For example, if a pathway contains 3 nonbranched steps, the reactions can be combined or added together to give a net reaction, thereby reducing memory required to store the reaction network data structure and the computational resources required for manipulation of the data structure.


The reactions that occur due to the activity of gene-encoded enzymes can be obtained from a genome database which lists genes identified from genome sequencing and subsequent genome annotation. Genome annotation consists of the locations of open reading frames and assignment of function from homology to other known genes or empirically determined activity. Such a genome database can be acquired through public or private databases containing annotated nucleic acid or protein sequences, including sequences from CHO cells. If desired, a model developer can perform a network reconstruction and establish the model content associations between the genes, proteins, and reactions as described, for example, in Covert et al. Trends in Biochemical Sciences 26:179-186 (2001) and Palsson, WO 00/46405.


As reactions are added to a reaction network data structure or metabolic reaction database, those having known or putative associations to the proteins/enzymes which allow/catalyze the reaction and the associated genes that code for these proteins can be identified by annotation. Accordingly, the appropriate associations for all of the reactions to their related proteins or genes or both can be assigned. These associations can be used to capture the non-linear relationship between the genes and proteins as well as between proteins and reactions. In some cases one gene codes for one protein which then perform one reaction. However, often there are multiple genes which are required to create an active enzyme complex and often there are multiple reactions that can be carried out by one protein or multiple proteins that can carry out the same reaction. These associations capture the logic (i.e. AND or OR relationships) within the associations Annotating a metabolic reaction database with these associations can allow the methods to be used to determine the effects of adding or eliminating a particular reaction not only at the reaction level, but at the genetic or protein level in the context of running a simulation or predicting an activity.


A reaction network data structure of the invention can be used to determine the activity of one or more reactions in a plurality of reactions occurring in a cell independent of any knowledge or annotation of the identity of the protein that performs the reaction or the gene encoding the protein. A model that is annotated with gene or protein identities can include reactions for which a protein or encoding gene is not assigned. While a large portion of the reactions in a cellular metabolic network are associated with genes in the organism's genome, there are also a substantial number of reactions included in a model for which there are no known genetic associations. Such reactions can be added to a reaction database based upon other information that is not necessarily related to genetics such as biochemical or cell based measurements or theoretical considerations based on observed biochemical or cellular activity. For example, there are many reactions that can either occur spontaneously or are not protein-enabled reactions. Furthermore, the occurrence of a particular reaction in a cell for which no associated proteins or genetics have been currently identified can be indicated during the course of model building by the iterative model building methods of the invention.


The reactions in a reaction network data structure or reaction database can be assigned to subsystems by annotation, if desired. The reactions can be subdivided according to biological criteria, such as according to traditionally identified metabolic pathways (glycolysis, amino acid metabolism and the like) or according to mathematical or computational criteria that facilitate manipulation of a model that incorporates or manipulates the reactions. Methods and criteria for subdviding a reaction database are described in further detail in Schilling et al., J. Theor. Biol. 203:249-283 (2000), and in Schuster et al., Bioinformatics 18:351-361 (2002). The use of subsystems can be advantageous for a number of analysis methods, such as extreme pathway analysis, and can make the management of model content easier. Although assigning reactions to subsystems can be achieved without affecting the use of the entire model for simulation, assigning reactions to subsystems can allow a user to search for reactions in a particular subsystem which may be useful in performing various types of analyses. Therefore, a reaction network data structure can include any number of desired subsystems including, for example, 2 or more subsystems, 5 or more subsystems, 10 or more subsystems, 25 or more subsystems or 50 or more subsystems.


The reactions in a reaction network data structure or metabolic reaction database can be annotated with a value indicating the confidence with which the reaction is believed to occur in a cell or organism. The level of confidence can be, for example, a function of the amount and form of supporting data that is available. This data can come in various forms including published literature, documented experimental results, or results of computational analyses. Furthermore, the data can provide direct or indirect evidence for the existence of a chemical reaction in a cell based on genetic, biochemical, and/or physiological data.


Constraints can be placed on the value of any of the fluxes in the metabolic network using a constraint set. These constraints can be representative of a minimum or maximum allowable flux through a given reaction, possibly resulting from a limited amount of an enzyme present. Additionally, the constraints can determine the direction or reversibility of any of the reactions or transport fluxes in the reaction network data structure. Based on the in vivo environment where multiple cells interact, such as in a human organism, the metabolic resources available to the cell for biosynthesis of essential molecules can be determined.


As described previously (see U.S. publication 2006/014789), for a reaction network, constraints can be placed on each reaction, with the constraints provided in a format that can be used to constrain the reactions of a stoichiometric matrix. The format for the constraints used for a matrix or in linear programming can be conveniently represented as a linear inequality such as






bj≦vj≦aj: j=1 . . . n  (Eq. 3)


where vj is the metabolic flux vector, bj is the minimum flux value and aj is the maximum flux value. Thus, aj can take on a finite value representing a maximum allowable flux through a given reaction or bj can take on a finite value representing minimum allowable flux through a given reaction. Additionally, if one chooses to leave certain reversible reactions or transport fluxes to operate in a forward and reverse manner the flux may remain unconstrained by setting bj to negative infinity and aj to positive infinity. If reactions proceed only in the forward reaction, bj is set to zero while aj is set to positive infinity. As an example, to simulate the event of a genetic deletion or non-expression of a particular protein, the flux through all of the corresponding metabolic reactions related to the gene or protein in question are reduced to zero by setting aj and bj to be zero. Furthermore, if one wishes to simulate the absence of a particular growth substrate one can simply constrain the corresponding transport fluxes that allow the metabolite to enter the cell to be zero by setting aj and bj to be zero. On the other hand, if a substrate is only allowed to enter or exit the cell via transport mechanisms, the corresponding fluxes can be properly constrained to reflect this scenario.


The ability of a reaction to be actively occurring is dependent on a large number of additional factors beyond just the availability of substrates. These factors, which can be represented as variable constraints in the models and methods of the invention include, for example, the presence of cofactors necessary to stabilize the protein/enzyme, the presence or absence of enzymatic inhibition and activation factors, the active formation of the protein/enzyme through translation of the corresponding mRNA transcript, the transcription of the associated gene(s) or the presence of chemical signals and/or proteins that assist in controlling these processes that ultimately determine whether a chemical reaction is capable of being carried out within an organism. Regulation can be represented in an in silico model by providing a variable constraint as set forth below.


As used herein, the term “regulated,” when used in reference to a reaction in a data structure, is intended to mean a reaction that experiences an altered flux due to a change in the value of a constraint or a reaction that has a variable constraint.


As used herein, the term “regulatory reaction” is intended to mean a chemical conversion or interaction that alters the activity of a protein, macromolecule or enzyme. A chemical conversion or interaction can directly alter the activity of a protein, macromolecule or enzyme such as occurs when the protein, macromolecule or enzyme is post-translationally modified or can indirectly alter the activity of a protein, macromolecule or enzyme such as occurs when a chemical conversion or binding event leads to altered expression of the protein, macromolecule or enzyme. Thus, transcriptional or translational regulatory pathways can indirectly alter a protein, macromolecule or enzyme or an associated reaction. Similarly, indirect regulatory reactions can include reactions that occur due to downstream components or participants in a regulatory reaction network. When used in reference to a data structure or in silico model, for example, the term is intended to mean a first reaction that is related to a second reaction by a function that alters the flux through the second reaction by changing the value of a constraint on the second reaction.


As used herein, the term “regulatory data structure” is intended to mean a representation of an event, reaction or network of reactions that activate or inhibit a reaction, the representation being in a format that can be manipulated or analyzed. An event that activates a reaction can be an event that initiates the reaction or an event that increases the rate or level of activity for the reaction. An event that inhibits a reaction can be an event that stops the reaction or an event that decreases the rate or level of activity for the reaction. Reactions that can be represented in a regulatory data structure include, for example, reactions that control expression of a macromolecule that in turn, performs a reaction such as transcription and translation reactions, reactions that lead to post translational modification of a protein or enzyme such as phosphorylation, dephosphorylation, prenylation, methylation, oxidation or covalent modification, reactions that process a protein or enzyme such as removal of a pre- or pro-sequence, reactions that degrade a protein or enzyme or reactions that lead to assembly of a protein or enzyme.


As used herein, the term “regulatory event” is intended to mean a modifier of the flux through a reaction that is independent of the amount of reactants available to the reaction. A modification included in the term can be a change in the presence, absence, or amount of an enzyme that performs a reaction. A modifier included in the term can be a regulatory reaction such as a signal transduction reaction or an environmental condition such as a change in pH, temperature, redox potential or time. It will be understood that when used in reference to a model or data structure of the invention, a regulatory event is intended to be a representation of a modifier of the flux through reaction that is independent of the amount of reactants available to the reaction.


The effects of regulation on one or more reactions that occur in a cell can be predicted using an in silico cell model of the invention. Regulation can be taken into consideration in the context of a particular condition being examined by providing a variable constraint for the reaction in an in silico model. Such constraints constitute condition-dependent constraints. A data structure can represent regulatory reactions as Boolean logic statements (Reg-reaction). The variable takes on a value of 1 when the reaction is available for use in the reaction network and will take on a value of 0 if the reaction is restrained due to some regulatory feature. A series of Boolean statements can then be introduced to mathematically represent the regulatory network as described for example in Covert et al. J. Theor. Biol. 213:73-88 (2001). For example, in the case of a transport reaction (A_in) that imports metabolite A, where metabolite A inhibits reaction R2, a Boolean rule can state that:





Reg-R2=IF NOT(A_in).  (Eq. 4)


This statement indicates that reaction R2 can occur if reaction A_in is not occurring (i.e. if metabolite A is not present). Similarly, it is possible to assign the regulation to a variable A which would indicate an amount of A above or below a threshold that leads to the inhibition of reaction R2. Any function that provides values for variables corresponding to each of the reactions in the biochemical reaction network can be used to represent a regulatory reaction or set of regulatory reactions in a regulatory data structure. Such functions can include, for example, fuzzy logic, heuristic rule-based descriptions, differential equations or kinetic equations detailing system dynamics.


A reaction constraint placed on a reaction can be incorporated into an in silico model using the following general equation:





(Reg-Reaction)*bj≦vj≦aj*(Reg-Reaction),∀j=1 . . . n  (Eq. 5)


For the example of reaction R2 this equation is written as follows:





(0)*Reg-R2≦R2≦(∞)*Reg-R2.  (Eq. 6)


Thus, during the course of a simulation, depending upon the presence or absence of metabolite A in the interior of the cell where reaction R2 occurs, the value for the upper boundary of flux for reaction R2 will change from 0 to infinity, respectively. With the effects of a regulatory event or network taken into consideration by a constraint function and the condition-dependent constraints set to an initial relevant value, the behavior of the reaction network can be simulated for the conditions considered as set forth below.


Although regulation has been exemplified above for the case where a variable constraint is dependent upon the outcome of a reaction in the data structure, a plurality of variable constraints can be included in an in silico model to represent regulation of a plurality of reactions. Furthermore, in the exemplary case set forth above, the regulatory structure includes a general control stating that a reaction is inhibited by a particular environmental condition. Using a general control of this type, it is possible to incorporate molecular mechanisms and additional detail into the regulatory structure that is responsible for determining the active nature of a particular chemical reaction within an organism.


Regulation can also be simulated by a model of the invention and used to predict a physiological function of a cell without knowledge of the precise molecular mechanisms involved in the reaction network being modeled. Thus, the model can be used to predict, in silico, overall regulatory events or causal relationships that are not apparent from in vivo observation of any one reaction in a network or whose in vivo effects on a particular reaction are not known. Such overall regulatory effects can include those that result from overall environmental conditions such as changes in pH, temperature, redox potential, or the passage of time.


Those of skill in the art will recognize that instructions for the software implementing a method and model of the present disclosure can be written in any known computer language, such as Java, C, C++, Visual Basic, FORTRAN or COBOL, and compiled using any compatible compiler; and that the software can run from instructions stored in a memory or computer-readable medium on a computing system.


A computing system can be a single computer executing the instructions or a plurality of computers in a distributed computing network executing parts of the instructions sequentially or in parallel. The single computer or one of the plurality of computers can comprise a single processor (for example, a microprocessor or digital signal processor) executing assigned instructions or a plurality of processors executing different parts of the assigned instructions sequentially or in parallel. The single computer or one of the plurality of the computers can further comprise one or more of a system unit housing, a video display device, a memory, computational entities such as operating systems, drivers, graphical user interfaces, applications programs, and one or more interaction devices, such as a touch pad or screen. Such interaction devices or graphical user interfaces, and the like, can be used to output a result to a user, including a visual output or data output, as desired.


A memory or computer-readable medium for storing the software implementing a method and model of the present disclosure can be any medium that participates in providing instructions to a processor for execution. Such a medium may take many forms, including, but not limited to, non-volatile media, volatile media, and transmission media. Non-volatile media include, for example, optical or magnetic disks. Volatile media include dynamic memory. Transmission media include coaxial cables, copper wire, and fiber optics. Transmission media can also take the form of acoustic or light waves, such as those generated during radio frequency and infrared data communications. Common forms of machine-readable media include, for example, floppy disk, a flexible disk, hard disk, magnetic tape, any other magnetic medium, a CD-ROM, DVD, any other optical medium, punch cards, paper tape, any other physical medium with patterns of holes, a RAM, a PROM, an EPROM, a FLASH EPROM, any other memory chip or cartridge, or any other medium from which a computer can read. A carrier wave can also be used but is distinct from a computer readable medium or media. Thus, a computer readable medium or media as used herein specifically excludes a carrier wave.


The memory or computer-readable medium can be contained within a single computer or distributed in a network. A network can be any of a number of network systems known in the art such as a Local Area Network (LAN), or a Wide Area Network (WAN). The LAN or WAN can be a wired network (e.g., Ethernet) or a wireless network (e.g., WLAN). Client-server environments, database servers and networks that can be used to implement certain aspects of the present disclosure are well known in the art. For example, database servers can run on an operating system such as UNIX, running a relational database management system, a World Wide Web application and a World Wide Web server. Other types of memories and computer readable media area also contemplated to function within the scope of the present disclosure.


A database or data structure embodying certain aspects or components of the present disclosure can be represented in a markup language format including, for example, Standard Generalized Markup Language (SGML), Hypertext Markup Language (HTML) or Extensible Markup Language (XML). Markup languages can be used to tag the information stored in a database or data structure of the invention, thereby providing convenient annotation and transfer of data between databases and data structures. In particular, an XML format can be useful for structuring the data representation of reactions, reactants, and their annotations; for exchanging database contents, for example, over a network or the Internet; for updating individual elements using the document object model; or for providing different access to multiple users for different information content of a database or data structure embodying certain aspects of the present disclosure. XML programming methods and editors for writing XML codes are known in the art as described, for example, in Ray, “Learning XML” O'Reilly and Associates, Sebastopol, Calif. (2001).


Those of skill in the art would appreciate that the various illustrative blocks, modules, elements, components, methods, and algorithms described herein may be implemented as electronic hardware, computer software, or combinations of both. Furthermore, these may be partitioned differently than what is described. To illustrate this interchangeability of hardware and software, various illustrative blocks, modules, elements, components, methods, and algorithms have been described above generally in terms of their functionality. Whether such functionality is implemented as hardware or software depends upon the particular application and design constraints imposed on the overall system. Skilled artisans can implement the described functionality in varying ways for each particular application.


A set of constraints can be applied to a reaction network data structure to simulate the flux of mass through the reaction network under a particular set of environmental conditions specified by a constraints set. Because the time constants characterizing metabolic transients and/or metabolic reactions are typically very rapid, on the order of milli-seconds to seconds, compared to the time constants of cell growth on the order of hours to days, the transient mass balances can be simplified to only consider the steady state behavior. Referring now to an example where the reaction network data structure is a stoichiometric matrix, the steady state mass balances can be applied using the following system of linear equations






S·v=0  (Eq. 7)


where S is the stoichiometric matrix as defined above and v is the flux vector. This equation defines the mass, energy, and redox potential constraints placed on the metabolic network as a result of stoichiometry. Together Equations 1 and 5 representing the reaction constraints and mass balances, respectively, effectively define the capabilities and constraints of the metabolic genotype and the organism's metabolic potential. All vectors, v, that satisfy Equation 5 are said to occur in the mathematical nullspace of S. Thus, the null space defines steady-state metabolic flux distributions that do not violate the mass, energy, or redox balance constraints. Typically, the number of fluxes is greater than the number of mass balance constraints, thus a plurality of flux distributions satisfy the mass balance constraints and occupy the null space. The null space, which defines the feasible set of metabolic flux distributions, is further reduced in size by applying the reaction constraints set forth in Equation 1 leading to a defined solution space. A point in this space represents a flux distribution and hence a metabolic phenotype for the network. An optimal solution within the set of all solutions can be determined using mathematical optimization methods when provided with a stated objective and a constraint set. The calculation of any solution constitutes a simulation of the model.


Objectives for activity of a cell can be chosen. While the overall objective of a multi-cellular organism may be growth or reproduction, individual human cell types generally have much more complex objectives, even to the seemingly extreme objective of apoptosis (programmed cell death), which may benefit the organism but certainly not the individual cell. For example, certain cell types may have the objective of maximizing energy production, while others have the objective of maximizing the production of a particular hormone, extracellular matrix component, or a mechanical property such as contractile force. In cases where cell reproduction is slow, such as human skeletal muscle, growth and its effects need not be taken into account. In other cases, biomass composition and growth rate could be incorporated into a “maintenance” type of flux, where rather than optimizing for growth, production of precursors is set at a level consistent with experimental knowledge and a different objective is optimized.


Certain cell types, including cancer cells, can be viewed as having an objective of maximizing cell growth. Growth can be defined in terms of biosynthetic requirements based on literature values of biomass composition or experimentally determined values such as those obtained as described above. Thus, biomass generation can be defined as an exchange reaction that removes intermediate metabolites in the appropriate ratios and represented as an objective function. In addition to draining intermediate metabolites this reaction flux can be formed to utilize energy molecules such as ATP, NADH and NADPH so as to incorporate any maintenance requirement that must be met. This new reaction flux then becomes another constraint/balance equation that the system must satisfy as the objective function. Using a stoichiometric matrix as an example, adding such a constraint is analogous to adding an additional column Vgrowth to the stoichiometric matrix to represent fluxes to describe the production demands placed on the metabolic system. Setting this new flux as the objective function and asking the system to maximize the value of this flux for a given set of constraints on all the other fluxes is then a method to simulate the growth of the organism.


Continuing with the example of the stoichiometric matrix applying a constraint set to a reaction network data structure can be illustrated as follows. The solution to equation 5 can be formulated as an optimization problem, in which the flux distribution that minimizes a particular objective is found. Mathematically, this optimization problem can be stated as:





Minimize Z  (Eq. 8)





where z=Σci·vi  (Eq. 9)


where Z is the objective which is represented as a linear combination of metabolic fluxes vi using the weights ci in this linear combination. The optimization problem can also be stated as the equivalent maximization problem; i.e. by changing the sign on Z. Any commands for solving the optimazation problem can be used including, for example, linear programming commands.


A computer system of the invention can further include a user interface capable of receiving a representation of one or more reactions. A user interface of the invention can also be capable of sending at least one command for modifying the data structure, the constraint set or the commands for applying the constraint set to the data representation, or a combination thereof. The interface can be a graphic user interface having graphical means for making selections such as menus or dialog boxes. The interface can be arranged with layered screens accessible by making selections from a main screen. The user interface can provide access to other databases useful in the invention such as a metabolic reaction database or links to other databases having information relevant to the reactions or reactants in the reaction network data structure or to a cell's physiology. Also, the user interface can display a graphical representation of a reaction network or the results of a simulation using a model of the invention.


Once an initial reaction network data structure and set of constraints has been created, this model can be tested by preliminary simulation. During preliminary simulation, gaps in the network or “dead-ends” in which a metabolite can be produced but not consumed or where a metabolite can be consumed but not produced can be identified. Based on the results of preliminary simulations, areas of the metabolic reconstruction that require an additional reaction can be identified. The determination of these gaps can be readily calculated through appropriate queries of the reaction network data structure and need not require the use of simulation strategies, however, simulation would be an alternative approach to locating such gaps.


In the preliminary simulation testing and model content refinement stage the existing model is subjected to a series of functional tests to determine if it can perform basic requirements such as the ability to produce the required biomass constituents and generate predictions concerning the basic physiological characteristics of the particular cell type being modeled. The more preliminary testing that is conducted, the higher the quality of the model that will be generated. Typically, the majority of the simulations used in this stage of development will be single optimizations. A single optimization can be used to calculate a single flux distribution demonstrating how metabolic resources are routed determined from the solution to one optimization problem. An optimization problem can be solved using linear programming as disclosed herein. The result can be viewed as a display of a flux distribution on a reaction map. Temporary reactions can be added to the network to determine if they should be included into the model based on modeling/simulation requirements.


Once a model of the invention is sufficiently complete with respect to the content of the reaction network data structure according to the criteria set forth above, the model can be used to simulate activity of one or more reactions in a reaction network. The results of a simulation can be displayed in a variety of formats including, for example, a table, graph, reaction network, flux distribution map or a phenotypic phase plane graph.


As used herein, the term “physiological function,” when used in reference to a cell, is intended to mean an activity of the cell as a whole. An activity included in the term can be the magnitude or rate of a change from an initial state of a cell to a final state of the cell. An activity included in the term can be, for example, growth, energy production, redox equivalent production, biomass production, development, or consumption of carbon nitrogen, sulfur, phosphate, hydrogen or oxygen. An activity can also be an output of a particular reaction that is determined or predicted in the context of substantially all of the reactions that affect the particular reaction in a cell or that occur in a cell. Examples of a particular reaction included in the term are production of biomass precursors, production of a protein, production of an amino acid, production of a purine, production of a pyrimidine, production of a lipid, production of a fatty acid, production of a cofactor or transport of a metabolite, and the like. A physiological function can include an emergent property which emerges from the whole but not from the sum of parts where the parts are observed in isolation (see for example, Palsson, Nat. Biotech 18:1147-1150 (2000)).


A physiological function of reactions can be determined using phase plane analysis of flux distributions. Phase planes are representations of the feasible set which can be presented in two or three dimensions. As an example, two parameters that describe the growth conditions such as substrate and oxygen uptake rates can be defined as two axes of a two-dimensional space. The optimal flux distribution can be calculated from a reaction network data structure and a set of constraints as set forth above for all points in this plane by repeatedly solving the linear programming problem while adjusting the exchange fluxes defining the two-dimensional space. A finite number of qualitatively different metabolic pathway utilization patterns can be identified in such a plane, and lines can be drawn to demarcate these regions. The demarcations defining the regions can be determined using shadow prices of linear optimization as described, for example in Chvatal, Linear Programming New York, W.H. Freeman and Co. (1983). The regions are referred to as regions of constant shadow price structure. The shadow prices define the intrinsic value of each reactant toward the objective function as a number that is either negative, zero, or positive and are graphed according to the uptake rates represented by the x and y axes. When the shadow prices become zero as the value of the uptake rates are changed there is a qualitative shift in the optimal reaction network.


One demarcation line in the phenotype phase plane is defined as the line of optimality (LO). This line represents the optimal relation between respective metabolic fluxes. The LO can be identified by varying the x-axis flux and calculating the optimal y-axis flux with the objective function defined as the growth flux. From the phenotype phase plane analysis the conditions under which a desired activity is optimal can be determined. The maximal uptake rates lead to the definition of a finite area of the plot that is the predicted outcome of a reaction network within the environmental conditions represented by the constraint set. Similar analyses can be performed in multiple dimensions where each dimension on the plot corresponds to a different uptake rate. These and other methods for using phase plane analysis, such as those described in Edwards et al., Biotech Bioeng. 77:27-36 (2002), can be used to analyze the results of a simulation using an in silico model of the invention.


A physiological function of a cell can also be determined using a reaction map to display a flux distribution. A reaction map of a cell can be used to view reaction networks at a variety of levels. In the case of a cellular metabolic reaction network, a reaction map can contain the entire reaction complement representing a global perspective. Alternatively, a reaction map can focus on a particular region of metabolism such as a region corresponding to a reaction subsystem described above or even on an individual pathway or reaction.


The methods of the invention can be used to determine the activity of a plurality of cell reactions including, for example, biosynthesis of an amino acid, degradation of an amino acid, biosynthesis of a purine, biosynthesis of a pyrimidine, biosynthesis of a lipid, metabolism of a fatty acid, biosynthesis of a cofactor, transport of a metabolite, metabolism of an alternative carbon source, or other reactions as disclosed herein.


The methods of the invention can be used to determine a phenotype of a cell mutant. The activity of one or more reactions can be determined using the methods described herein, wherein the reaction network data structure lacks one or more gene-associated reactions that occur in a cell or organism. Alternatively, the methods can be used to determine the activity of one or more reactions when a reaction that does not naturally occur in the model of a cell or organism, for example, is added to the reaction network data structure. Deletion of a gene can also be represented in a model of the invention by constraining the flux through the reaction to zero, thereby allowing the reaction to remain within the data structure. Thus, simulations can be made to predict the effects of adding or removing genes to or from a cell. The methods can be particularly useful for determining the effects of adding or deleting a gene that encodes for a gene product that performs a reaction in a peripheral metabolic pathway.


A target for an agent that affects a function of a cell can be predicted using the methods of the invention, for example a target pathway for determining a selectable marker for a cell line, as disclosed herein. Such predictions can be made by removing a reaction to simulate total inhibition or prevention by a drug or agent. Alternatively, partial inhibition or reduction in the activity a particular reaction can be predicted by performing the methods with altered constraints. For example, reduced activity can be introduced into a model of the invention by altering the aj or bj values for the metabolic flux vector of a target reaction to reflect a finite maximum or minimum flux value corresponding to the level of inhibition. Similarly, the effects of activating a reaction, by initiating or increasing the activity of the reaction, can be predicted by performing the methods with a reaction network data structure lacking a particular reaction or by altering the aj or bj values for the metabolic flux vector of a target reaction to reflect a maximum or minimum flux value corresponding to the level of activation. The methods can be particularly useful for identifying a target in a peripheral metabolic pathway.


The methods of the invention can be used to determine the effects of one or more environmental components or conditions on an activity of, for example, a physiological function of a cell such as a media component or nutrient, as disclosed herein. As set forth above, an exchange reaction can be added to a reaction network data structure corresponding to uptake of an environmental component, release of a component to the environment, or other environmental demand. The effect of the environmental component or condition can be further investigated by running simulations with adjusted aj or bj values for the metabolic flux vector of the exchange reaction target reaction to reflect a finite maximum or minimum flux value corresponding to the effect of the environmental component or condition. The environmental component can be, for example an alternative carbon source or a metabolite that when added to the environment of a cell such as the medium in which the cell is grown can be taken up and metabolized. The environmental component can also be a combination of components present for example in a minimal medium composition. Thus, the methods can be used to determine an optimal or minimal medium composition that is capable of supporting a particular activity of a cell.


It is understood that modifications which do not substantially affect the activity of the various embodiments of this invention are also provided within the definition of the invention provided herein. Accordingly, the following examples are intended to illustrate but not limit the present invention.


Example I
CHO Metabolic Model

Metabolic Network Reconstruction for CHO Cell Line in SimPheny™. The metabolic model of CHO cell line was reconstructed in SimPheny™ using a whole transcripotome library, on-line databases and published literature on CHO cell line metabolism. Major pathways in central metabolism were included in the metabolic network reconstruction of the CHO cell, including glycolysis, the citric acid (TCA) cycle, pentose phosphate pathway, nonessential amino acid biosynthesis, nonessential fatty acid synthesis and fatty acid β-oxidation (Hayduk et al., Electrophoresis 25:2545-2556 (2004); Hayduk and Lee, Biotechnol. Bioeng. 90:354-364 (2005); Lee et al., Biotechnol. Prog. 19:1734-1741 (2003); Van Dyk et al., Proteomics 3:147-156 (2003); Hayter et al., Appl. Microbiol. Biotechnol. 34:559-564 (1991)). Transport reactions for essential amino acids (i.e. histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine), essential fatty acids (i.e. a-linolenic acid, C18:2, and linoleic acid, C18:3), and other nutrient uptake were included and verified using published CHO medium composition (Kaufmann et al., Biotechnol. Bioeng. 63:573-582 (1999); Hayter et al., Biotechnol. Bioeng. 42:1077-1085 (1993)). The stoichiometry of the electron transport system was specified with a P/O ratio of 2.5 for NADH (measure of oxidative phosphorylation) based on the value determined for mammalian cells (Seewoster and Lehmann, Appl. Microbiol. Biotechnol. 44:344-250 91995)). To ensure that all the biosynthetic components can be synthesized in the network, reactions for biosynthesis of carbohydrates, RNA, DNA, phospholipids, cholesterol, and sphingolipids were added to the reconstructed CHO metabolic network even in the absence of direct genetic or biochemical evidence in CHO cells. Reaction reversibility and intracellular localization were verified using published literature and online databases (refs. Narkewicz et al., Biochem. J. 313 (Pt 3) 991-996 (1996); Lao and Toth, Biotechnol. Prog. 13:688-691 (1997)). Beyond central metabolic pathways, our CHO metabolic model also contains pathways for protein biosynthesis (including specific monoclonal antibodies) and glycosylation. Additionally, prior publications of predictive cell models assumed that essential amino acids are not degraded, however degradation of essential amino acids does occur in CHO cells. Thus, degradation pathways of essential amino acids were included in the herein described CHO cell model. The complete metabolic network includes a total of 550 intracellular reactions and 524 metabolites distributed in intracellular compartments including cytosol, mitochondria, endoplasmic reticulum, peroxisome, as well as the extra-cellular space. All the metabolic reactions in this reconstructed network are elementally and charge-balanced and none of the metabolic pathways is lumped (i.e. several consecutive pathway reactions are merged into one) or simplified.


CHO Metabolic Model Update Using the Whole Transcriptome Data

To update and expand the CHO model, a whole transcriptome library was developed by growing CHO cell lines in batch cultivation and collecting samples in different stages of cell growth. For this purpose, multiple samples were taken throughout the cell culture including from exponential growth and stationary phase and mRNAs were isolated from each sample. Isolated mRNAs were combined into a transcriptome library and the library construction was normalized from the total RNA and sequenced using an Illumina sequencer. The reads were assembled using the Oases assembly algorithm (http://www.ebi.ac.uk/˜zerbino/oases/). The sequenced and assembled contigs were then used to aid in model update and expansion.


Novel enzymatic reactions and pathways were identified through sequence homology to human proteins in the Human Metabolic Reconstruction (US Patent Application Publication 2008/0133196). To accomplish this, the entire exome was subjected to a six frame translation. Putative peptide sequences between stop sites were each subjected to a blastp search for filtering purposes.


The data was filtered against a combined human/mouse/rat RefSeq protein database. All polypeptides from the 6 frame translation of the CHO exome that did not have a significant hit in the human/mouse/rat RefSeq protein database (with at least one match with an E-value<0.1), or that were short (<15 amino acids) were removed. FASTA files were generated of the remaining polypeptides from the translated CHO contigs. These FASTA files were subsequently loaded into the Genomatica BLAST server, and the corresponding list of translated CHO contig IDs were loaded into SimPheny. Blast databases were constructed from the FASTA files. Protein sequence files and their respective BLAST databases for the human and hepatocyte model proteins were also built from RefSeq build 37.1 (download on Jun. 7, 2010). The SimPheny Auto Model program was subsequently used to perform a bidirectional protein BLAST (blastp) of the translated CHO exome against the protein lists from the GT life sciences Human and Hepatocyte models (based off of RefSeq Build 36.2).


The auto model based off of the human hepatocyte model returned 268 reactions, covering 48% of the gene associated reactions in the human hepatocyte model. The auto model based off of the entire human model included 1265 contigs that show homology to RefSeq IDs from the human model (which contains 1809) and allowed the inclusion of 675 reactions (out of 2300 human model reactions). The included reactions were also subjected to manual curation.


Another method was also used, in which a nucleotide BLAST (blastn) was conducted between the CHO exome nucleotide sequences and all RefSeq mRNAs associated with the UCSD human model Entrez Gene numbers. This Human model is different in that the Locus IDs are Entrez Gene IDs (while the GT Human and Hepatocyte models are based on RefSeq). The top 5 CHO contigs with an E-value less than 1×10−10 for each human RefSeq ID were retained to aid in pathway extension. Using this approach, there were 1856 unique RefSeq IDs (out of 2430) that mapped to at least 1 contig with an E-value >1×10−10. These RefSeq IDs mapped back to 1103 unique genes (out of 1493 genes in HR1). The CHO model including the transcriptome data has 800 intracellular, 86 exchange reactions, and 789 metabolites (as described in Tables 1-4). The CHO model described herein, which includes the transcriptome data, is predictive of metabolism and physiological function in CHO cells.


CHO Metabolic Model Analysis

Precursor Metabolite, Energy, and Biomass Synthesis in the Reconstructed Metabolic Model of CHO Cell Line. To assess the network's ability to synthesize biomass components, precursor metabolite formation and energy (ATP) production are simulated using glucose as a sole carbon source. The reconstructed network can correctly generate all precursor metabolites at values equal to or below the maximum theoretical values from glucose, similar to previously reconstructed models for microbial cells such as E. coli and S. cerevisiae (Waterston et al., Nature 420:520-562 (2002); Lu et al., Process Biochemistry 40:1917-1921 (2005)). In addition, using a P/O ratio of 2.5 (Baik et al., Biotechnol. Bioeng. 93:361-371 (2006); Seewoster et al., Appl. Microbiol. Biotechnol. 44:344-350 (1995)), the metabolic model can simulate ATP formation at a maximum yield of 32.75 mol ATP/mol glucose, consistent with a draft network reconstruction of human metabolism in SimPheny™ and previously published values for mammalian cells (Van Dyk et al., Proteomics 3:147-156 (2003); Seewoster et al., supra).


In the absence of comprehensive thermodynamic or kinetic constraints, groups of metabolic reactions in the reconstructed network can be coupled to create cycles that erroneously generate energy and redox potential without carbon expenditure. The CHO cell reconstructed metabolic model can test and verify that no spurious or invalid network cycles that can generate free energy in the form of ATP, NADH, NADPH and FADH2.


The metabolic network can also be tested for its ability to synthesize all the biosynthetic components. For example, the correct synthesis of all non-essential amino acids and fatty acids from glucose can be tested.


It is contemplated that the conditionally essential amino acids cysteine and tyrosine are synthesized only when essential methionine and phenylalanine are supplied to the network. It is also contemplated that the conditionally essential fatty acids are synthesized when essential α-linolenic and linoleic fatty acid are supplied to the network. In addition, the network can also be tested to verify that the essential amino acid (EAA) and essential fatty acid (EFA) biosynthetic pathways are not present in the model and that EAAs and EFAs are available for protein, lipid, and biomass biosynthesis only via uptake from extra-cellular space (i.e. the media).


The metabolic model requirements for cofactors and vitamins can be tested. It is contemplated that the nutritional requirements in CHO cells will agree with the metabolic model requirements. For example, fatty acyl-CoA formation in phospholipid synthesis requires Coenzyme A that is synthesized from pantothenate (vitamin B5). Pantothenate is an essential vitamin that is also supplied to mammalian cell lines in the media (Kaufmann et al., Biotechnol. Bioeng. 63:573-582 (1999); Hayter et al., Biotechnol. Bioeng. 42:1077-1085 91993); Krambeck and Betenbaugh Biotechnol. Bioeng. 92:711-728 (2005)). In the metabolic network, it is contemplated that lipid synthesis is coupled to pantothenate supplementation and the network will be unable to make biomass in the absence of vitamin B5 intake. Choline is another essential nutrient for mammals that is required for the formation of phosphocholine (Kaufmann et al., Biotechnol. Bioeng. 63:573-582 (1999); Hayter et al., Biotechnol. Bioeng. 42:1077-1085 91993); Hossler et al., Biotechnol. Bioeng. 95:946-960 (2006)). The CHO metabolic network does not contain any of the reactions for choline synthesis and to satisfy phospholipid biosynthetic requirements, the metabolic network must take up choline from the extra-cellular space. In the absence of choline supplementation, it is contemplated that the CHO metabolic network will be unable to make phosphocholine and biomass.


Ethanolamine and putrescine are also precursors supplied in mammalian cell media (Kaufmann et al., Biotechnol. Bioeng. 63:572-582 (1999); Hayter et al., Biotechnol. Bioeng. 42:1077-1085 (1993)). Ethanolamine is an alternative route for the biosynthesis of phosphoethanolamine and it can be included in the CHO model. There is no evidence in the previous literature that putrescine is metabolized in CHO cells. Thus, putrescine exchange can be excluded from the model.


Validation and Analysis of the CHO Model: Fatty Acid Metabolism in CHO Model.

The metabolic capabilities of the reconstructed CHO model are evaluated using linear optimization and constraint-based modeling approach (see section B.5). To validate the reconstructed CHO metabolic model, the ATP production from one mole of eicosanoate (C20:0), octadecenoate (C18:1) and palmitate (C16:0) are simulated. To demonstrate how each of these fatty acids can be catabolized to produce energy, the influx of all other carbon sources including glucose is constrained to zero and internal demand for cytosolic ATP is maximized. Previously, mammalian cell simulations in SimPheny™ demonstrated that a unit of proton per fatty acid was required to balance fatty acyl CoA formation in the cell. The proton demand is also identified and supplied to the CHO metabolic network. The liable explanation for proton demand is the role of the proton electrochemical gradient across the inner membrane to energize the long-chain fatty acid transport apparatus. This has been observed in E. coli and has been shown to be required for optimal fatty acid transport (Nyberg et al., Biotechnol. Bioeng. 62:324-335 (1999)).


It is contemplated that, the energy (ATP) production is calculated to be 136.5 mol ATP/mol of eicosanoate (C20:0), 120.75 mol ATP/mol of octadecenoate (C18:1) and 108 mol ATP/mol of palmitate (C 16:0). These results are compared with analogous ATP production calculations that are generated using the reconstructed myocyte model in SimPheny™ (Table 10). The calculated ATP values are slightly different between two models. Published experimental data and previous reconstructions of mitochondrial metabolism match results calculated in myocyte model and report that 106 mol of ATP is produced from one mole of palmitate, when the P/O ratio is 2.5 (Seewoster et al., Appl. Microbiol. Biotechnol. 44:344-350 (1995); Nyberg et al., Biotechnol. Bioeng. 62:336-347 (1999)).









TABLE 10







Maximum ATP produced from 1 mol of fatty acid.















CHO model






with irreversible




Myocyte
CHO
NADP-dependent


Fatty Acid
Abbreviation
model
model
malic enzyme














Eicosanoate
C20:0
134
136.5
134


Octadecenoate
C18:1
118.5
120.75
118.5


Palmitate
C16:0
106
108
106









Further evaluation of the CHO metabolic network allows for identification of the metabolic difference, which causes a variation of 2 ATP mols. Mitochondrial and cytosolic NADP dependent malic enzymes are assigned to be irreversible in the myocyte model. In the reconstructed CHO metabolic model, reactions that are catalyzed by the NADP dependent malic enzyme are included to be reversible, based on the previous experimental evidence generated using various types of mammalian cell types and tissues (Altamirano et al., Biotechnol. Prog. 17:1032-1041 (2001); Provost and Bastin, J. Process Control 14:717-728 (2004); Provost et al., Bioprocess Biosyst. Eng. 29:349-366 (2006). In this case, cytosolic NADP-dependent malic enzyme performs in the reverse direction allowing for transfer of reducing equivalents from the cytosol into mitochondria via the shuttle mechanism (Altamirano et al., Biotechnol. Prog. 17:1032-1041 (2001)) which consequently contributes to additional production of ATP. Constraining NADP-dependent malic enzymes to be irreversible in the CHO model can led to no flux distribution through the cytosolic and mitochondrial NADP dependent malic enzymes and generated maximum ATP production results that were equal to the results generated using the myocyte model in SimPheny™ (Table 10).


Example II
Model-Based Media Optimization

This example describes the identification and development of model-based media formulations using the CHO metabolic model. The CHO metabolic reconstruction are utilized to design an optimal media formulation. This is done to demonstrate the value of a rational model-driven media optimization strategy for improved productivity in CHO cell culture. Four media modifications are experimentally implemented, including three generated by the model and one based on the empirical observation of nutrient depletion in the cell culture (which is used routinely in the industry for media optimization, and is commonly known as a ‘depletion’ or ‘spent media’ analysis). Using the basic cell culture parameters (e.g. cell viability, growth, and metabolite concentrations measured by Nova and HPLC), three formulations are designed using the model to eliminate byproduct formation and increase growth and protein production. Additionally, a formulation is developed based on the ‘depletion’ analysis and is used to benchmark the advantage of a rational modeling approach over the current industry standards used for media optimization. It is contemplated that, metabolite modifications identified by the model are unique and non-intuitive and have no or minimum overlap with those identified by ‘depletion’ analysis.


For this study, all shake flasks are set up, controlled, and analyzed in the same manner as the base case control in experimental lab. It is contemplated that the results from the model-driven media formulation study will show that the objectives of increasing growth and protein production are successful and that model-based formulations outperformed the industry standard ‘depletion’ analysis. For example, since fed-batch is the preferred mode of cell culture, results for a fed-batch study are shown in FIG. 1 (similar results were also generated in batch cell culture, data not shown). Model-driven media formulations (‘Design 1, 2, and 3’) can show significant improvements in fed-batch over both the control and the depletion analysis (Depletion') results. Peak viable cell density can increase by up to 36% compared with the baseline control values. Byproduct formation of lactate and alanine is lowered in the model-based formulations, while higher product titers, up to a striking 131%, are achieved. Ammonium, another key byproduct, levels are unchanged in the model-driven formulations, whereas the level in the depletion analysis increased significantly (89%, data not shown). Model-driven media formulation (‘Design 2’) can show the greatest increase in titer and also the greatest decrease in byproduct formation.


The depletion analysis, commonly used in mammalian cell culture (i.e., the industry standard), showed the least amount of improvement in terms of increasing maximum viable cell density and final product titers. The product titer in the depletion study (Depletion') can increase compared with the base case formulation, which explains why depletion analysis can gain popularity in cell culture protein production. However, the percent increase is not nearly as high as is seen in the model-designed formulations (i.e., only 11% increase over the baseline (control) product titer was observed, as opposed to 90%, 103%, and 131% in the model-based formulations). In addition, the highest accumulated byproduct concentrations are observed for two out of the three byproducts in the depletion analysis (alanine and ammonium). The entire study is performed in just a few months. It is contemplated that the model-based media formulations can show a clear advantage over existing media optimization strategies for reducing byproducts and increasing protein titers and serve as a good example of the predictive capabilities of a model-driven analysis. In summary, the reconstructed models can show that:

    • CHO cell line metabolism can be correctly represented in varying growth conditions;
    • Model-based designs can reduce byproducts and improve cell growth and productivity;
    • Model-based media designs were unique and non-intuitive (with no or minimum overlap with designs generated by empirical approaches used routinely in the industry).


Example III
Model-Based Selection System Design

This example describes the identification and development of selectable markers in CHO cell lines. Using this example, the ability of the model to identify existing selection systems in CHO cell lines can be done. Essential metabolic reactions that are candidate targets for cell line selection are computationally identified using a network deletion analysis to identify the essential reactions in the model when the media components are systematically removed from the simulated conditions (computationally, each deletion analysis is performed by removing one reaction from the network, removing one metabolite from the media, and maximizing the flux for cell biomass and monoclonal antibody production).


Each simulated deletion is performed in two in silico media conditions: (i) the complete CHO cell culture media (as described in the literature and verified analytically in-house), and (ii) media lacking one media components that may be used for selection of the CHO cell line lacking specific gene activities. For example, it is contemplated that this model will identify dihydrofolate reductase and glutamine synthetase as selectable markers in a CHO cell line.


Example IV
Cell Culture Simulation

To evaluate the modeling capabilities of the reconstructed network, published experimental data for tissue Plasminogen Activator (t-PA) producing cell line CHO TF 70R (Altamirano et al., Biotechnol. Prog., 17:1032-1041 (2001)) was used to evaluate the modeling capabilities of the reconstructed network under chemostat growth conditions. Using different objective functions, the byproduct secretion rates were calculated and the accuracy of the model was benchmarked by comparing those values to experimental measurements. Model-based simulation results for chemostat condition closely mimicked CHO metabolism in byproduct secretion rates.


REFERENCE LIST



  • 1 J. S. Edwards and B. O. Palsson, “Robustness analysis of the Escherichia coli metabolic network,” Biotechnol. Prog. 16(6), 927 (2000).

  • 2 M. Garcia-Rios, et al., “Cloning of a polycistronic cDNA from tomato encoding gamma-glutamyl kinase and gamma-glutamyl phosphate reductase,” Proc. Natl. Acad. Sci. U.S. A 94(15), 8249 (1997).

  • 3 E. G. Hanania, et al., “Automated in situ measurement of cell-specific antibody secretion and laser-mediated purification for rapid cloning of highly-secreting producers,” Biotechnol. Bioeng. 91(7), 872 (2005).

  • 4 F. T. Kao and T. T. Puck, “Genetics of somatic mammalian cells. IV. Properties of Chinese hamster cell mutants with respect to the requirement for proline,” Genetics 55(3), 513 (1967).

  • 5 F. T. Kao and T. T. Puck, “Genetics of somatic mammalian cells, VII. Induction and isolation of nutritional mutants in Chinese hamster cells,” Proc. Natl. Acad. Sci. U.S. A 60(4), 1275 (1968).

  • 6 S. L. Naylor, J. K. Townsend, and R. J. Klebe, “Characterization of naturally occurring auxotrophic mammalian cells,” Somatic. Cell Genet. 5(2), 271 (1979).

  • 7 Y. Santiago, et al., “Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases,” Proc. Natl. Acad. Sci. U.S. A 105(15), 5809 (2008).



Throughout this application various publications have been referenced. The disclosures of these publications in their entireties are hereby incorporated by reference in this application in order to more fully describe the state of the art to which this invention pertains. Although the invention has been described with reference to the examples provided above, it should be understood that various modifications can be made without departing from the spirit of the invention.












TABLE 4





No
Abbreviation
Compartment
Name


















1
10fthf
Cytosol
10-Formyltetrahydrofolate


2
10fthf
Mitochondria
10-Formyltetrahydrofolate


3
12dgr_CHO
Cytosol
1,2-Diacylglycerol, CHO


4
13dpg
Cytosol
3-Phospho-D-glyceroyl phosphate


5
1ag3p_CHO
Cytosol
1-Acyl-sn-glycerol 3-phosphate, CHO


6
1aglycpc_CHO
Cytosol
1-Acyl-sn-glycero-3-phosphocholine, CHO specific


7
1pyr5c
Cytosol
1-Pyrroline-5-carboxylate


8
1pyr5c
Mitochondria
1-Pyrroline-5-carboxylate


9
25aics
Cytosol
(S)-2-[5-Amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamido]succinate


10
2aadp
Mitochondria
L-2-Aminoadipate


11
2amuc
Cytosol
2-Aminomuconate


12
2aobut
Mitochondria
L-2-Amino-3-oxobutanoate


13
2maacoa
Mitochondria
2-Methyl-3-acetoacetyl-CoA


14
2mb2coa
Mitochondria
trans-2-Methylbut-2-enoyl-CoA


15
2mbcoa
Mitochondria
2-Methylbutanoyl-CoA


16
2mp2coa
Mitochondria
2-Methylprop-2-enoyl-CoA


17
2obut
Cytosol
2-Oxobutanoate


18
2obut
Mitochondria
2-Oxobutanoate


19
2oxoadp
Cytosol
2-Oxoadipate


20
2oxoadp
Mitochondria
2-Oxoadipate


21
2pg
Cytosol
D-Glycerate 2-phosphate


22
34hpp
Cytosol
3-(4-Hydroxyphenyl)pyruvate


23
34hpp
Mitochondria
3-(4-Hydroxyphenyl)pyruvate


24
3dsphgn
Cytosol
3-Dehydrosphinganine


25
3hanthrn
Cytosol
3-Hydroxyanthranilate


26
3hbycoa
Mitochondria
(S)-3-Hydroxybutyryl-CoA


27
3hmbcoa
Mitochondria
(S)-3-Hydroxy-2-methylbutyryl-CoA


28
3hmp
Mitochondria
(S)-3-hydroxyisobutyrate


29
3mb2coa
Mitochondria
3-Methylbut-2-enoyl-CoA


30
3mgcoa
Mitochondria
3-Methylglutaconyl-CoA


31
3mob
Mitochondria
3-Methyl-2-oxobutanoate


32
3mop
Mitochondria
(S)-3-Methyl-2-oxopentanoate


33
3pg
Cytosol
3-Phospho-D-glycerate


34
3php
Cytosol
3-Phosphohydroxypyruvate


35
3sala
Cytosol
3-Sulfino-L-alanine


36
3sala
Mitochondria
3-Sulfino-L-alanine


37
44mctr
Endoplasmic
4,4-dimethylcholesta-8,14,24-trienol




Reticulum


38
44mzym
Endoplasmic
4,4-dimethylzymosterol




Reticulum


39
4abut
Cytosol
4-Aminobutanoate


40
4abut
Mitochondria
4-Aminobutanoate


41
4abutn
Cytosol
4-Aminobutanal


42
4fumacac
Cytosol
4-Fumarylacetoacetate


43
4izp
Cytosol
4-Imidazolone-5-propanoate


44
4mlacac
Cytosol
4-Maleylacetoacetate


45
4mop
Mitochondria
4-Methyl-2-oxopentanoate


46
4mzym_int1
Endoplasmic
4-Methylzymosterol intermediate 1




Reticulum


47
4mzym_int2
Endoplasmic
4-Methylzymosterol intermediate 2




Reticulum


48
4ppan
Cytosol
D-4′-Phosphopantothenate


49
4ppcys
Cytosol
N-((R)-4-Phosphopantothenoyl)-L-cysteine


50
5aizc
Cytosol
5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylate


51
5aop
Cytosol
5-Amino-4-oxopentanoate


52
5aop
Mitochondria
5-Amino-4-oxopentanoate


53
5dpmev
Peroxisome
(R)-5-Diphosphomevalonate


54
5fthf
Cytosol
5-Formiminotetrahydrofolate


55
5mta
Cytosol
5-Methylthioadenosine


56
5mthf
Cytosol
5-Methyltetrahydrofolate


57
5pmev
Peroxisome
(R)-5-Phosphomevalonate


58
6pgc
Cytosol
6-Phospho-D-gluconate


59
6pgc
Endoplasmic
6-Phospho-D-gluconate




Reticulum


60
6pgl
Cytosol
6-phospho-D-glucono-1,5-lactone


61
6pgl
Endoplasmic
6-phospho-D-glucono-1,5-lactone




Reticulum


62
6pthp
Cytosol
6-Pyruvoyl-5,6,7,8-tetrahydropterin


63
7dhchsterol
Endoplasmic
7-Dehydrocholesterol




Reticulum


64
a3n4m2mf
Golgi Apparatus
Gal b1-4 GlcNAc b1-2 (GlcNAc b1-3 Gal b1-4 GlcNAc b1-4) Man a1-3(Gal b1-4





GlcNAc b1-2 Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


65
a4n5m2mf
Golgi Apparatus
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(Gal b1-4 GlcNAc b1-





2(GlcNAc b1-3 Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-





6) GlcNAcOH


66
a5n6m2mf
Golgi Apparatus
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-3(GlcNAcb1-3Galb1-4GlcNAcb1-





2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fucal-





6)GlcNAcOH


67
a6n7m2mf
Golgi Apparatus
Galb1-4GlcNAcb1-2(GlcNAcb1-3Galb1-4GlcNAcb1-4)Mana1-3(Galb1-4GlcNAcb1-





3Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-





4GlcNAcb1-4(Fuca1-6)GlcNAcOH


68
aacoa
Cytosol
Acetoacetyl-CoA


69
aacoa
Mitochondria
Acetoacetyl-CoA


70
ac
Cytosol
Acetate


71
acac
Cytosol
Acetoacetate


72
acac
Mitochondria
Acetoacetate


73
accoa
Cytosol
Acetyl-CoA


74
accoa
Mitochondria
Acetyl-CoA


75
acgam
Cytosol
N-Acetyl-D-glucosamine


76
acgam1p
Cytosol
N-Acetyl-D-glucosamine 1-phosphate


77
acgam6p
Cytosol
N-Acetyl-D-glucosamine 6-phosphate


78
acmana
Cytosol
N-Acetyl-D-mannosamine


79
acmanap
Cytosol
N-Acetyl-D-mannosamine 6-phosphate


80
acmucsal
Cytosol
2-Amino-3-carboxymuconate semialdehyde


81
acnam
Cytosol
N-Acetylneuraminate


82
acnr9p
Cytosol
N-Acetylneuraminate 9-phosphate


83
acrn
Cytosol
O-Acetylcarnitine


84
acrn
Mitochondria
O-Acetylcarnitine


85
ade
Cytosol
Adenine


86
ade
Extra-organism
Adenine


87
adn
Cytosol
Adenosine


88
adp
Cytosol
ADP


89
adp
Mitochondria
ADP


90
adp
Peroxisome
ADP


91
agm
Mitochondria
Agmatine


92
ahcys
Cytosol
S-Adenosyl-L-homocysteine


93
ahdt
Cytosol
2-Amino-4-hydroxy-6-(erythro-1,2,3-trihydroxypropyl)dihydropteridine triphosphate


94
aicar
Cytosol
5-Amino-1-(5-Phospho-D-ribosyl)imidazole-4-carboxamide


95
air
Cytosol
5-amino-1-(5-phospho-D-ribosyl)imidazole


96
akg
Cytosol
2-Oxoglutarate


97
akg
Mitochondria
2-Oxoglutarate


98
ala-L
Cytosol
L-Alanine


99
ala-L
Extra-organism
L-Alanine


100
amet
Cytosol
S-Adenosyl-L-methionine


101
ametam
Cytosol
S-Adenosylmethioninamine


102
amp
Cytosol
AMP


103
amp
Mitochondria
AMP


104
amp
Peroxisome
AMP


105
ampsal
Mitochondria
L-2-Aminoadipate 6-semialdehyde


106
amucsal
Cytosol
2-Aminomuconate semialdehyde


107
arachda
Cytosol
Arachidonic acid (C20:4)


108
arachda
Extra-organism
Arachidonic acid (C20:4)


109
arachdcoa
Cytosol
arachidonoyl-CoA (C20:4CoA, n-6)


110
arachdcoa
Mitochondria
arachidonoyl-CoA (C20:4CoA, n-6)


111
arachdcrn
Cytosol
C20:4 carnitine


112
arachdcrn
Mitochondria
C20:4 carnitine


113
arg-L
Cytosol
L-Arginine


114
arg-L
Extra-organism
L-Arginine


115
arg-L
Mitochondria
L-Arginine


116
argsuc
Cytosol
N(omega)-(L-Arginino)succinate


117
asn-L
Cytosol
L-Asparagine


118
asn-L
Extra-organism
L-Asparagine


119
asp-L
Cytosol
L-Aspartate


120
asp-L
Extra-organism
L-Aspartate


121
asp-L
Mitochondria
L-Aspartate


122
atp
Cytosol
ATP


123
atp
Mitochondria
ATP


124
atp
Peroxisome
ATP


125
b2coa
Mitochondria
trans-But-2-enoyl-CoA


126
btcoa
Mitochondria
Butanoyl-CoA (C4:0CoA)


127
but
Cytosol
Butyrate


128
camp
Cytosol
cAMP


129
cbasp
Cytosol
N-Carbamoyl-L-aspartate


130
cbp
Cytosol
Carbamoyl phosphate


131
cbp
Mitochondria
Carbamoyl phosphate


132
cdp
Cytosol
CDP


133
cdp
Mitochondria
CDP


134
cdpchol
Cytosol
CDPcholine


135
cdpdag_CHO
Cytosol
CDPdiacylglycerol, CHO specific


136
cdpdag_CHO
Mitochondria
CDPdiacylglycerol, CHO specific


137
cdpea
Cytosol
CDPethanolamine


138
cer_CHO
Cytosol
ceramide, CHO specific


139
cgly
Cytosol
Cys-Gly


140
cgmp
Cytosol
3′,5′-Cyclic GMP


141
chito2pdol
Cytosol
N,N′-Diacetylchitobiosyldiphosphodolichol, mammals


142
chol
Cytosol
Choline


143
chol
Extra-organism
Choline


144
cholcoa
Peroxisome
Choloyl-CoA


145
cholcoads
Peroxisome
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholest-24-enoyl-CoA


146
cholcoaone
Peroxisome
3alpha,7alpha,12alpha-Trihydroxy-5beta-24-oxocholestanoyl-CoA


147
cholcoar
Peroxisome
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholestanoyl-CoA


148
cholcoas
Peroxisome
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholestanoyl-CoA(S)


149
cholp
Cytosol
Choline phosphate


150
cholsd
Endoplasmic
5alpha-Cholesta-7,24-dien-3beta-ol




Reticulum


151
cholse_CHO
Cytosol
Cholesterol ester, CHO specific


152
chsterol
Cytosol
Cholesterol


153
chsterol
Endoplasmic
Cholesterol




Reticulum


154
cit
Cytosol
Citrate


155
cit
Extra-organism
Citrate


156
cit
Mitochondria
Citrate


157
citr-L
Cytosol
L-Citrulline


158
citr-L
Mitochondria
L-Citrulline


159
clpn_CHO
Cytosol
cardiolipin, CHO specific


160
clpn_CHO
Mitochondria
cardiolipin, CHO specific


161
clpndcoa
Cytosol
clupanodonyl CoA (C22:5CoA)


162
clpndcoa
Mitochondria
clupanodonyl CoA (C22:5CoA)


163
clpndcrn
Cytosol
docosapentaenoyl carnitine (C22:5)


164
clpndcrn
Mitochondria
docosapentaenoyl carnitine (C22:5)


165
cmp
Cytosol
CMP


166
cmp
Golgi Apparatus
CMP


167
cmp
Mitochondria
CMP


168
cmpacna
Cytosol
CMP-N-acetylneuraminate


169
cmpacna
Golgi Apparatus
CMP-N-acetylneuraminate


170
co2
Cytosol
CO2


171
co2
Endoplasmic
CO2




Reticulum


172
co2
Extra-organism
CO2


173
co2
Mitochondria
CO2


174
co2
Peroxisome
CO2


175
coa
Cytosol
Coenzyme A


176
coa
Mitochondria
Coenzyme A


177
coa
Peroxisome
Coenzyme A


178
cpppg3
Cytosol
Coproporphyrinogen III


179
crn
Cytosol
L-Carnitine


180
crn
Mitochondria
L-Carnitine


181
ctp
Cytosol
CTP


182
ctp
Mitochondria
CTP


183
cvncoa
Cytosol
cervonyl CoA (C22:6CoA)


184
cvncoa
Mitochondria
cervonyl CoA (C22:6CoA)


185
cvncrn
Cytosol
cervonyl carnitine (C22:6Crn)


186
cvncrn
Mitochondria
cervonyl carnitine (C22:6Crn)


187
cys-L
Cytosol
L-Cysteine


188
cys-L
Extra-organism
L-Cysteine


189
cysth-L
Cytosol
L-Cystathionine


190
cytd
Cytosol
Cytidine


191
dadp
Cytosol
dADP


192
datp
Cytosol
dATP


193
dca
Cytosol
Decanoate


194
dcamp
Cytosol
N6-(1,2-Dicarboxyethyl)-AMP


195
dccoa
Mitochondria
Decanoyl-CoA (C10:0CoA)


196
dcdp
Cytosol
dCDP


197
dcer_CHO
Cytosol
dihydroceramide, CHO specific


198
dcsa
Cytosol
docosanoate (n-C22:0)


199
dcsacoa
Cytosol
docosanoyl-CoA (C22:0CoA)


200
dcshea
Cytosol
docosahexaenoate (C22:6)


201
dcshea
Extra-organism
docosahexaenoate (C22:6)


202
dcshea3
Cytosol
docosahexaenoate (C22:6, n-3)


203
dcspea
Cytosol
docosapentaenoic acid (C22:5)


204
dcspea
Extra-organism
docosapentaenoic acid (C22:5)


205
dcspea3
Cytosol
docosapentaenoate (C22:5, n-3)


206
dcspea6
Cytosol
docosapentaenoate (C22:5, n-6)


207
dctp
Cytosol
dCTP


208
ddca
Cytosol
dodecanoate (C12:0)


209
ddcoa
Cytosol
Dodecanoyl-CoA (n-C12:0CoA)


210
ddcoa
Mitochondria
Dodecanoyl-CoA (n-C12:0CoA)


211
ddsmsterol
Endoplasmic
7-Dehydrodesmosterol




Reticulum


212
dedol
Cytosol
Dehydrodolichol, mammals


213
dedoldp
Cytosol
Dehydrodolichol diphosphate, mammals


214
dedolp
Cytosol
Deydodolichol phosphate, mammals


215
dgdp
Cytosol
dGDP


216
dgtp
Cytosol
dGTP


217
dhap
Cytosol
Dihydroxyacetone phosphate


218
dhbpt
Cytosol
6,7-Dihydrobiopterin


219
dhf
Cytosol
7,8-Dihydrofolate


220
dhor-S
Cytosol
(S)-Dihydroorotate


221
dmpp
Cytosol
Dimethylallyl diphosphate


222
dmpp
Peroxisome
Dimethylallyl diphosphate


223
doldp2
Endoplasmic
Dolichol diphosphate, mammals




Reticulum


224
dolglcp2
Cytosol
Dolichyl beta-D-glucosyl phosphate, mammals


225
dolglcp2
Endoplasmic
Dolichyl beta-D-glucosyl phosphate, mammals




Reticulum


226
dolichol2
Cytosol
Dolichol, mammals


227
dolichol2
Endoplasmic
Dolichol, mammals




Reticulum


228
dolmanp2
Cytosol
Dolichyl phosphate D-mannose, mammals


229
dolmanp2
Endoplasmic
Dolichyl phosphate D-mannose, mammals




Reticulum


230
dolp2
Cytosol
Dolichol phosphate, mammals


231
dolp2
Endoplasmic
Dolichol phosphate, mammals




Reticulum


232
dpcoa
Cytosol
Dephospho-CoA


233
dshcoa3
Cytosol
docosahexaenoyl-CoA (C22:6CoA, n-3)


234
dshcoa3
Mitochondria
docosahexaenoyl-CoA (C22:6CoA, n-3)


235
dsmsterol
Endoplasmic
Desmosterol




Reticulum


236
dspcoa3
Cytosol
docosapentaenoyl-CoA (C22:5CoA, n-3)


237
dspcoa3
Mitochondria
docosapentaenoyl-CoA (C22:5CoA, n-3)


238
dspcoa6
Cytosol
docosapentaenoyl-CoA (C22:5CoA, n-6)


239
dspcoa6
Mitochondria
docosapentaenoyl-CoA (C22:5CoA, n-6)


240
dtdp
Cytosol
dTDP


241
dtmp
Cytosol
dTMP


242
dttp
Cytosol
dTTP


243
dudp
Cytosol
dUDP


244
dump
Cytosol
dUMP


245
duri
Cytosol
Deoxyuridine


246
dutp
Cytosol
dUTP


247
e4p
Cytosol
D-Erythrose 4-phosphate


248
ecsa
Cytosol
Eicosanoate (n-C20:0)


249
ecsa
Extra-organism
Eicosanoate (n-C20:0)


250
ecsacoa
Cytosol
Eicosanoyl-CoA (n-C20:0CoA)


251
ecsacoa
Mitochondria
Eicosanoyl-CoA (n-C20:0CoA)


252
ecsacrn
Cytosol
eicosanoylcarnitine, C20:0crn


253
ecsacrn
Mitochondria
eicosanoylcarnitine, C20:0crn


254
ecsdea9
Cytosol
eicosadienoate (C20:2, n-9)


255
ecsea9
Cytosol
eicosenoate (C20:1, n-9)


256
ecspea
Cytosol
Eicosapentaenoic acid (C20:5)


257
ecspea
Extra-organism
Eicosapentaenoic acid (C20:5)


258
ecspea3
Cytosol
eicosapentaenoate (C20:5, n-3)


259
ecspecoa
Cytosol
eicosapentaenoyl-CoA (C20:5CoA)


260
ecspecoa
Mitochondria
eicosapentaenoyl-CoA (C20:5CoA)


261
ecspecrn
Cytosol
eicosapentaenoyl carnitine (C20:5Crn)


262
ecspecrn
Mitochondria
eicosapentaenoyl carnitine (C20:5Crn)


263
ecstea
Cytosol
eicosatrienoate (C20:3)


264
ecstea
Extra-organism
eicosatrienoate (C20:3)


265
ecstea6
Cytosol
eicosatrienoate (C20:3, n-6)


266
ecstea9
Cytosol
eicosatrienoate (C20:3, n-9)


267
ecsttea3
Cytosol
eicosatetraenoate (C20:4, n-3)


268
ecsttea6
Cytosol
eicosatetraenoate (C20:4, n-6)


269
edcoa
Mitochondria
endecanoyl-CoA (C11:0CoA)


270
esdcoa9
Cytosol
eicosadienoyl-CoA (C20:2CoA, n-9)


271
esecoa9
Cytosol
eicosenoyl-CoA (C20:1CoA, n-9)


272
esecoa9
Mitochondria
eicosenoyl-CoA (C20:1CoA, n-9)


273
espcoa3
Cytosol
eicosapentaenoyl-CoA (C20:5CoA, n-3)


274
espcoa3
Mitochondria
eicosapentaenoyl-CoA (C20:5CoA, n-3)


275
estcoa
Cytosol
eicosatrienoyl-CoA (C20:3CoA)


276
estcoa
Mitochondria
eicosatrienoyl-CoA (C20:3CoA)


277
estcoa6
Cytosol
eicosatrienoyl-CoA (C20:3CoA, n-6)


278
estcoa6
Mitochondria
eicosatrienoyl-CoA (C20:3CoA, n-6)


279
estcoa9
Cytosol
eicosatrienoyl-CoA (C20:3CoA, n-9)


280
estcoa9
Mitochondria
eicosatrienoyl-CoA (C20:3CoA, n-9)


281
estcrn
Cytosol
eicosatrienoyl carnitine (C20:3Crn)


282
estcrn
Mitochondria
eicosatrienoyl carnitine (C20:3Crn)


283
etha
Cytosol
Ethanolamine


284
etha
Extra-organism
Ethanolamine


285
ethap
Cytosol
Ethanolamine phosphate


286
ettcoa3
Cytosol
eicosatetraenoyl-CoA (C20:4CoA, n-3)


287
ettcoa6
Cytosol
eicosatetraenoyl-CoA (C20:4CoA, n-6)


288
ettcoa6
Mitochondria
eicosatetraenoyl-CoA (C20:4CoA, n-6)


289
f26bp
Cytosol
D-Fructose 2,6-bisphosphate


290
f6p
Cytosol
D-Fructose 6-phosphate


291
facoa_avg_CHO
Cytosol
Averaged fatty acyl CoA, CHO specific


292
fad
Mitochondria
FAD


293
fad
Peroxisome
FAD


294
fadh2
Mitochondria
FADH2


295
fadh2
Peroxisome
FADH2


296
fald
Cytosol
Formaldehyde


297
fald
Peroxisome
Formaldehyde


298
fdp
Cytosol
D-Fructose 1,6-bisphosphate


299
fe2
Cytosol
Fe2+


300
fe2
Extra-organism
Fe2+


301
fe2
Mitochondria
Fe2+


302
fgam
Cytosol
N2-Formyl-N1-(5-phospho-D-ribosyl)glycinamide


303
ficytcc
Mitochondria
Ferricytochrome c


304
focytcc
Mitochondria
Ferrocytochrome c


305
fol
Cytosol
Folate


306
fol
Extra-organism
Folate


307
for
Cytosol
Formate


308
for
Endoplasmic
Formate




Reticulum


309
for
Extra-organism
Formate


310
for
Mitochondria
Formate


311
forglu
Cytosol
N-Formimidoyl-L-glutamate


312
fpram
Cytosol
2-(Formamido)-N1-(5-phospho-D-ribosyl)acetamidine


313
fprica
Cytosol
5-Formamido-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide


314
frdp
Cytosol
Farnesyl diphosphate


315
frdp
Endoplasmic
Farnesyl diphosphate




Reticulum


316
fum
Cytosol
Fumarate


317
fum
Mitochondria
Fumarate


318
g1m8mpdol
Endoplasmic
alpha-D-Glucosyl-(alpha-D-mannosyl)8-beta-D-mannosyl-




Reticulum
diacetylchitobiosyldiphosphodolichol, mammal


319
g1p
Cytosol
D-Glucose 1-phosphate


320
g2m8m
Endoplasmic
(alpha-D-Glucosyl)2-(alpha-D-mannosyl)8-beta-D-mannosyl-diacetylchitobiose




Reticulum


321
g2m8mpdol
Endoplasmic
(alpha-D-Glucosyl)2-(alpha-D-mannosyl)8-beta-D-mannosyl-




Reticulum
diacetylchitobiosyldiphosphodolichol, mammal


322
g3m8m
Endoplasmic
(alpha-D-Glucosyl)3-(alpha-D-mannosyl)8-beta-D-mannosyl-diacetylchitobiose




Reticulum


323
g3m8mpdol
Endoplasmic
(alpha-D-Glucosyl)3-(alpha-D-mannosyl)8-beta-D-mannosyl-




Reticulum
diacetylchitobiosyldiphosphodolichol, mammal


324
g3p
Cytosol
Glyceraldehyde 3-phosphate


325
g6p
Cytosol
D-Glucose 6-phosphate


326
g6p
Endoplasmic
D-Glucose 6-phosphate




Reticulum


327
gam
Cytosol
D-Glucosamine


328
gam6p
Cytosol
D-Glucosamine 6-phosphate


329
gar
Cytosol
N1-(5-Phospho-D-ribosyl)glycinamide


330
gdp
Cytosol
GDP


331
gdp
Golgi Apparatus
GDP


332
gdp
Mitochondria
GDP


333
gdpddm
Cytosol
GDP-4-dehydro-6-deoxy-D-mannose


334
gdpfuc
Cytosol
GDP-L-fucose


335
gdpfuc
Golgi Apparatus
GDP-L-fucose


336
gdpman
Cytosol
GDP-D-mannose


337
glc-D
Cytosol
D-Glucose


338
glc-D
Endoplasmic
D-Glucose




Reticulum


339
glc-D
Extra-organism
D-Glucose


340
gln-L
Cytosol
L-Glutamine


341
gln-L
Extra-organism
L-Glutamine


342
gln-L
Mitochondria
L-Glutamine


343
glu-L
Cytosol
L-Glutamate


344
glu-L
Extra-organism
L-Glutamate


345
glu-L
Mitochondria
L-Glutamate


346
glu5p
Mitochondria
L-Glutamate 5-phosphate


347
glu5sa
Cytosol
L-Glutamate 5-semialdehyde


348
glu5sa
Mitochondria
L-Glutamate 5-semialdehyde


349
glucys
Cytosol
gamma-L-Glutamyl-L-cysteine


350
glutcoa
Mitochondria
Glutaryl-CoA


351
gly
Cytosol
Glycine


352
gly
Extra-organism
Glycine


353
gly
Mitochondria
Glycine


354
gly
Peroxisome
Glycine


355
glyc
Cytosol
Glycerol


356
glyc3p
Cytosol
sn-Glycerol 3-phosphate


357
glyc3p
Mitochondria
sn-Glycerol 3-phosphate


358
glycogen
Cytosol
glycogen


359
gmp
Cytosol
GMP


360
gmp
Golgi Apparatus
GMP


361
grdp
Cytosol
Geranyl diphosphate


362
gthox
Cytosol
Oxidized glutathione


363
gthrd
Cytosol
Reduced glutathione


364
gtp
Cytosol
GTP


365
gtp
Mitochondria
GTP


366
h
Cytosol
H+


367
h
Endoplasmic
H+




Reticulum


368
h
Extra-organism
H+


369
h
Golgi Apparatus
H+


370
h
Mitochondria
H+


371
h
Peroxisome
H+


372
h2o
Cytosol
H2O


373
h2o
Endoplasmic
H2O




Reticulum


374
h2o
Extra-organism
H2O


375
h2o
Golgi Apparatus
H2O


376
h2o
Mitochondria
H2O


377
h2o
Peroxisome
H2O


378
h2o2
Cytosol
Hydrogen peroxide


379
h2o2
Mitochondria
Hydrogen peroxide


380
h2o2
Peroxisome
Hydrogen peroxide


381
hco3
Cytosol
Bicarbonate


382
hco3
Mitochondria
Bicarbonate


383
hcys-L
Cytosol
L-Homocysteine


384
hdca
Cytosol
hexadecanoate (n-C16:0)


385
hdca
Extra-organism
hexadecanoate (n-C16:0)


386
hdcea
Cytosol
hexadecenoate (n-C16:1)


387
hdcea
Extra-organism
hexadecenoate (n-C16:1)


388
hdcea7
Cytosol
hexadecenoate (C16:1, n-7)


389
hdcecrn
Cytosol
Hexadecenoyl carnitine


390
hdcecrn
Mitochondria
Hexadecenoyl carnitine


391
hdcoa
Cytosol
Hexadecenoyl-CoA (n-C16:1CoA)


392
hdcoa
Mitochondria
Hexadecenoyl-CoA (n-C16:1CoA)


393
hdcoa7
Cytosol
hexadecenoyl-CoA (C16:1CoA, n-7)


394
hdcoa7
Mitochondria
hexadecenoyl-CoA (C16:1CoA, n-7)


395
hgentis
Cytosol
Homogentisate


396
hibcoa
Mitochondria
(S)-3-Hydroxyisobutyryl-CoA


397
his-L
Cytosol
L-Histidine


398
his-L
Extra-organism
L-Histidine


399
hkyn
Cytosol
3-Hydroxy-L-kynurenine


400
hmbil
Cytosol
Hydroxymethylbilane


401
hmgcoa
Cytosol
Hydroxymethylglutaryl-CoA


402
hmgcoa
Mitochondria
Hydroxymethylglutaryl-CoA


403
hpcoa
Mitochondria
heptanoyl-CoA (C7:0CoA)


404
hpdca
Cytosol
heptadecanoate (C17:0)


405
hpdcoa
Cytosol
heptadecanoyl CoA (C17:0CoA)


406
hpdcoa
Mitochondria
heptadecanoyl CoA (C17:0CoA)


407
hxa
Cytosol
Hexanoate


408
hxan
Cytosol
Hypoxanthine


409
hxan
Extra-organism
Hypoxanthine


410
hxcoa
Mitochondria
Hexanoyl-CoA (C6:0CoA)


411
ibcoa
Mitochondria
Isobutyryl-CoA


412
icit
Cytosol
Isocitrate


413
icit
Mitochondria
Isocitrate


414
idp
Cytosol
IDP


415
ile-L
Cytosol
L-Isoleucine


416
ile-L
Extra-organism
L-Isoleucine


417
ile-L
Mitochondria
L-Isoleucine


418
ilnlc
Cytosol
isolinoleic acid (C18:2, n-9)


419
ilnlcoa
Cytosol
isolinoleoyl-CoA (C18:2CoA, n-9)


420
imp
Cytosol
IMP


421
inost
Cytosol
myo-Inositol


422
inost
Extra-organism
myo-Inositol


423
ins
Cytosol
Inosine


424
ins
Extra-organism
Inosine


425
ipdp
Cytosol
Isopentenyl diphosphate


426
ipdp
Peroxisome
Isopentenyl diphosphate


427
itp
Cytosol
ITP


428
ivcoa
Mitochondria
Isovaleryl-CoA


429
kynr-L
Cytosol
L-Kynurenine


430
lac-L
Cytosol
L-Lactate


431
lac-L
Extra-organism
L-Lactate


432
lanost
Endoplasmic
Lanosterol




Reticulum


433
lathost
Endoplasmic
Lathosterol




Reticulum


434
leu-L
Cytosol
L-Leucine


435
leu-L
Extra-organism
L-Leucine


436
leu-L
Mitochondria
L-Leucine


437
Lfmkynr
Cytosol
L-Formylkynurenine


438
lgnccoa
Cytosol
lignocericyl coenzyme A


439
lgnccoa
Mitochondria
lignocericyl coenzyme A


440
lgnccrn
Cytosol
lignoceryl carnitine


441
lgnccrn
Mitochondria
lignoceryl carnitine


442
lnlecoa
Cytosol
Linolenoyl-CoA (C18:3CoA)


443
lnlecoa
Mitochondria
Linolenoyl-CoA (C18:3CoA)


444
lnlecrn
Cytosol
linolenoyl carnitine (C18:3Crn)


445
lnlecrn
Mitochondria
linolenoyl carnitine (C18:3Crn)


446
lnlne
Cytosol
Linolenic acid (C18:3)


447
lnlne
Extra-organism
Linolenic acid (C18:3)


448
Lsacchrp
Mitochondria
L-Saccharopine


449
lys-L
Cytosol
L-Lysine


450
lys-L
Extra-organism
L-Lysine


451
lys-L
Mitochondria
L-Lysine


452
m1mpdol
Cytosol
alpha-D-mannosyl-beta-D-mannosyl-diacylchitobiosyldiphosphodolichol, mammals


453
m2mpdol
Cytosol
(alpha-D-mannosyl)2-beta-D-mannosyl-diacetylchitobiosyldiphosphodolichol,





mammals


454
m3mpdol
Cytosol
(alpha-D-mannosyl)3-beta-D-mannosyl-diacetylchitodiphosphodolichol, mammals


455
m4m
Golgi Apparatus
(alpha-D-mannosyl)4-beta-D-mannosyl-diacetylchitobiose


456
m4mpdol
Cytosol
(alpha-D-Mannosyl)4-beta-D-mannosyl-diacetylchitobiosyldiphosphodolichol,





mammals


457
m4mpdol
Endoplasmic
(alpha-D-Mannosyl)4-beta-D-mannosyl-diacetylchitobiosyldiphosphodolichol,




Reticulum
mammals


458
m5m
Golgi Apparatus
(alpha-D-mannosyl)5-beta-D-mannosyl-diacetylchitobiose


459
m5mpdol
Endoplasmic
(alpha-D-Mannosyl)5-beta-D-mannosyl-diacetylchitobiosyldiphosphodolichol,




Reticulum
mammals


460
m6m
Golgi Apparatus
(alpha-D-mannosyl)6-beta-D-mannosyl-diacetylchitobiose


461
m6mpdol
Endoplasmic
(alpha-D-Mannosyl)6-beta-D-mannosyl-diacetylchitobiosyldiphosphodolichol,




Reticulum
mammals


462
m7m
Endoplasmic
(alpha-D-mannosyl)7-beta-D-mannosyl-diacetylchitobiose




Reticulum


463
m7m
Golgi Apparatus
(alpha-D-mannosyl)7-beta-D-mannosyl-diacetylchitobiose


464
m7mpdol
Endoplasmic
(alpha-D-Mannosyl)7-beta-D-mannosyl-diacetylchitobiosyldiphosphodolichol,




Reticulum
mammals


465
m8m
Endoplasmic
(alpha-D-mannosyl)8-beta-D-mannosyl-diacetylchitobiose




Reticulum


466
m8m
Golgi Apparatus
(alpha-D-mannosyl)8-beta-D-mannosyl-diacetylchitobiose


467
m8mpdol
Endoplasmic
(alpha-D-Mannosyl)8-beta-D-mannosyl-diacetylchitobiosyldiphosphodolichol,




Reticulum
mammals


468
mal-L
Cytosol
L-Malate


469
mal-L
Mitochondria
L-Malate


470
malcoa
Cytosol
Malonyl-CoA


471
man
Cytosol
D-Mannose


472
man
Endoplasmic
D-Mannose




Reticulum


473
man
Golgi Apparatus
D-Mannose


474
man1p
Cytosol
D-Mannose 1-phosphate


475
man6p
Cytosol
D-Mannose 6-phosphate


476
mercppyr
Cytosol
Mercaptopyruvate


477
met-L
Cytosol
L-Methionine


478
met-L
Extra-organism
L-Methionine


479
methf
Cytosol
5,10-Methenyltetrahydrofolate


480
methf
Mitochondria
5,10-Methenyltetrahydrofolate


481
mev-R
Cytosol
(R)-Mevalonate


482
mev-R
Peroxisome
(R)-Mevalonate


483
mglyc_CHO
Cytosol
monoacylglycerol, CHO specific


484
mi1p-D
Cytosol
1D-myo-Inositol 1-phosphate


485
mlthf
Cytosol
5,10-Methylenetetrahydrofolate


486
mlthf
Mitochondria
5,10-Methylenetetrahydrofolate


487
mmal
Cytosol
Methylmalonate


488
mmal
Mitochondria
Methylmalonate


489
mmalsa-S
Cytosol
(S)-Methylmalonate semialdehyde


490
mmalsa-S
Mitochondria
(S)-Methylmalonate semialdehyde


491
mmcoa-R
Mitochondria
(R)-Methylmalonyl-CoA


492
mmcoa-S
Mitochondria
(S)-Methylmalonyl-CoA


493
mpdol
Cytosol
beta-D-Mannosyldiacetylchitobiosyldiphosphodolichol, mammals


494
N-bi
Cytosol
Gal b1-4 GlcNAc b1-2 Man a1-3(Gal b1-4 GlcNAc b1-2 Man a1-6) Man b1-





4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


495
N-bi
Extra-organism
Gal b1-4 GlcNAc b1-2 Man a1-3(Gal b1-4 GlcNAc b1-2 Man a1-6) Man b1-





4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


496
N-bi
Golgi Apparatus
Gal b1-4 GlcNAc b1-2 Man a1-3(Gal b1-4 GlcNAc b1-2 Man a1-6) Man b1-





4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


497
N-biS1
Cytosol
Gal b1-4 GlcNAc b1-2 Man a1-3(NeuAc a2-3 Gal b1-4 GlcNAc b1-2 Man a1-





6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


498
N-biS1
Extra-organism
Gal b1-4 GlcNAc b1-2 Man a1-3(NeuAc a2-3 Gal b1-4 GlcNAc b1-2 Man a1-





6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


499
N-biS1
Golgi Apparatus
Gal b1-4 GlcNAc b1-2 Man a1-3(NeuAc a2-3 Gal b1-4 GlcNAc b1-2 Man a1-





6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


500
N-tetra/N-triLac1
Cytosol
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(Gal b1-4 GlcNAc b1-





2(Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


501
N-tetra/N-triLac1
Extra-organism
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(Gal b1-4 GlcNAc b1-





2(Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


502
N-tetra/N-triLac1
Golgi Apparatus
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(Gal b1-4 GlcNAc b1-





2(Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


503
N-tetraLac1
Cytosol
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(Gal b1-4 GlcNAc b1-





2(Gal b1-4 GlcNAc b1-3 Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


504
N-tetraLac1
Extra-organism
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(Gal b1-4 GlcNAc b1-





2(Gal b1-4 GlcNAc b1-3 Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


505
N-tetraLac1
Golgi Apparatus
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(Gal b1-4 GlcNAc b1-





2(Gal b1-4 GlcNAc b1-3 Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


506
N-tetraLac1S1
Cytosol
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(Gal b1-4 GlcNAc b1-





2(NeuAc a2-3 Gal b1-4 GlcNAc b1-3 Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-





4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


507
N-tetraLac1S1
Extra-organism
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(Gal b1-4 GlcNAc b1-





2(NeuAc a2-3 Gal b1-4 GlcNAc b1-3 Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-





4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


508
N-tetraLac1S1
Golgi Apparatus
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(Gal b1-4 GlcNAc b1-





2(NeuAc a2-3 Gal b1-4 GlcNAc b1-3 Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-





4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


509
N-tetraLac1S2
Cytosol
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-4





GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-3 Gal b1-4 GlcNAc b1-6) Man a1-





6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


510
N-tetraLac1S2
Extra-organism
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-4





GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-3 Gal b1-4 GlcNAc b1-6) Man a1-





6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


511
N-tetraLac1S2
Golgi Apparatus
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-4





GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-3 Gal b1-4 GlcNAc b1-6) Man a1-





6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


512
N-tetraLac1S3
Cytosol
Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-4





GlcNAc b1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-





4GlcNAcb1-4(Fuc a1-6)GlcNAcOH


513
N-tetraLac1S3
Extra-organism
Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-4





GlcNAc b1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-





4GlcNAcb1-4(Fuc a1-6)GlcNAcOH


514
N-tetraLac1S3
Golgi Apparatus
Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-4





GlcNAc b1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-





4GlcNAcb1-4(Fuc a1-6)GlcNAcOH


515
N-tetraLac1S4
Cytosol
NeuAca2-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-





3Galb1-4 GlcNAc b1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-





6)Manb1-4GlcNAcb1-4(Fuc a1-6)GlcNAcOH


516
N-tetraLac1S4
Extra-organism
NeuAca2-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-





3Galb1-4 GlcNAc b1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-





6)Manb1-4GlcNAcb1-4(Fuc a1-6)GlcNAcOH


517
N-tetraLac1S4
Golgi Apparatus
NeuAca2-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-





3Galb1-4 GlcNAc b1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-





6)Manb1-4GlcNAcb1-4(Fuc a1-6)GlcNAcOH


518
N-tetraLac2
Cytosol
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-3(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-





4(Fuca1-6)GlcNAcOH


519
N-tetraLac2
Extra-organism
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-3(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-





4(Fuca1-6)GlcNAcOH


520
N-tetraLac2
Golgi Apparatus
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-3(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-





4(Fuca1-6)GlcNAcOH


521
N-tetraLac2S1
Cytosol
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-3(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-





4GlcNAcb1-4(Fuca1-6)GlcNAcOH


522
N-tetraLac2S1
Extra-organism
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-3(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-





4GlcNAcb1-4(Fuca1-6)GlcNAcOH


523
N-tetraLac2S1
Golgi Apparatus
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-3(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-





4GlcNAcb1-4(Fuca1-6)GlcNAcOH


524
N-tetraLac2S2
Cytosol
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-4GlcNAcb1-





3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-





6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


525
N-tetraLac2S2
Extra-organism
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-4GlcNAcb1-





3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-





6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


526
N-tetraLac2S2
Golgi Apparatus
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-4GlcNAcb1-





3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-





6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


527
N-tetraLac2S3
Cytosol
Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


528
N-tetraLac2S3
Extra-organism
Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


529
N-tetraLac2S3
Golgi Apparatus
Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


530
N-tetraLac2S4
Cytosol
NeuAca2-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-





3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


531
N-tetraLac2S4
Extra-organism
NeuAca2-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-





3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


532
N-tetraLac2S4
Golgi Apparatus
NeuAca2-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-





3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


533
N-tetraLac3
Cytosol
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-4)Mana1-3(Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-





6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


534
N-tetraLac3
Extra-organism
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-4)Mana1-3(Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-





6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


535
N-tetraLac3
Golgi Apparatus
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-4)Mana1-3(Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-





6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


536
N-tetraLac3S1
Cytosol
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-4)Mana1-3(Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


537
N-tetraLac3S1
Extra-organism
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-4)Mana1-3(Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


538
N-tetraLac3S1
Golgi Apparatus
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-4)Mana1-3(Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


539
N-tetraLac3S2
Cytosol
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-





3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


540
N-tetraLac3S2
Extra-organism
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-





3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


541
N-tetraLac3S2
Golgi Apparatus
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-





3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


542
N-tetraLac3S3
Cytosol
Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-4)Mana1-





3(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-





3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


543
N-tetraLac3S3
Extra-organism
Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-4)Mana1-





3(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-





3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


544
N-tetraLac3S3
Golgi Apparatus
Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-4)Mana1-





3(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-





3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


545
N-tetraS1/N-triLac1S1
Cytosol
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-





4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-





6) GlcNAcOH


546
N-tetraS1/N-triLac1S1
Extra-organism
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-





4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-





6) GlcNAcOH


547
N-tetraS1/N-triLac1S1
Golgi Apparatus
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-





4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-





6) GlcNAcOH


548
N-tetraS2/N-triLac1S2
Cytosol
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-





4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


549
N-tetraS2/N-triLac1S2
Extra-organism
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-





4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


550
N-tetraS2/N-triLac1S2
Golgi Apparatus
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-





4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


551
N-tetraS3
Cytosol
Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-





3 Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-





4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


552
N-tetraS3
Extra-organism
Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-





3 Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-





4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


553
N-tetraS3
Golgi Apparatus
Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-





3 Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-





4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


554
N-tetraS4
Cytosol
NeuAc a2-3 Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-4) Man a1-





3(NeuAc a2-3 Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-6) Man a1-





6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


555
N-tetraS4
Extra-organism
NeuAc a2-3 Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-4) Man a1-





3(NeuAc a2-3 Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-6) Man a1-





6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


556
N-tetraS4
Golgi Apparatus
NeuAc a2-3 Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-4) Man a1-





3(NeuAc a2-3 Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-6) Man a1-





6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


557
N-tri
Cytosol
Gal b1-4 GlcNAc b1-2 (Gal b1-4 GlcNAc b1-4) Man a1-3(Gal b1-4 GlcNAc b1-





2 Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


558
N-tri
Extra-organism
Gal b1-4 GlcNAc b1-2 (Gal b1-4 GlcNAc b1-4) Man a1-3(Gal b1-4 GlcNAc b1-





2 Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


559
N-tri
Golgi Apparatus
Gal b1-4 GlcNAc b1-2 (Gal b1-4 GlcNAc b1-4) Man a1-3(Gal b1-4 GlcNAc b1-





2 Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


560
N-triS1
Cytosol
Gal b1-4 GlcNAc b1-2 (Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-4





GlcNAc b1-2 Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


561
N-triS1
Extra-organism
Gal b1-4 GlcNAc b1-2 (Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-4





GlcNAc b1-2 Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


562
N-triS1
Golgi Apparatus
Gal b1-4 GlcNAc b1-2 (Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-4





GlcNAc b1-2 Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


563
N-triS2
Cytosol
Gal b1-4 GlcNAc b1-2 (NeuAc a2-3 Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-3





Gal b1-4 GlcNAc b1-2 Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


564
N-triS2
Extra-organism
Gal b1-4 GlcNAc b1-2 (NeuAc a2-3 Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-3





Gal b1-4 GlcNAc b1-2 Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


565
N-triS2
Golgi Apparatus
Gal b1-4 GlcNAc b1-2 (NeuAc a2-3 Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-3





Gal b1-4 GlcNAc b1-2 Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


566
n2m2m
Golgi Apparatus
((N-acetyl-D-glucosaminyl)2-(alpha-D-mannosyl)2-beta-D-mannosyl-diacetylchitobiose


567
n2m2mf
Golgi Apparatus
GlcNAc b1-2 Man a1-3(GlcNAc b1-2 Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-





6) GlcNAcOH


568
n3m2m
Golgi Apparatus
((N-acetyl-D-glucosaminyl)3-(alpha-D-mannosyl)2-beta-D-mannosyl-diacetylchitobiose


569
n3m2mf
Golgi Apparatus
GlcNAc b1-2 (GlcNAc b1-4) Man a1-3(GlcNAc b1-2 Man a1-6) Man b1-4 GlcNAc b1





4(Fuc a1-6) GlcNAcOH


570
n4m2m
Golgi Apparatus
((N-acetyl-D-glucosaminyl)4-(alpha-D-mannosyl)2-beta-D-mannosyl-diacetylchitobiose


571
n4m2mf
Golgi Apparatus
GlcNAc b1-2(GlcNAc b1-4) Man a1-3(GlcNAc b1-2(GlcNAc b1-6) Man a1-





6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


572
na1
Cytosol
Sodium


573
na1
Extra-organism
Sodium


574
nad
Cytosol
Nicotinamide adenine dinucleotide


575
nad
Endoplasmic
Nicotinamide adenine dinucleotide




Reticulum


576
nad
Mitochondria
Nicotinamide adenine dinucleotide


577
nadh
Cytosol
Nicotinamide adenine dinucleotide - reduced


578
nadh
Endoplasmic
Nicotinamide adenine dinucleotide - reduced




Reticulum


579
nadh
Mitochondria
Nicotinamide adenine dinucleotide - reduced


580
nadp
Cytosol
Nicotinamide adenine dinucleotide phosphate


581
nadp
Endoplasmic
Nicotinamide adenine dinucleotide phosphate




Reticulum


582
nadp
Mitochondria
Nicotinamide adenine dinucleotide phosphate


583
nadph
Cytosol
Nicotinamide adenine dinucleotide phosphate - reduced


584
nadph
Endoplasmic
Nicotinamide adenine dinucleotide phosphate - reduced




Reticulum


585
nadph
Mitochondria
Nicotinamide adenine dinucleotide phosphate - reduced


586
naglc2p
Cytosol
N-Acetyl-D-glucosaminyldiphosphodolichol (mammals)


587
nh4
Cytosol
Ammonium


588
nh4
Extra-organism
Ammonium


589
nh4
Mitochondria
Ammonium


590
nm2m
Golgi Apparatus
(N-acetyl-D-glucosaminyl-(alpha-D-mannosyl)2-beta-D-mannosyl-diacetylchitobiose


591
nm4m
Golgi Apparatus
(alpha-D-mannosyl)4-beta-D-mannosyl-diacetylchitobiose


592
nncoa
Mitochondria
nonanoyl-CoA (C9:0CoA)


593
nrvnc
Cytosol
nervonic acid


594
nrvnc
Extra-organism
nervonic acid


595
nrvnccoa
Cytosol
nervonyl coenzyme A


596
nrvnccoa
Mitochondria
nervonyl coenzyme A


597
nrvnccrn
Cytosol
Nervonyl carnitine


598
nrvnccrn
Mitochondria
Nervonyl carnitine


599
o2
Cytosol
O2


600
o2
Endoplasmic
O2




Reticulum


601
o2
Extra-organism
O2


602
o2
Mitochondria
O2


603
o2
Peroxisome
O2


604
o2−
Cytosol
Superoxide


605
o2−
Mitochondria
Superoxide


606
o2−
Peroxisome
Superoxide


607
oaa
Cytosol
Oxaloacetate


608
oaa
Mitochondria
Oxaloacetate


609
occoa
Mitochondria
Octanoyl-CoA (C8:0CoA)


610
ocdca
Cytosol
octadecanoate (n-C18:0)


611
ocdca
Extra-organism
octadecanoate (n-C18:0)


612
ocdcea
Cytosol
octadecenoate (n-C18:1)


613
ocdcea
Extra-organism
octadecenoate (n-C18:1)


614
ocdcea9
Cytosol
octadecenoate (C18:1, n-9)


615
ocdctra3
Cytosol
octadecatrienoate (C18:3, n-3)


616
ocdctra6
Cytosol
octadecatrienoate (C18:3, n-6)


617
ocdcya
Cytosol
octadecdienoate (n-C18:2)


618
ocdcya
Extra-organism
octadecdienoate (n-C18:2)


619
ocddea6
Cytosol
octadecadienoate (C18:2, n-6)


620
ocdycacoa
Cytosol
octadecadienoyl-CoA (n-C18:2CoA)


621
ocdycacoa
Mitochondria
octadecadienoyl-CoA (n-C18:2CoA)


622
ocdycacoa6
Cytosol
octadecadienoyl-CoA (C18:2CoA, n-6)


623
ocdycacoa6
Mitochondria
octadecadienoyl-CoA (C18:2CoA, n-6)


624
ocdycacrn
Cytosol
octadecadienoyl carnitine (C18:2Crn)


625
ocdycacrn
Mitochondria
octadecadienoyl carnitine (C18:2Crn)


626
ocsttea6
Cytosol
ocosatetraenoate (C22:4, n-6)


627
octa
Cytosol
octanoate


628
odcoa3
Cytosol
octadecatrienoyl-CoA (C18:3CoA, n-3)


629
odcoa3
Mitochondria
octadecatrienoyl-CoA (C18:3CoA, n-3)


630
odcoa6
Cytosol
octadecatrienoyl-CoA (C18:3CoA, n-6)


631
odcoa6
Mitochondria
octadecatrienoyl-CoA (C18:3CoA, n-6)


632
odecoa
Cytosol
Octadecenoyl-CoA (n-C18:1CoA)


633
odecoa
Mitochondria
Octadecenoyl-CoA (n-C18:1CoA)


634
odecoa9
Cytosol
octadecenoyl-CoA (C18:1CoA, n-9)


635
odecoa9
Mitochondria
octadecenoyl-CoA (C18:1CoA, n-9)


636
odecrn
Cytosol
octadecenoyl carnitine


637
odecrn
Mitochondria
octadecenoyl carnitine


638
orn-L
Cytosol
L-Ornithine


639
orn-L
Extra-organism
L-Ornithine


640
orn-L
Mitochondria
L-Ornithine


641
orot
Cytosol
Orotate


642
orot5p
Cytosol
Orotidine 5′-phosphate


643
osttcoa6
Cytosol
ocosatetraenoyl-CoA (C22:4CoA, n-6)


644
osttcoa6
Mitochondria
ocosatetraenoyl-CoA (C22:4CoA, n-6)


645
pa_CHO
Cytosol
Phosphatidate, CHO specific


646
pa_CHO
Mitochondria
Phosphatidate, CHO specific


647
pan4p
Cytosol
Pantetheine 4′-phosphate


648
pc_CHO
Cytosol
phosphatidylcholine, CHO specific


649
pdcoa
Cytosol
pentadecanoyl-CoA (C15:0CoA)


650
pdcoa
Mitochondria
pentadecanoyl-CoA (C15:0CoA)


651
pe_CHO
Cytosol
phosphatidylethanolamine, CHO specific


652
pep
Cytosol
Phosphoenolpyruvate


653
pep
Mitochondria
Phosphoenolpyruvate


654
pg_CHO
Mitochondria
phosphatidylglycerol, CHO specific


655
pgp_CHO
Mitochondria
Phosphatidylglycerophosphate, CHO specific


656
phe-L
Cytosol
L-Phenylalanine


657
phe-L
Extra-organism
L-Phenylalanine


658
pheme
Cytosol
Protoheme


659
pheme
Extra-organism
Protoheme


660
pheme
Mitochondria
Protoheme


661
phpyr
Cytosol
Phenylpyruvate


662
pi
Cytosol
Phosphate


663
pi
Endoplasmic
Phosphate




Reticulum


664
pi
Extra-organism
Phosphate


665
pi
Golgi Apparatus
Phosphate


666
pi
Mitochondria
Phosphate


667
pi
Peroxisome
Phosphate


668
pino_CHO
Cytosol
phosphatidyl-1D-myo-inositol, CHO specific


669
pmtcoa
Cytosol
Palmitoyl-CoA (n-C16:0CoA)


670
pmtcoa
Mitochondria
Palmitoyl-CoA (n-C16:0CoA)


671
pmtcrn
Cytosol
L-Palmitoylcarnitine (C16:0Crn)


672
pmtcrn
Mitochondria
L-Palmitoylcarnitine (C16:0Crn)


673
pnto-R
Cytosol
(R)-Pantothenate


674
pnto-R
Extra-organism
(R)-Pantothenate


675
ppa
Cytosol
Propionate


676
ppbng
Cytosol
Porphobilinogen


677
ppcoa
Cytosol
Propanoyl-CoA (C3:0CoA)


678
ppcoa
Mitochondria
Propanoyl-CoA (C3:0CoA)


679
ppcoa
Peroxisome
Propanoyl-CoA (C3:0CoA)


680
ppi
Cytosol
Diphosphate


681
ppi
Endoplasmic
Diphosphate




Reticulum


682
ppi
Mitochondria
Diphosphate


683
ppi
Peroxisome
Diphosphate


684
ppp9
Cytosol
Protoporphyrin


685
ppp9
Mitochondria
Protoporphyrin


686
pppg9
Cytosol
Protoporphyrinogen IX


687
pppi
Cytosol
Inorganic triphosphate


688
pram
Cytosol
5-Phospho-beta-D-ribosylamine


689
pro-L
Cytosol
L-Proline


690
pro-L
Extra-organism
L-Proline


691
pro-L
Mitochondria
L-Proline


692
prpp
Cytosol
5-Phospho-alpha-D-ribose 1-diphosphate


693
ps_CHO
Cytosol
Phosphatidylserine, CHO specific


694
pser-L
Cytosol
O-Phospho-L-serine


695
ptcoa
Mitochondria
Pentanoyl-CoA (C5:0CoA)


696
ptdca
Cytosol
pentadecanoate (C15:0)


697
ptrc
Cytosol
Putrescine


698
ptrc
Extra-organism
Putrescine


699
ptrc
Mitochondria
Putrescine


700
pyr
Cytosol
Pyruvate


701
pyr
Extra-organism
Pyruvate


702
pyr
Mitochondria
Pyruvate


703
q10h2
Mitochondria
Ubiquinol-10


704
r1p
Cytosol
alpha-D-Ribose 1-phosphate


705
r5p
Cytosol
alpha-D-Ribose 5-phosphate


706
ru5p-D
Cytosol
D-Ribulose 5-phosphate


707
s7p
Cytosol
Sedoheptulose 7-phosphate


708
sarcs
Cytosol
Sarcosine


709
sarcs
Peroxisome
Sarcosine


710
ser-L
Cytosol
L-Serine


711
ser-L
Extra-organism
L-Serine


712
ser-L
Mitochondria
L-Serine


713
so3
Cytosol
Sulfite


714
so3
Extra-organism
Sulfite


715
sphgmy_CHO
Cytosol
Sphingomyeline, CHO specific


716
sphgn
Cytosol
Sphinganine


717
spmd
Cytosol
Spermidine


718
spmd
Extra-organism
Spermidine


719
sprm
Cytosol
Spermine


720
spyr
Cytosol
3-Sulfinylpyruvate


721
spyr
Mitochondria
3-Sulfinylpyruvate


722
sql
Endoplasmic
Squalene




Reticulum


723
Ssq23epx
Endoplasmic
(S)-Squalene-2,3-epoxide




Reticulum


724
strcoa
Cytosol
Stearyl-CoA (n-C18:0CoA)


725
strcoa
Mitochondria
Stearyl-CoA (n-C18:0CoA)


726
strcrn
Cytosol
Stearoylcarnitine (C18:0Crn)


727
strcrn
Mitochondria
Stearoylcarnitine (C18:0Crn)


728
strdnccoa
Cytosol
stearidonyl coenzyme A (C18:4CoA)


729
succ
Mitochondria
Succinate


730
succoa
Mitochondria
Succinyl-CoA


731
sucsal
Mitochondria
Succinic semialdehyde


732
tcggrpp
Cytosol
trans,trans,cis-Geranylgeranyl pyrophosphate


733
tdcoa
Cytosol
Tetradecanoyl-CoA (n-C14:0CoA)


734
tdcoa
Mitochondria
Tetradecanoyl-CoA (n-C14:0CoA)


735
tdcrn
Cytosol
tetradecanoylcarnitine (C14:0Crn)


736
tdcrn
Mitochondria
tetradecanoylcarnitine (C14:0Crn)


737
tdecoa7
Cytosol
tetradecenoyl-CoA (C14:1CoA, n-7)


738
tdecoa7
Mitochondria
tetradecenoyl-CoA (C14:1CoA, n-7)


739
thbpt
Cytosol
Tetrahydrobiopterin


740
thcholstoic
Peroxisome
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholestanoate


741
thf
Cytosol
5,6,7,8-Tetrahydrofolate


742
thf
Mitochondria
5,6,7,8-Tetrahydrofolate


743
thr-L
Cytosol
L-Threonine


744
thr-L
Extra-organism
L-Threonine


745
thr-L
Mitochondria
L-Threonine


746
thymd
Cytosol
Thymidine


747
thymd
Extra-organism
Thymidine


748
trdcoa
Mitochondria
tridecanoyl-CoA (C13:0CoA)


749
trdox
Cytosol
Oxidized thioredoxin


750
trdrd
Cytosol
Reduced thioredoxin


751
triglyc_CHO
Cytosol
Triglyceride, CHO specific


752
trp-L
Cytosol
L-Tryptophan


753
trp-L
Extra-organism
L-Tryptophan


754
tsul
Cytosol
Thiosulfate


755
ttc
Cytosol
tetracosanoate (n-C24:0)


756
ttc
Extra-organism
tetracosanoate (n-C24:0)


757
ttdca
Cytosol
tetradecanoate (C14:0)


758
ttdca
Extra-organism
tetradecanoate (C14:0)


759
ttdcea7
Cytosol
tetradecenoate (C14:1, n-7)


760
tyr-L
Cytosol
L-Tyrosine


761
tyr-L
Extra-organism
L-Tyrosine


762
tyr-L
Mitochondria
L-Tyrosine


763
uacgam
Cytosol
UDP-N-acetyl-D-glucosamine


764
uacgam
Golgi Apparatus
UDP-N-acetyl-D-glucosamine


765
ubq10
Mitochondria
Ubiquinone-10


766
udp
Cytosol
UDP


767
udp
Golgi Apparatus
UDP


768
udpg
Cytosol
UDPglucose


769
udpgal
Cytosol
UDPgalactose


770
udpgal
Golgi Apparatus
UDPgalactose


771
ump
Cytosol
UMP


772
ump
Golgi Apparatus
UMP


773
uppg3
Cytosol
Uroporphyrinogen III


774
urcan
Cytosol
Urocanate


775
urea
Cytosol
Urea


776
urea
Extra-organism
Urea


777
urea
Mitochondria
Urea


778
uri
Cytosol
Uridine


779
utp
Cytosol
UTP


780
val-L
Cytosol
L-Valine


781
val-L
Extra-organism
L-Valine


782
val-L
Mitochondria
L-Valine


783
xmp
Cytosol
Xanthosine 5′-phosphate


784
xol7a
Endoplasmic
7 alpha-Hydroxycholesterol




Reticulum


785
xol7aone
Endoplasmic
7alpha-Hydroxycholest-4-en-3-one




Reticulum


786
xu5p-D
Cytosol
D-Xylulose 5-phosphate


787
zym_int2
Endoplasmic
zymosterone




Reticulum


788
zymst
Endoplasmic
Zymosterol




Reticulum


789
zymstnl
Endoplasmic
Zymostenol




Reticulum



















TABLE 8






Gene

Reaction


No.
Description
Reaction
name







1281
Gal b1-4 GlcNAc b1-2 Man a1-3(Gal b1-4 GlcNAc b1-2 Man a1-6) Man b1-
[e]: N-bi <==>
EX_N-bi(e)



4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH exchange


1282
Gal b1-4 GlcNAc b1-2 Man a1-3(NeuAc a2-3 Gal b1-4 GlcNAc b1-2 Man a1-
[e]: N-biS1 <==>
EX_N-biS1(e)



6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH exchange


1283
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(Gal b1-4 GlcNAc b1-
[e]: N-tetra/N-triLac1 <==>
EX_N-tetra/N-triLac1(e)



2(Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-



6) GlcNAcOH exchange


1284
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(Gal b1-4 GlcNAc b1-
[e]: N-tetraLac1 <==>
EX_N-tetraLac1(e)



2(Gal b1-4 GlcNAc b1-3 Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-



4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH exchange


1285
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(Gal b1-4 GlcNAc b1-
[e]: N-tetraLac1S1 <==>
EX_N-tetraLac1S1(e)



2(NeuAc a2-3 Gal b1-4 GlcNAc b1-3 Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-



4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH exchange


1286
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-4
[e]: N-tetraLac1S2 <==>
EX_N-tetraLac1S2(e)



GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-3 Gal b1-4 GlcNAc b1-



6) Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH exchange


1287
Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-
[e]: N-tetraLac1S3 <==>
EX_N-tetraLac1S3(e)



4 GlcNAc b1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-



6)Manb1-4GlcNAcb1-4(Fuc a1-6)GlcNAcOH exchange


1288
NeuAca2-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-4)Mana1-
[e]: N-tetraLac1S4 <==>
EX_N-tetraLac1S4(e)



3(NeuAca2-3Galb1-4 GlcNAc b1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-



4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuc a1-6)GlcNAcOH exchange


1289
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-3(Galb1-4GlcNAcb1-3Galb1-
[e]: N-tetraLac2 <==>
EX_N-tetraLac2(e)



4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-



4GlcNAcb1-4(Fuca1-6)GlcNAcOH exchange


1290
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-3(Galb1-4GlcNAcb1-3Galb1-
[e]: N-tetraLac2S1 <==>
EX_N-tetraLac2S1(e)



4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-



6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH exchange


1291
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-
[e]: N-tetraLac2S2 <==>
EX_N-tetraLac2S2(e)



4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-



4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH exchange


1292
Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-
[e]: N-tetraLac2S3 <==>
EX_N-tetraLac2S3(e)



4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-



4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH exchange


1293
NeuAca2-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-4)Mana1-
[e]: N-tetraLac2S4 <==>
EX_N-tetraLac2S4(e)



3(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-



4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-



6)GlcNAcOH exchange


1294
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-4)Mana1-3(Galb1-
[e]: N-tetraLac3 <==>
EX_N-tetraLac3(e)



4GlcNAcb1-3Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-



6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH exchange


1295
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-4)Mana1-3(Galb1-
[e]: N-tetraLac3S1 <==>
EX_N-tetraLac3S1(e)



4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-



4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH exchange


1296
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-4)Mana1-
[e]: N-tetraLac3S2 <==>
EX_N-tetraLac3S2(e)



3(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-



4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-



6)GlcNAcOH exchange


1297
Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
[e]: N-tetraLac3S3 <==>
EX_N-tetraLac3S3(e)



4)Mana1-3(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-



3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-



4(Fuca1-6)GlcNAcOH exchange


1298
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-
[e]: N-tetraS1/N-triLac1S1
EX_N-tetraS1/N-triLac1S1(e)



4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-
<==>



4(Fuc a1-6) GlcNAcOH exchange


1299
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-
[e]: N-tetraS2/N-triLac1S2
EX_N-tetraS2/N-triLac1S2(e)



4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-
<==>



4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH exchange


1300
Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-
[e]: N-tetraS3 <==>
EX_N-tetraS3(e)



3 Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-



4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH exchange


1301
NeuAc a2-3 Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-4) Man a1-
[e]: N-tetraS4 <==>
EX_N-tetraS4(e)



3(NeuAc a2-3 Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-



6) Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH exchange


1302
Gal b1-4 GlcNAc b1-2 (Gal b1-4 GlcNAc b1-4) Man a1-3(Gal b1-4 GlcNAc b1-
[e]: N-tri <==>
EX_N-tri(e)



2 Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH exchange


1303
Gal b1-4 GlcNAc b1-2 (Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-4
[e]: N-triS1 <==>
EX_N-triS1(e)



GlcNAc b1-2 Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH exchange


1304
Gal b1-4 GlcNAc b1-2 (NeuAc a2-3 Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-
[e]: N-triS2 <==>
EX_N-triS2(e)



3 Gal b1-4 GlcNAc b1-2 Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-



6) GlcNAcOH exchange


1305
Adenine exchange
[e]: ade <==>
EX_ade(e)


1306
L-Alanine exchange
[e]: ala-L <==>
EX_ala-L(e)


1307
Arachidonic acid (C20:4) exchange
[e]: arachda <==>
EX_arachda(e)


1308
L-Arginine exchange
[e]: arg-L <==>
EX_arg-L(e)


1309
L-Asparagine exchange
[e]: asn-L <==>
EX_asn-L(e)


1310
L-Aspartate exchange
[e]: asp-L <==>
EX_asp-L(e)


1311
Choline exchange
[e]: chol <==>
EX_chol(e)


1312
Citrate exchange
[e]: cit <==>
EX_cit(e)


1313
CO2 exchange
[e]: co2 <==>
EX_co2(e)


1314
L-Cysteine exchange
[e]: cys-L <==>
EX_cys-L(e)


1315
docosahexaenoate (C22:6) exchange
[e]: dcshea <==>
EX_dcshea(e)


1316
docosapentaenoic acid (C22:5) exchange
[e]: dcspea <==>
EX_dcspea(e)


1317
Eicosanoate (n-C20:0) exchange
[e]: ecsa <==>
EX_ecsa(e)


1318
Eicosapentaenoic acid (C20:5) exchange
[e]: ecspea <==>
EX_ecspea(e)


1319
eicosatrienoate exchange
[e]: ecstea <==>
EX_ecstea(e)


1320
Ethanolamine exchange
[e]: etha <==>
EX_etha(e)


1321
Fe2+ exchange
[e]: fe2 <==>
EX_fe2(e)


1322
Folate exchange
[e]: fol <==>
EX_fol(e)


1323
Formate exchange
[e]: for <==>
EX_for(e)


1324
D-Glucose exchange
[e]: glc-D <==>
EX_glc(e)


1325
L-Glutamine exchange
[e]: gln-L <==>
EX_gln-L(e)


1326
L-Glutamate exchange
[e]: glu-L <==>
EX_glu-L(e)


1327
Glycine exchange
[e]: gly <==>
EX_gly(e)


1328
H+ exchange
[e]: h <==>
EX_h(e)


1329
H2O exchange
[e]: h2o <==>
EX_h2o(e)


1330
Fatty acid (Palmitate, n-C16:0) exchange
[e]: hdca <==>
EX_hdca(e)


1331
hexadecenoate (n-C16:1) exchange
[e]: hdcea <==>
EX_hdcea(e)


1332
L-Histidine exchange
[e]: his-L <==>
EX_his-L(e)


1333
Hypoxanthine exchange
[e]: hxan <==>
EX_hxan(e)


1334
L-Isoleucine exchange
[e]: ile-L <==>
EX_ile-L(e)


1335
myo-Inositol exchange
[e]: inost <==>
EX_inost(e)


1336
Inosine exchange
[e]: ins <==>
EX_ins(e)


1337
L-Lactate exchange
[e]: lac-L <==>
EX_lac-L(e)


1338
L-Leucine exchange
[e]: leu-L <==>
EX_leu-L(e)


1339
Linolenic acid (C18:3) exchange
[e]: lnlne <==>
EX_lnlne(e)


1340
L-Lysine exchange
[e]: lys-L <==>
EX_lys-L(e)


1341
L-Methionine exchange
[e]: met-L <==>
EX_met-L(e)


1342
Sodium exchange
[e]: na1 <==>
EX_na1(e)


1343
Ammonium exchange
[e]: nh4 <==>
EX_nh4(e)


1344
nervonic acid exchange
[e]: nrvnc <==>
EX_nrvnc(e)


1345
O2 exchange
[e]: o2 <==>
EX_o2(e)


1346
Octadecanoate (stearate) exchange
[e]: ocdca <==>
EX_ocdca(e)


1347
octadecenoate (n-C18:1) exchange
[e]: ocdcea <==>
EX_ocdcea(e)


1348
octadecynoate (n-C18:2) exchange
[e]: ocdcya <==>
EX_ocdcya(e)


1349
L-Phenylalanine exchange
[e]: phe-L <==>
EX_phe-L(e)


1350
Protoheme exchange
[e]: pheme <==>
EX_pheme(e)


1351
Phosphate exchange
[e]: pi <==>
EX_pi(e)


1352
(R)-Pantothenate exchange
[e]: pnto-R <==>
EX_pnto-R(e)


1353
L-Proline exchange
[e]: pro-L <==>
EX_pro-L(e)


1354
Putrescine exchange
[e]: ptrc <==>
EX_ptrc(e)


1355
Pyruvate exchange
[e]: pyr <==>
EX_pyr(e)


1356
Exchange for Serine
[e]: ser-L <==>
EX_ser-L(e)


1357
Sulfite exchange
[e]: so3 <==>
EX_so3(e)


1358
Spermidine exchange
[e]: spmd <==>
EX_spmd(e)


1359
L-Threonine exchange
[e]: thr-L <==>
EX_thr-L(e)


1360
Thymidine exchange
[e]: thymd <==>
EX_thymd(e)


1361
L-Tryptophan exchange
[e]: trp-L <==>
EX_trp-L(e)


1362
tetracosanoate (n-C24:0) exchange
[e]: ttc <==>
EX_ttc(e)


1363
tetradecanoate (n-C14:0) exchange
[e]: ttdca <==>
EX_ttdca(e)


1364
L-Tyrosine exchange
[e]: tyr-L <==>
EX_tyr-L(e)


1365
Urea exchange
[e]: urea <==>
EX_urea(e)


1366
L-Valine exchange
[e]: val-L <==>
EX_val-L(e)



















TABLE 9





No.
Metab Abbreviation
Compartment
Metabolite Name


















1
10fthf
Cytosol
10-Formyltetrahydrofolate


2
10fthf
Mitochondria
10-Formyltetrahydrofolate


3
10fthf5glu
Cytosol
10-formyltetrahydrofolate-[Glu](5)


4
10fthf5glu
Mitochondria
10-formyltetrahydrofolate-[Glu](5)


5
10fthf6glu
Cytosol
10-formyltetrahydrofolate-[Glu](6)


6
10fthf6glu
Mitochondria
10-formyltetrahydrofolate-[Glu](6)


7
10fthf7glu
Cytosol
10-formyltetrahydrofolate-[Glu](7)


8
10fthf7glu
Mitochondria
10-formyltetrahydrofolate-[Glu](7)


9
12dgr_CHO
Cytosol
1,2-Diacylglycerol, CHO


10
12ppd-R
Cytosol
(R)-Propane-1,2-diol


11
12ppd-S
Cytosol
(S)-Propane-1,2-diol


12
13dpg
Cytosol
3-Phospho-D-glyceroyl phosphate


13
17ahprgnlone
Cytosol
17alpha-Hydroxypregnenolone


14
17ahprgstrn
Cytosol
17alpha-Hydroxyprogesterone


15
1ag3p_CHO
Cytosol
1-Acyl-sn-glycerol 3-phosphate, CHO


16
1aglycpc_CHO
Cytosol
1-Acyl-sn-glycero-3-phosphocholine, CHO specific


17
1pyr5c
Cytosol
1-Pyrroline-5-carboxylate


18
1pyr5c
Mitochondria
1-Pyrroline-5-carboxylate


19
23dpg
Cytosol
3-Phospho-D-glycerol phosphate


20
25aics
Cytosol
(S)-2-[5-Amino-1-(5-phospho-D-ribosyl)imidazole-4-





carboxamido]succinate


21
2aacl
Cytosol
2-Aminoacrylate


22
2aadp
Mitochondria
L-2-Aminoadipate


23
2aeppn
Cytosol
(2-Aminoethyl)phosphonate


24
2amuc
Cytosol
2-Aminomuconate


25
2aobut
Mitochondria
L-2-Amino-3-oxobutanoate


26
2dp6mep
Mitochondria
2-Decaprenyl-6-methoxyphenol


27
2dp6mobq
Mitochondria
2-Decaprenyl-6-methoxy-1,4-benzoquinone


28
2dp6mobq_me
Mitochondria
2-Decaprenyl-3-methyl-6-methoxy-1,4-benzoquinone


29
2dpmhobq
Mitochondria
2-Decaprenyl-3-methyl-5-hydroxy-6-methoxy-1,4-





benzoquinone


30
2dr1p
Cytosol
2-Deoxy-D-ribose 1-phosphate


31
2hbut
Cytosol
2-Hydroxybutyrate


32
2maacoa
Mitochondria
2-Methyl-3-acetoacetyl-CoA


33
2mb2coa
Mitochondria
trans-2-Methylbut-2-enoyl-CoA


34
2mbcoa
Mitochondria
2-Methylbutanoyl-CoA


35
2mop
Mitochondria
2-Methyl-3-oxopropanoate


36
2mp2coa
Mitochondria
2-Methylprop-2-enoyl-CoA


37
2obut
Cytosol
2-Oxobutanoate


38
2obut
Mitochondria
2-Oxobutanoate


39
2oxoadp
Cytosol
2-Oxoadipate


40
2oxoadp
Mitochondria
2-Oxoadipate


41
2pg
Cytosol
D-Glycerate 2-phosphate


42
34hpp
Cytosol
3-(4-Hydroxyphenyl)pyruvate


43
34hpp
Mitochondria
3-(4-Hydroxyphenyl)pyruvate


44
3dpdhb
Mitochondria
3-Decaprenyl-4,5-dihdydroxybenzoate


45
3dpdhb_me
Mitochondria
3-Decaprenyl-4-hydroxy-5-methoxybenzoate


46
3dsphgn
Cytosol
3-Dehydrosphinganine


47
3h26dm5coa
Mitochondria
3-Hydroxy-2,6-dimethyl-5-methylene-heptanoyl-





CoA


48
3h26dm5coa
Peroxisome
3-Hydroxy-2,6-dimethyl-5-methylene-heptanoyl-





CoA


49
3hanthrn
Cytosol
3-Hydroxyanthranilate


50
3hbycoa
Mitochondria
(S)-3-Hydroxybutyryl-CoA


51
3hbycoa
Peroxisome
(S)-3-Hydroxybutyryl-CoA


52
3hmbcoa
Mitochondria
(S)-3-Hydroxy-2-methylbutyryl-CoA


53
3hmp
Mitochondria
(S)-3-hydroxyisobutyrate


54
3hpcoa
Mitochondria
3-Hydroxypropionyl-CoA


55
3htmelys
Cytosol
3-Hydroxy-N6,N6,N6-trimethyl-L-lysine


56
3htmelys
Mitochondria
3-Hydroxy-N6,N6,N6-trimethyl-L-lysine


57
3mb2coa
Mitochondria
3-Methylbut-2-enoyl-CoA


58
3mgcoa
Mitochondria
3-Methylglutaconyl-CoA


59
3mob
Mitochondria
3-Methyl-2-oxobutanoate


60
3mop
Mitochondria
(S)-3-Methyl-2-oxopentanoate


61
3odcoa
Peroxisome
3-Oxodecanoyl-CoA


62
3oddcoa
Peroxisome
3-Oxododecanoyl-CoA


63
3ohdcoa
Peroxisome
3-Oxohexadecanoyl-CoA


64
3ohxccoa
Peroxisome
3-Oxohexacosanoyl-CoA


65
3oodcoa
Peroxisome
3-Oxooctadecanoyl-CoA


66
3otdcoa
Peroxisome
3-Oxotetradecanoyl-CoA


67
3padsel
Cytosol
3′-Phosphoadenylylselenate


68
3pg
Cytosol
3-Phospho-D-glycerate


69
3php
Cytosol
3-Phosphohydroxypyruvate


70
3sala
Cytosol
3-Sulfino-L-alanine


71
3sala
Mitochondria
3-Sulfino-L-alanine


72
44mctr
Endoplasmic Reticulum
4,4-dimethylcholesta-8,14,24-trienol


73
44mzym
Endoplasmic Reticulum
4,4-dimethylzymosterol


74
46dhqnl
Cytosol
4,6-Dihydroxyquinoline


75
48dhqnl
Cytosol
4,8-Dihydroxyquinoline


76
4abut
Cytosol
4-Aminobutanoate


77
4abut
Mitochondria
4-Aminobutanoate


78
4abutn
Cytosol
4-Aminobutanal


79
4fumacac
Cytosol
4-Fumarylacetoacetate


80
4h2oxg
Cytosol
D-4-Hydroxy-2-oxoglutarate


81
4h2oxg
Mitochondria
D-4-Hydroxy-2-oxoglutarate


82
4izp
Cytosol
4-Imidazolone-5-propanoate


83
4mlacac
Cytosol
4-Maleylacetoacetate


84
4mop
Mitochondria
4-Methyl-2-oxopentanoate


85
4mzym_int1
Endoplasmic Reticulum
4-Methylzymosterol intermediate 1


86
4mzym_int2
Endoplasmic Reticulum
4-Methylzymosterol intermediate 2


87
4ppan
Cytosol
D-4′-Phosphopantothenate


88
4ppcys
Cytosol
N-((R)-4-Phosphopantothenoyl)-L-cysteine


89
4tmeabut
Cytosol
4-Trimethylammoniobutanal


90
4tmeabut
Mitochondria
4-Trimethylammoniobutanal


91
56dthm
Cytosol
5,6-Dihydrothymine


92
56dura
Cytosol
5,6-dihydrouracil


93
5aizc
Cytosol
5-amino-1-(5-phospho-D-ribosyl)imidazole-4-





carboxylate


94
5aop
Cytosol
5-Amino-4-oxopentanoate


95
5aop
Mitochondria
5-Amino-4-oxopentanoate


96
5dhf
Cytosol
pentaglutamyl folate (DHF)


97
5dhf
Mitochondria
pentaglutamyl folate (DHF)


98
5dpmev
Peroxisome
(R)-5-Diphosphomevalonate


99
5fthf
Cytosol
5-Formiminotetrahydrofolate


100
5hkyrm
Cytosol
5-Hydroxykynurenamine


101
5mdr1p
Cytosol
5-Methylthio-5-deoxy-D-ribose 1-phosphate


102
5mta
Cytosol
5-Methylthioadenosine


103
5mthf
Cytosol
5-Methyltetrahydrofolate


104
5oxpro
Cytosol
5-Oxoproline


105
5pmev
Peroxisome
(R)-5-Phosphomevalonate


106
5thf
Cytosol
pentaglutamyl folate (THF)


107
5thf
Mitochondria
pentaglutamyl folate (THF)


108
6dhf
Cytosol
haxglutamyl folate (DHF)


109
6dhf
Mitochondria
haxglutamyl folate (DHF)


110
6pgc
Cytosol
6-Phospho-D-gluconate


111
6pgc
Endoplasmic Reticulum
6-Phospho-D-gluconate


112
6pgl
Cytosol
6-phospho-D-glucono-1,5-lactone


113
6pgl
Endoplasmic Reticulum
6-phospho-D-glucono-1,5-lactone


114
6pthp
Cytosol
6-Pyruvoyl-5,6,7,8-tetrahydropterin


115
6thf
Cytosol
hexaglutamyl folate (THF)


116
6thf
Mitochondria
hexaglutamyl folate (THF)


117
7dhchsterol
Endoplasmic Reticulum
7-Dehydrocholesterol


118
7dhf
Cytosol
heptaglutamyl folate (DHF)


119
7dhf
Mitochondria
heptaglutamyl folate (DHF)


120
7thf
Cytosol
heptaglutamyl folate (THF)


121
7thf
Mitochondria
heptaglutamyl folate (THF)


122
a3n4m2mf
Golgi Apparatus
Gal b1-4 GlcNAc b1-2 (GlcNAc b1-3 Gal b1-





4 GlcNAc b1-4) Man a1-3(Gal b1-4 GlcNAc b1-





2 Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-





6) GlcNAcOH


123
a4n5m2mf
Golgi Apparatus
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-





4) Man a1-3(Gal b1-4 GlcNAc b1-2(GlcNAc b1-





3 Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-





4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


124
a5n6m2mf
Golgi Apparatus
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-





3(GlcNAcb1-3Galb1-4GlcNAcb1-2(Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-





4GlcNAcb1-4(Fuc a1-6)GlcNAcOH


125
a6n7m2mf
Golgi Apparatus
Galb1-4GlcNAcb1-2(GlcNAcb1-3Galb1-4GlcNAcb1





4)Mana1-3(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





2(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-





6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcOH


126
aacoa
Cytosol
Acetoacetyl-CoA


127
aacoa
Mitochondria
Acetoacetyl-CoA


128
aacoa
Peroxisome
Acetoacetyl-CoA


129
ac
Cytosol
Acetate


130
acac
Cytosol
Acetoacetate


131
acac
Mitochondria
Acetoacetate


132
acac
Peroxisome
Acetoacetate


133
acACP
Cytosol
Acetyl-ACP


134
acald
Cytosol
Acetaldehyde


135
acald
Peroxisome
Acetaldehyde


136
accoa
Cytosol
Acetyl-CoA


137
accoa
Mitochondria
Acetyl-CoA


138
accoa
Peroxisome
Acetyl-CoA


139
acg5p
Mitochondria
N-Acetyl-L-glutamyl 5-phosphate


140
acg5sa
Mitochondria
N-Acetyl-L-glutamate 5-semialdehyde


141
acgal
Lysosome
N-Acetyl-D-galactosamine


142
acgam
Cytosol
N-Acetyl-D-glucosamine


143
acgam
Lysosome
N-Acetyl-D-glucosamine


144
acgam1p
Cytosol
N-Acetyl-D-glucosamine 1-phosphate


145
acgam6p
Cytosol
N-Acetyl-D-glucosamine 6-phosphate


146
acmana
Cytosol
N-Acetyl-D-mannosamine


147
acmanap
Cytosol
N-Acetyl-D-mannosamine 6-phosphate


148
acmucsal
Cytosol
2-Amino-3-carboxymuconate semialdehyde


149
acnam
Cytosol
N-Acetylneuraminate


150
acnam
Lysosome
N-Acetylneuraminate


151
acnam
Nucleus
N-Acetylneuraminate


152
acnr9p
Cytosol
N-Acetylneuraminate 9-phosphate


153
acorn
Cytosol
N2-Acetyl-L-ornithine


154
ACP
Cytosol
acyl carrier protein


155
ACP
Mitochondria
acyl carrier protein


156
acrn
Cytosol
O-Acetylcarnitine


157
acrn
Mitochondria
O-Acetylcarnitine


158
ade
Cytosol
Adenine


159
ade
Extra-organism
Adenine


160
adn
Cytosol
Adenosine


161
adp
Cytosol
ADP


162
adp
Mitochondria
ADP


163
adp
Nucleus
ADP


164
adp
Peroxisome
ADP


165
adrncoa
Mitochondria
adrenyl-CoA (C22:4CoA)


166
adrncoa
Peroxisome
adrenyl-CoA (C22:4CoA)


167
adrnl
Cytosol
Adrenaline


168
adsel
Cytosol
Adenylylselenate


169
agm
Mitochondria
Agmatine


170
ahcys
Cytosol
S-Adenosyl-L-homocysteine


171
ahcys
Mitochondria
S-Adenosyl-L-homocysteine


172
ahdt
Cytosol
2-Amino-4-hydroxy-6-(erythro-1,2,3-





trihydroxypropyl)dihydropteridine triphosphate


173
ahdt
Nucleus
2-Amino-4-hydroxy-6-(erythro-1,2,3-





trihydroxypropyl)dihydropteridine triphosphate


174
ahpoxbut
Cytosol
4-(2-Amino-3-hydroxyphenyl)-2,4-dioxobutanoate


175
aicar
Cytosol
5-Amino-1-(5-Phospho-D-ribosyl)imidazole-4-





carboxamide


176
air
Cytosol
5-amino-1-(5-phospho-D-ribosyl)imidazole


177
akg
Cytosol
2-Oxoglutarate


178
akg
Mitochondria
2-Oxoglutarate


179
ala-L
Cytosol
L-Alanine


180
ala-L
Extra-organism
L-Alanine


181
ala-L
Mitochondria
L-Alanine


182
alpam
Mitochondria
S-aminomethyldihydrolipoamide


183
alpro
Mitochondria
S-Aminomethyldihydrolipoylprotein


184
amet
Cytosol
S-Adenosyl-L-methionine


185
amet
Mitochondria
S-Adenosyl-L-methionine


186
ametam
Cytosol
S-Adenosylmethioninamine


187
amp
Cytosol
AMP


188
amp
Endoplasmic Reticulum
AMP


189
amp
Mitochondria
AMP


190
amp
Peroxisome
AMP


191
ampsal
Mitochondria
L-2-Aminoadipate 6-semialdehyde


192
amucsal
Cytosol
2-Aminomuconate semialdehyde


193
apoC-Lys
Cytosol
Apocarboxylase (Lys residue)


194
apoC-Lys
Mitochondria
Apocarboxylase (Lys residue)


195
apoC-Lys_btn
Cytosol
Holocarboxylase (biotin covalent bound to Lys





residue of apoC)


196
apoC-Lys_btn
Mitochondria
Holocarboxylase (biotin covalent bound to Lys





residue of apoC)


197
aprut
Cytosol
N-Acetylputrescine


198
aps
Cytosol
Adenosine 5′-phosphosulfate


199
arachcoa
Mitochondria
arachidyl coenzyme A


200
arachcoa
Peroxisome
arachidyl coenzyme A


201
arachda
Cytosol
Arachidonic acid (C20:4)


202
arachda
Extra-organism
Arachidonic acid (C20:4)


203
arachdcoa
Cytosol
arachidonoyl-CoA (C20:4CoA, n-6)


204
arachdcoa
Mitochondria
arachidonoyl-CoA (C20:4CoA, n-6)


205
arachdcoa
Peroxisome
arachidonoyl-CoA (C20:4CoA, n-6)


206
arachdcrn
Cytosol
C20:4 carnitine


207
arachdcrn
Mitochondria
C20:4 carnitine


208
arg-L
Cytosol
L-Arginine


209
arg-L
Extra-organism
L-Arginine


210
arg-L
Mitochondria
L-Arginine


211
argsuc
Cytosol
N(omega)-(L-Arginino)succinate


212
ascb
Cytosol
L-Ascorbate


213
ascb
Extra-organism
L-Ascorbate


214
asn-L
Cytosol
L-Asparagine


215
asn-L
Extra-organism
L-Asparagine


216
asn-L
Mitochondria
L-Asparagine


217
Asn-X-Ser/Thr
Lysosome
protein-linked asparagine residue (N-glycosylation





site)


218
asp-L
Cytosol
L-Aspartate


219
asp-L
Extra-organism
L-Aspartate


220
asp-L
Mitochondria
L-Aspartate


221
atp
Cytosol
ATP


222
atp
Endoplasmic Reticulum
ATP


223
atp
Mitochondria
ATP


224
atp
Nucleus
ATP


225
atp
Peroxisome
ATP


226
b2coa
Mitochondria
trans-But-2-enoyl-CoA


227
b2coa
Peroxisome
trans-But-2-enoyl-CoA


228
bcar
Cytosol
beta-Carotene


229
btamp
Cytosol
Biotinyl-5′-AMP


230
btamp
Mitochondria
Biotinyl-5′-AMP


231
btcoa
Mitochondria
Butanoyl-CoA (C4:0CoA)


232
btn
Cytosol
Biotin


233
btn
Mitochondria
Biotin


234
but
Cytosol
Butyrate


235
but
Mitochondria
Butyrate


236
bz
Endoplasmic Reticulum
Benzoate


237
c2m26dcoa
Mitochondria
cis-2-Methyl-5-isopropylhexa-2,5-dienoyl-CoA


238
c2m26dcoa
Peroxisome
cis-2-Methyl-5-isopropylhexa-2,5-dienoyl-CoA


239
cala
Cytosol
N-Carbamoyl-beta-alanine


240
camp
Cytosol
cAMP


241
cbasp
Cytosol
N-Carbamoyl-L-aspartate


242
cbp
Cytosol
Carbamoyl phosphate


243
cbp
Mitochondria
Carbamoyl phosphate


244
cdp
Cytosol
CDP


245
cdp
Mitochondria
CDP


246
cdp
Nucleus
CDP


247
cdpchol
Cytosol
CDPcholine


248
cdpdag_CHO
Cytosol
CDPdiacylglycerol, CHO specific


249
cdpdag_CHO
Mitochondria
CDPdiacylglycerol, CHO specific


250
cdpea
Cytosol
CDPethanolamine


251
cer_CHO
Cytosol
ceramide, CHO specific


252
cgly
Cytosol
Cys-Gly


253
cgly
Extra-organism
Cys-Gly


254
cgmp
Cytosol
3′,5′-Cyclic GMP


255
chito2pdol
Cytosol
N,N′-Diacetylchitobiosyldiphosphodolichol,





mammals


256
chol
Cytosol
Choline


257
chol
Extra-organism
Choline


258
cholcoa
Peroxisome
Choloyl-CoA


259
cholcoads
Peroxisome
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholest-24-





enoyl-CoA


260
cholcoaone
Peroxisome
3alpha,7alpha,12alpha-Trihydroxy-5beta-24-





oxocholestanoyl-CoA


261
cholcoar
Endoplasmic Reticulum
3alpha,7alpha,12alpha-Trihydroxy-5beta-





cholestanoyl-CoA


262
cholcoar
Peroxisome
3alpha,7alpha,12alpha-Trihydroxy-5beta-





cholestanoyl-CoA


263
cholcoas
Peroxisome
3alpha,7alpha,12alpha-Trihydroxy-5beta-





cholestanoyl-CoA(S)


264
cholp
Cytosol
Choline phosphate


265
cholsd
Endoplasmic Reticulum
5alpha-Cholesta-7,24-dien-3beta-ol


266
cholse_CHO
Cytosol
Cholesterol ester, CHO specific


267
chsterol
Cytosol
Cholesterol


268
chsterol
Endoplasmic Reticulum
Cholesterol


269
chsterol
Extra-organism
Cholesterol


270
chsterol
Golgi Apparatus
Cholesterol


271
cis-dd2coa
Mitochondria
3-cis-Dodecenoyl-CoA


272
cit
Cytosol
Citrate


273
cit
Extra-organism
Citrate


274
cit
Mitochondria
Citrate


275
citr-L
Cytosol
L-Citrulline


276
citr-L
Mitochondria
L-Citrulline


277
clpn_CHO
Cytosol
cardiolipin, CHO specific


278
clpn_CHO
Mitochondria
cardiolipin, CHO specific


279
clpndcoa
Cytosol
clupanodonyl CoA (C22:5CoA)


280
clpndcoa
Mitochondria
clupanodonyl CoA (C22:5CoA)


281
clpndcoa
Peroxisome
clupanodonyl CoA (C22:5CoA)


282
clpndcrn
Cytosol
docosapentaenoyl carnitine (C22:5)


283
clpndcrn
Mitochondria
docosapentaenoyl carnitine (C22:5)


284
cmp
Cytosol
CMP


285
cmp
Golgi Apparatus
CMP


286
cmp
Mitochondria
CMP


287
cmp
Nucleus
CMP


288
cmp2amep
Cytosol
CMP-2-aminoethylphosphonate


289
cmpacna
Cytosol
CMP-N-acetylneuraminate


290
cmpacna
Golgi Apparatus
CMP-N-acetylneuraminate


291
cmpacna
Nucleus
CMP-N-acetylneuraminate


292
cmpntm2amep
Cytosol
CMP-N-trimethyl-2-aminoethylphosphonate


293
co2
Cytosol
CO2


294
co2
Endoplasmic Reticulum
CO2


295
co2
Extra-organism
CO2


296
co2
Golgi Apparatus
CO2


297
co2
Mitochondria
CO2


298
co2
Peroxisome
CO2


299
coa
Cytosol
Coenzyme A


300
coa
Endoplasmic Reticulum
Coenzyme A


301
coa
Mitochondria
Coenzyme A


302
coa
Peroxisome
Coenzyme A


303
coke
Endoplasmic Reticulum
cocaine


304
core6
Lysosome
Core 6


305
cpppg3
Cytosol
Coproporphyrinogen III


306
crn
Cytosol
L-Carnitine


307
crn
Mitochondria
L-Carnitine


308
cs_a
Lysosome
chondroitin sulfate A (GalNAc4S-GlcA), free chain


309
cs_a_deg1
Lysosome
chondroitin sulfate A (GalNAc4S-GlcA),





degradation product 1


310
cs_a_deg2
Lysosome
chondroitin sulfate A (GalNAc4S-GlcA),





degradation product 2


311
cs_a_deg3
Lysosome
chondroitin sulfate A (GalNAc4S-GlcA),





degradation product 3


312
cs_a_deg4
Lysosome
chondroitin sulfate A (GalNAc4S-GlcA),





degradation product 4


313
cs_a_deg5
Lysosome
chondroitin sulfate A (GalNAc4S-GlcA),





degradation product 5


314
cs_b
Lysosome
chondroitin sulfate B/dermatan sulfate (IdoA2S-





GalNAc4S), free chain


315
cs_b_deg1
Lysosome
chondroitin sulfate B/dermatan sulfate (IdoA2S-





GalNAc4S), degradation product 1


316
cs_b_deg2
Lysosome
chondroitin sulfate B/dermatan sulfate (IdoA2S-





GalNAc4S), degradation product 2


317
cs_c
Lysosome
chondroitin sulfate C (GalNAc6S-GlcA), free chain


318
cs_c_deg1
Lysosome
chondroitin sulfate C (GalNAc6S-GlcA), degradation





product 1


319
cs_c_deg2
Lysosome
chondroitin sulfate C (GalNAc6S-GlcA), degradation





product 2


320
cs_c_deg3
Lysosome
chondroitin sulfate C (GalNAc6S-GlcA), degradation





product 3


321
cs_c_deg4
Lysosome
chondroitin sulfate C (GalNAc6S-GlcA), degradation





product 4


322
cs_c_deg5
Lysosome
chondroitin sulfate C (GalNAc6S-GlcA), degradation





product 5


323
cs_d
Lysosome
chondroitin sulfate D (GlcNAc6S-GlcA2S), free





chain


324
cs_d_deg1
Lysosome
chondroitin sulfate D (GlcNAc6S-GlcA2S),





degradation product 1


325
cs_d_deg2
Lysosome
chondroitin sulfate D (GlcNAc6S-GlcA2S),





degradation product 2


326
cs_d_deg3
Lysosome
chondroitin sulfate D (GlcNAc6S-GlcA2S),





degradation product 3


327
cs_d_deg4
Lysosome
chondroitin sulfate D (GlcNAc6S-GlcA2S),





degradation product 4


328
cs_d_deg5
Lysosome
chondroitin sulfate D (GlcNAc6S-GlcA2S),





degradation product 5


329
cs_d_deg6
Lysosome
chondroitin sulfate D (GlcNAc6S-GlcA2S),





degradation product 6


330
cs_e
Lysosome
chondroitin sulfate E (GalNAc4,6diS-GlcA), free





chain


331
cs_e_deg1
Lysosome
chondroitin sulfate E (GalNAc4,6diS-GlcA),





degradation product 1


332
cs_e_deg2
Lysosome
chondroitin sulfate E (GalNAc4,6diS-GlcA),





degradation product 2


333
cs_e_deg3
Lysosome
chondroitin sulfate E (GalNAc4,6diS-GlcA),





degradation product 3


334
cs_e_deg4
Lysosome
chondroitin sulfate E (GalNAc4,6diS-GlcA),





degradation product 4


335
cs_e_deg5
Lysosome
chondroitin sulfate E (GalNAc4,6diS-GlcA),





degradation product 5


336
cs_e_deg6
Lysosome
chondroitin sulfate E (GalNAc4,6diS-GlcA),





degradation product 6


337
cs_e_deg7
Lysosome
chondroitin sulfate E (GalNAc4,6diS-GlcA),





degradation product 7


338
ctp
Cytosol
CTP


339
ctp
Mitochondria
CTP


340
ctp
Nucleus
CTP


341
cvncoa
Cytosol
cervonyl CoA (C22:6CoA)


342
cvncoa
Mitochondria
cervonyl CoA (C22:6CoA)


343
cvncoa
Peroxisome
cervonyl CoA (C22:6CoA)


344
cvncrn
Cytosol
cervonyl carnitine (C22:6Crn)


345
cvncrn
Mitochondria
cervonyl carnitine (C22:6Crn)


346
cys-L
Cytosol
L-Cysteine


347
cys-L
Extra-organism
L-Cysteine


348
cys-L
Mitochondria
L-Cysteine


349
cysth-L
Cytosol
L-Cystathionine


350
cytd
Cytosol
Cytidine


351
dad-2
Cytosol
Deoxyadenosine


352
dadp
Cytosol
dADP


353
dadp
Nucleus
dADP


354
datp
Cytosol
dATP


355
datp
Nucleus
dATP


356
dca
Cytosol
Decanoate


357
dcamp
Cytosol
N6-(1,2-Dicarboxyethyl)-AMP


358
dccoa
Cytosol
Decanoyl-CoA (C10:0CoA)


359
dccoa
Mitochondria
Decanoyl-CoA (C10:0CoA)


360
dccoa
Peroxisome
Decanoyl-CoA (C10:0CoA)


361
dcdp
Cytosol
dCDP


362
dcdp
Nucleus
dCDP


363
dcer_CHO
Cytosol
dihydroceramide, CHO specific


364
dcholcoa
Peroxisome
chenodeoxycholoyl coenzyme a


365
dcmp
Cytosol
dCMP


366
dcmp
Nucleus
dCMP


367
dcsa
Cytosol
docosanoate (n-C22:0)


368
dcsacoa
Cytosol
docosanoyl-CoA (C22:0CoA)


369
dcshea
Cytosol
docosahexaenoate (C22:6)


370
dcshea
Extra-organism
docosahexaenoate (C22:6)


371
dcshea3
Cytosol
docosahexaenoate (C22:6, n-3)


372
dcshea3
Extra-organism
docosahexaenoate (C22:6, n-3)


373
dcspea
Cytosol
docosapentaenoic acid (C22:5)


374
dcspea
Extra-organism
docosapentaenoic acid (C22:5)


375
dcspea3
Cytosol
docosapentaenoate (C22:5, n-3)


376
dcspea6
Cytosol
docosapentaenoate (C22:5, n-6)


377
dcsptn1coa
Mitochondria
docosa-4,7,10,13,16-pentaenoyl coenzyme A





(C22:5CoA)


378
dcsptn1coa
Peroxisome
docosa-4,7,10,13,16-pentaenoyl coenzyme A





(C22:5CoA)


379
dctp
Cytosol
dCTP


380
dctp
Nucleus
dCTP


381
dcyt
Nucleus
Deoxycytidine


382
ddca
Cytosol
dodecanoate (C12:0)


383
ddcoa
Cytosol
Dodecanoyl-CoA (n-C12:0CoA)


384
ddcoa
Mitochondria
Dodecanoyl-CoA (n-C12:0CoA)


385
ddcoa
Peroxisome
Dodecanoyl-CoA (n-C12:0CoA)


386
ddsmsterol
Endoplasmic Reticulum
7-Dehydrodesmosterol


387
dedol
Cytosol
Dehydrodolichol, mammals


388
dedoldp
Cytosol
Dehydrodolichol diphosphate, mammals


389
dedolp
Cytosol
Deydodolichol phosphate, mammals


390
dgcholcoa
Peroxisome
Chenodeoxyglycocholoyl-CoA


391
dgdp
Cytosol
dGDP


392
dgdp
Nucleus
dGDP


393
dgmp
Cytosol
dGMP


394
dgmp
Mitochondria
dGMP


395
dgsn
Cytosol
Deoxyguanosine


396
dgsn
Mitochondria
Deoxyguanosine


397
dgtp
Cytosol
dGTP


398
dgtp
Nucleus
dGTP


399
dhap
Cytosol
Dihydroxyacetone phosphate


400
dhap
Peroxisome
Dihydroxyacetone phosphate


401
dhbpt
Cytosol
6,7-Dihydrobiopterin


402
dhcholestanate
Endoplasmic Reticulum
3alpha,7alpha-Dihydroxy-5beta-cholestanate


403
dhcholestanate
Peroxisome
3alpha,7alpha-Dihydroxy-5beta-cholestanate


404
dhcholestancoa
Endoplasmic Reticulum
3alpha,7alpha-Dihydroxy-5beta-cholestanoyl-CoA


405
dhcholestancoa
Peroxisome
3alpha,7alpha-Dihydroxy-5beta-cholestanoyl-CoA


406
dhf
Cytosol
7,8-Dihydrofolate


407
dhf
Mitochondria
7,8-Dihydrofolate


408
dhlam
Mitochondria
Dihydrolipoamide


409
dhlpro
Mitochondria
Dihydrolipolprotein


410
dhmdlald
Cytosol
3,4-Dihydroxymandelaldehyde


411
dhocholoylcoa
Peroxisome
3alpha,7alpha,12alpha,26-Tetrahydroxy-5beta-





cholestane


412
dhor-S
Cytosol
(S)-Dihydroorotate


413
dhpethg
Cytosol
3,4-Dihydroxyphenylethyleneglycol


414
didp
Cytosol
dIDP


415
didp
Nucleus
dIDP


416
dimp
Cytosol
dIMP


417
din
Cytosol
Deoxyinosine


418
ditp
Cytosol
dITP


419
ditp
Nucleus
dITP


420
dlnlcgcoa
Mitochondria
dihomo-gamma-linolenyl coenzyme A (C20:3CoA)


421
dmhptcoa
Mitochondria
2,6 dimethylheptanoyl-CoA


422
dmnoncoa
Cytosol
4,8 dimethylnonanoyl-CoA


423
dmnoncoa
Mitochondria
4,8 dimethylnonanoyl-CoA


424
dmnoncoa
Peroxisome
4,8 dimethylnonanoyl-CoA


425
dmpp
Cytosol
Dimethylallyl diphosphate


426
dmpp
Peroxisome
Dimethylallyl diphosphate


427
dnad
Cytosol
Deamino-NAD+


428
dnad
Mitochondria
Deamino-NAD+


429
dnad
Nucleus
Deamino-NAD+


430
doldp2
Endoplasmic Reticulum
Dolichol diphosphate, mammals


431
dolglcp2
Cytosol
Dolichyl beta-D-glucosyl phosphate, mammals


432
dolglcp2
Endoplasmic Reticulum
Dolichyl beta-D-glucosyl phosphate, mammals


433
dolglcp_L
Cytosol
Dolichyl beta-D-glucosyl phosphate, human liver





homolog


434
dolglcp_U
Cytosol
Dolichyl beta-D-glucosyl phosphate, human uterine





homolog


435
dolichol2
Cytosol
Dolichol, mammals


436
dolichol2
Endoplasmic Reticulum
Dolichol, mammals


437
dolmanp2
Cytosol
Dolichyl phosphate D-mannose, mammals


438
dolmanp2
Endoplasmic Reticulum
Dolichyl phosphate D-mannose, mammals


439
dolp2
Cytosol
Dolichol phosphate, mammals


440
dolp2
Endoplasmic Reticulum
Dolichol phosphate, mammals


441
dolp_L
Cytosol
Dolichol phosphate, human liver homolog


442
dolp_U
Cytosol
Dolichol phosphate, human uterine homolog


443
dopmn
Cytosol
Dopamine


444
dpcoa
Cytosol
Dephospho-CoA


445
dpheacd
Cytosol
3,4-Dihydroxyphenylacetaldehyde


446
dshcoa3
Cytosol
docosahexaenoyl-CoA (C22:6CoA, n-3)


447
dshcoa3
Mitochondria
docosahexaenoyl-CoA (C22:6CoA, n-3)


448
dsmsterol
Endoplasmic Reticulum
Desmosterol


449
dspcoa3
Cytosol
docosapentaenoyl-CoA (C22:5CoA, n-3)


450
dspcoa3
Mitochondria
docosapentaenoyl-CoA (C22:5CoA, n-3)


451
dspcoa6
Cytosol
docosapentaenoyl-CoA (C22:5CoA, n-6)


452
dspcoa6
Mitochondria
docosapentaenoyl-CoA (C22:5CoA, n-6)


453
dtdp
Cytosol
dTDP


454
dtdp
Nucleus
dTDP


455
dtdpddg
Cytosol
dTDP-4-dehydro-6-deoxy-D-glucose


456
dtdpglc
Cytosol
dTDPglucose


457
dtmp
Cytosol
dTMP


458
dtt_ox
Cytosol
Oxidized dithiothreitol


459
dtt_rd
Cytosol
Reduced dithiothreitol


460
dttp
Cytosol
dTTP


461
dttp
Nucleus
dTTP


462
dudp
Cytosol
dUDP


463
dudp
Nucleus
dUDP


464
dump
Cytosol
dUMP


465
duri
Cytosol
Deoxyuridine


466
dutp
Cytosol
dUTP


467
dutp
Nucleus
dUTP


468
dxtrn
Cytosol
phosphorylase-limit dextrin (glycogenin-1,6{4[1,4-





Glc], 4[1,4-Glc]})


469
e4h2oxg
Cytosol
L-erythro-4-Hydroxyglutamate


470
e4h2oxg
Mitochondria
L-erythro-4-Hydroxyglutamate


471
e4p
Cytosol
D-Erythrose 4-phosphate


472
ecgon
Endoplasmic Reticulum
ecgonine


473
ecsa
Cytosol
Eicosanoate (n-C20:0)


474
ecsa
Extra-organism
Eicosanoate (n-C20:0)


475
ecsacoa
Cytosol
Eicosanoyl-CoA (n-C20:0CoA)


476
ecsacoa
Mitochondria
Eicosanoyl-CoA (n-C20:0CoA)


477
ecsacrn
Cytosol
eicosanoylcarnitine, C20:0crn


478
ecsacrn
Mitochondria
eicosanoylcarnitine, C20:0crn


479
ecsdea9
Cytosol
eicosadienoate (C20:2, n-9)


480
ecsea9
Cytosol
eicosenoate (C20:1, n-9)


481
ecspea
Cytosol
Eicosapentaenoic acid (C20:5)


482
ecspea
Extra-organism
Eicosapentaenoic acid (C20:5)


483
ecspea3
Cytosol
eicosapentaenoate (C20:5, n-3)


484
ecspecoa
Cytosol
eicosapentaenoyl-CoA (C20:5CoA)


485
ecspecoa
Mitochondria
eicosapentaenoyl-CoA (C20:5CoA)


486
ecspecrn
Cytosol
eicosapentaenoyl carnitine (C20:5Crn)


487
ecspecrn
Mitochondria
eicosapentaenoyl carnitine (C20:5Crn)


488
ecstea
Cytosol
eicosatrienoate (C20:3)


489
ecstea
Extra-organism
eicosatrienoate (C20:3)


490
ecstea6
Cytosol
eicosatrienoate (C20:3, n-6)


491
ecstea9
Cytosol
eicosatrienoate (C20:3, n-9)


492
ecsttea3
Cytosol
eicosatetraenoate (C20:4, n-3)


493
ecsttea6
Cytosol
eicosatetraenoate (C20:4, n-6)


494
edcoa
Mitochondria
endecanoyl-CoA (C11:0CoA)


495
egme
Endoplasmic Reticulum
ecgonine methyl ester


496
eicostetcoa
Mitochondria
eicosatetranoyl coenzyme A


497
esdcoa9
Cytosol
eicosadienoyl-CoA (C20:2CoA, n-9)


498
esecoa9
Cytosol
eicosenoyl-CoA (C20:1CoA, n-9)


499
esecoa9
Mitochondria
eicosenoyl-CoA (C20:1CoA, n-9)


500
espcoa3
Cytosol
eicosapentaenoyl-CoA (C20:5CoA, n-3)


501
espcoa3
Mitochondria
eicosapentaenoyl-CoA (C20:5CoA, n-3)


502
estcoa
Cytosol
eicosatrienoyl-CoA (C20:3CoA)


503
estcoa
Mitochondria
eicosatrienoyl-CoA (C20:3CoA)


504
estcoa6
Cytosol
eicosatrienoyl-CoA (C20:3CoA, n-6)


505
estcoa6
Mitochondria
eicosatrienoyl-CoA (C20:3CoA, n-6)


506
estcoa9
Cytosol
eicosatrienoyl-CoA (C20:3CoA, n-9)


507
estcoa9
Mitochondria
eicosatrienoyl-CoA (C20:3CoA, n-9)


508
estcrn
Cytosol
eicosatrienoyl carnitine (C20:3Crn)


509
estcrn
Mitochondria
eicosatrienoyl carnitine (C20:3Crn)


510
etfox
Mitochondria
Electron transfer flavoprotein oxidized


511
etfrd
Mitochondria
Electron transfer flavoprotein reduced


512
etha
Cytosol
Ethanolamine


513
etha
Extra-organism
Ethanolamine


514
ethap
Cytosol
Ethanolamine phosphate


515
ethap
Endoplasmic Reticulum
Ethanolamine phosphate


516
etoh
Cytosol
Ethanol


517
etoh
Peroxisome
Ethanol


518
ettcoa3
Cytosol
eicosatetraenoyl-CoA (C20:4CoA, n-3)


519
ettcoa6
Cytosol
eicosatetraenoyl-CoA (C20:4CoA, n-6)


520
ettcoa6
Mitochondria
eicosatetraenoyl-CoA (C20:4CoA, n-6)


521
f1a
Lysosome
F1alpha


522
f26bp
Cytosol
D-Fructose 2,6-bisphosphate


523
f6p
Cytosol
D-Fructose 6-phosphate


524
facoa_avg_CHO
Cytosol
Averaged fatty acyl CoA, CHO specific


525
fad
Mitochondria
FAD


526
fad
Peroxisome
FAD


527
fadh2
Mitochondria
FADH2


528
fadh2
Peroxisome
FADH2


529
fald
Cytosol
Formaldehyde


530
fald
Peroxisome
Formaldehyde


531
fdp
Cytosol
D-Fructose 1,6-bisphosphate


532
fe2
Cytosol
Fe2+


533
fe2
Extra-organism
Fe2+


534
fe2
Mitochondria
Fe2+


535
fgam
Cytosol
N2-Formyl-N1-(5-phospho-D-ribosyl)glycinamide


536
ficytcc
Mitochondria
Ferricytochrome c


537
fmn
Cytosol
flavin mononucleotide


538
focytcc
Mitochondria
Ferrocytochrome c


539
fol
Cytosol
Folate


540
fol
Extra-organism
Folate


541
for
Cytosol
Formate


542
for
Endoplasmic Reticulum
Formate


543
for
Extra-organism
Formate


544
for
Mitochondria
Formate


545
for
Nucleus
Formate


546
forglu
Cytosol
N-Formimidoyl-L-glutamate


547
fpram
Cytosol
2-(Formamido)-N1-(5-phospho-D-





ribosyl)acetamidine


548
fprica
Cytosol
5-Formamido-1-(5-phospho-D-ribosyl)imidazole-4-





carboxamide


549
frdp
Cytosol
Farnesyl diphosphate


550
frdp
Endoplasmic Reticulum
Farnesyl diphosphate


551
fuc-L
Lysosome
L-Fucose


552
fum
Cytosol
Fumarate


553
fum
Mitochondria
Fumarate


554
g1m8mpdol
Endoplasmic Reticulum
alpha-D-Glucosyl-(alpha-D-mannosyl)8-beta-D-





mannosyl-diacetylchitobiosyldiphosphodolichol,





mammal


555
g1p
Cytosol
D-Glucose 1-phosphate


556
g2m8m
Endoplasmic Reticulum
(alpha-D-Glucosyl)2-(alpha-D-mannosyl)8-beta-D-





mannosyl-diacetylchitobiose


557
g2m8mpdol
Endoplasmic Reticulum
(alpha-D-Glucosyl)2-(alpha-D-mannosyl)8-beta-D-





mannosyl-diacetylchitobiosyldiphosphodolichol,





mammal


558
g3m8m
Endoplasmic Reticulum
(alpha-D-Glucosyl)3-(alpha-D-mannosyl)8-beta-D-





mannosyl-diacetylchitobiose


559
g3m8mpdol
Endoplasmic Reticulum
(alpha-D-Glucosyl)3-(alpha-D-mannosyl)8-beta-D-





mannosyl-diacetylchitobiosyldiphosphodolichol,





mammal


560
g3p
Cytosol
Glyceraldehyde 3-phosphate


561
g6p
Cytosol
D-Glucose 6-phosphate


562
g6p
Endoplasmic Reticulum
D-Glucose 6-phosphate


563
gal
Cytosol
D-Galactose


564
gal
Lysosome
D-Galactose


565
gal1p
Cytosol
alpha-D-Galactose 1-phosphate


566
gam
Cytosol
D-Glucosamine


567
gam6p
Cytosol
D-Glucosamine 6-phosphate


568
gar
Cytosol
N1-(5-Phospho-D-ribosyl)glycinamide


569
gcald
Mitochondria
Glycolaldehyde


570
gdp
Cytosol
GDP


571
gdp
Golgi Apparatus
GDP


572
gdp
Mitochondria
GDP


573
gdp
Nucleus
GDP


574
gdpddm
Cytosol
GDP-4-dehydro-6-deoxy-D-mannose


575
gdpfuc
Cytosol
GDP-L-fucose


576
gdpfuc
Golgi Apparatus
GDP-L-fucose


577
gdpman
Cytosol
GDP-D-mannose


578
glc-D
Cytosol
D-Glucose


579
glc-D
Endoplasmic Reticulum
D-Glucose


580
glc-D
Extra-organism
D-Glucose


581
glc-D
Lysosome
D-Glucose


582
glcur
Lysosome
D-Glucuronate


583
gln-L
Cytosol
L-Glutamine


584
gln-L
Extra-organism
L-Glutamine


585
gln-L
Mitochondria
L-Glutamine


586
glu-L
Cytosol
L-Glutamate


587
glu-L
Extra-organism
L-Glutamate


588
glu-L
Mitochondria
L-Glutamate


589
glu5p
Mitochondria
L-Glutamate 5-phosphate


590
glu5sa
Cytosol
L-Glutamate 5-semialdehyde


591
glu5sa
Mitochondria
L-Glutamate 5-semialdehyde


592
gluala
Extra-organism
(5-L-Glutamyl)-L-amino acid


593
glucys
Cytosol
gamma-L-Glutamyl-L-cysteine


594
glutcoa
Mitochondria
Glutaryl-CoA


595
glx
Cytosol
Glyoxylate


596
glx
Mitochondria
Glyoxylate


597
gly
Cytosol
Glycine


598
gly
Extra-organism
Glycine


599
gly
Mitochondria
Glycine


600
gly
Peroxisome
Glycine


601
glyc
Cytosol
Glycerol


602
glyc
Mitochondria
Glycerol


603
glyc-S
Cytosol
(S)-Glycerate


604
glyc3p
Cytosol
sn-Glycerol 3-phosphate


605
glyc3p
Mitochondria
sn-Glycerol 3-phosphate


606
glyclt
Mitochondria
Glycolate


607
glycogen
Cytosol
glycogen


608
glygn1
Cytosol
glycogen, structure 1 (glycogenin-11[1,4-Glc])


609
glygn2
Cytosol
glycogen, structure 2 (glycogenin-1,6-{7[1,4-Glc],





4[1,4-Glc]})


610
glygn3
Cytosol
glycogen, structure 3 (glycogenin-7[1,4-Glc])


611
gmp
Cytosol
GMP


612
gmp
Golgi Apparatus
GMP


613
grdp
Cytosol
Geranyl diphosphate


614
gsn
Cytosol
Guanosine


615
gthox
Cytosol
Oxidized glutathione


616
gthox
Mitochondria
Oxidized glutathione


617
gthrd
Cytosol
Reduced glutathione


618
gthrd
Mitochondria
Reduced glutathione


619
gtp
Cytosol
GTP


620
gtp
Mitochondria
GTP


621
gtp
Nucleus
GTP


622
gua
Cytosol
Guanine


623
h
Cytosol
H+


624
h
Endoplasmic Reticulum
H+


625
h
Extra-organism
H+


626
h
Golgi Apparatus
H+


627
h
Lysosome
H+


628
h
Mitochondria
H+


629
h
Nucleus
H+


630
h
Peroxisome
H+


631
h2o
Cytosol
H2O


632
h2o
Endoplasmic Reticulum
H2O


633
h2o
Extra-organism
H2O


634
h2o
Golgi Apparatus
H2O


635
h2o
Lysosome
H2O


636
h2o
Mitochondria
H2O


637
h2o
Nucleus
H2O


638
h2o
Peroxisome
H2O


639
h2o2
Cytosol
Hydrogen peroxide


640
h2o2
Mitochondria
Hydrogen peroxide


641
h2o2
Nucleus
Hydrogen peroxide


642
h2o2
Peroxisome
Hydrogen peroxide


643
ha
Lysosome
hyaluronan


644
ha_deg1
Lysosome
hyaluronan degradation product 1


645
ha_pre1
Lysosome
hyaluronan biosynthesis, precursor 1


646
hco3
Cytosol
Bicarbonate


647
hco3
Mitochondria
Bicarbonate


648
hcys-L
Cytosol
L-Homocysteine


649
hdca
Cytosol
hexadecanoate (n-C16:0)


650
hdca
Endoplasmic Reticulum
hexadecanoate (n-C16:0)


651
hdca
Extra-organism
hexadecanoate (n-C16:0)


652
hdca
Peroxisome
hexadecanoate (n-C16:0)


653
hdcea
Cytosol
hexadecenoate (n-C16:1)


654
hdcea
Extra-organism
hexadecenoate (n-C16:1)


655
hdcea7
Cytosol
hexadecenoate (C16:1, n-7)


656
hdcecrn
Cytosol
Hexadecenoyl carnitine


657
hdcecrn
Mitochondria
Hexadecenoyl carnitine


658
hdcoa
Cytosol
Hexadecenoyl-CoA (n-C16:1CoA)


659
hdcoa
Mitochondria
Hexadecenoyl-CoA (n-C16:1CoA)


660
hdcoa7
Cytosol
hexadecenoyl-CoA (C16:1CoA, n-7)


661
hdcoa7
Mitochondria
hexadecenoyl-CoA (C16:1CoA, n-7)


662
hdd2coa
Mitochondria
trans-Hexadec-2-enoyl-CoA


663
hexccoa
Peroxisome
Hexacosanoyl-CoA (n-C26:0CoA)


664
hgentis
Cytosol
Homogentisate


665
hibcoa
Mitochondria
(S)-3-Hydroxyisobutyryl-CoA


666
hibcoa_#1
Mitochondria
(S)-3-Hydroxyisobutyryl-CoA


667
hindoald
Cytosol
5-Hydroxyindoleacetaldehyde


668
his-L
Cytosol
L-Histidine


669
his-L
Extra-organism
L-Histidine


670
hkyn
Cytosol
3-Hydroxy-L-kynurenine


671
hkyn_#1
Cytosol
3-Hydroxy-L-kynurenine


672
hkyna
Cytosol
3-Hydroxykynurenamine


673
hmbil
Cytosol
Hydroxymethylbilane


674
hmgcoa
Cytosol
Hydroxymethylglutaryl-CoA


675
hmgcoa
Endoplasmic Reticulum
Hydroxymethylglutaryl-CoA


676
hmgcoa
Mitochondria
Hydroxymethylglutaryl-CoA


677
hmgcoa
Peroxisome
Hydroxymethylglutaryl-CoA


678
hom-L
Cytosol
L-Homoserine


679
hom-L
Extra-organism
L-Homoserine


680
hpacald
Cytosol
4-Hydroxyphenylacetaldehyde


681
hpcoa
Mitochondria
heptanoyl-CoA (C7:0CoA)


682
hpdca
Cytosol
heptadecanoate (C17:0)


683
hpdcoa
Cytosol
heptadecanoyl CoA (C17:0CoA)


684
hpdcoa
Mitochondria
heptadecanoyl CoA (C17:0CoA)


685
hpyr
Cytosol
Hydroxypyruvate


686
hs
Lysosome
heparan sulfate, free chain


687
hs_deg1
Lysosome
heparan sulfate, degradation product 1


688
hs_deg10
Lysosome
heparan sulfate, degradation product 10


689
hs_deg11
Lysosome
heparan sulfate, degradation product 11


690
hs_deg12
Lysosome
heparan sulfate, degradation product 12


691
hs_deg13
Lysosome
heparan sulfate, degradation product 13


692
hs_deg18
Lysosome
heparan sulfate, degradation product 18


693
hs_deg19
Lysosome
heparan sulfate, degradation product 19


694
hs_deg2
Lysosome
heparan sulfate, degradation product 2


695
hs_deg5
Lysosome
heparan sulfate, degradation product 5


696
hs_deg6
Lysosome
heparan sulfate, degradation product 6


697
hs_deg7
Lysosome
heparan sulfate, degradation product 7


698
hs_deg9
Lysosome
heparan sulfate, degradation product 9


699
hxa
Cytosol
Hexanoate


700
hxan
Cytosol
Hypoxanthine


701
hxan
Extra-organism
Hypoxanthine


702
hxcoa
Mitochondria
Hexanoyl-CoA (C6:0CoA)


703
hxdcal
Endoplasmic Reticulum
Hexadecanal


704
hyptaur
Cytosol
Hypotaurine


705
ibcoa
Mitochondria
Isobutyryl-CoA


706
icit
Cytosol
Isocitrate


707
icit
Mitochondria
Isocitrate


708
id3acald
Cytosol
Indole-3-acetaldehyde


709
idp
Cytosol
IDP


710
idp
Nucleus
IDP


711
ile-L
Cytosol
L-Isoleucine


712
ile-L
Extra-organism
L-Isoleucine


713
ile-L
Mitochondria
L-Isoleucine


714
ilnlc
Cytosol
isolinoleic acid (C18:2, n-9)


715
ilnlcoa
Cytosol
isolinoleoyl-CoA (C18:2CoA, n-9)


716
imp
Cytosol
IMP


717
inost
Cytosol
myo-Inositol


718
inost
Extra-organism
myo-Inositol


719
ins
Cytosol
Inosine


720
ins
Extra-organism
Inosine


721
ipdp
Cytosol
Isopentenyl diphosphate


722
ipdp
Peroxisome
Isopentenyl diphosphate


723
itaccoa
Mitochondria
Itaconyl-CoA


724
itacon
Mitochondria
Itaconate


725
itp
Cytosol
ITP


726
itp
Nucleus
ITP


727
ivcoa
Mitochondria
Isovaleryl-CoA


728
k
Cytosol
K+


729
k
Golgi Apparatus
K+


730
kdnp
Cytosol
2-keto-3-deoxy-D-glycero-D-galactononic acid 9-





phosphate


731
ksi
Lysosome
keratan sulfate I


732
ksi_deg1
Lysosome
keratan sulfate I, degradation product 1


733
ksi_deg10
Lysosome
keratan sulfate I, degradation product 10


734
ksi_deg11
Lysosome
keratan sulfate I, degradation product 11


735
ksi_deg12
Lysosome
keratan sulfate I, degradation product 12


736
ksi_deg13
Lysosome
keratan sulfate I, degradation product 13


737
ksi_deg14
Lysosome
keratan sulfate I, degradation product 14


738
ksi_deg15
Lysosome
keratan sulfate I, degradation product 15


739
ksi_deg16
Lysosome
keratan sulfate I, degradation product 16


740
ksi_deg17
Lysosome
keratan sulfate I, degradation product 17


741
ksi_deg18
Lysosome
keratan sulfate I, degradation product 18


742
ksi_deg19
Lysosome
keratan sulfate I, degradation product 19


743
ksi_deg2
Lysosome
keratan sulfate I, degradation product 2


744
ksi_deg20
Lysosome
keratan sulfate I, degradation product 20


745
ksi_deg21
Lysosome
keratan sulfate I, degradation product 21


746
ksi_deg22
Lysosome
keratan sulfate I, degradation product 22


747
ksi_deg23
Lysosome
keratan sulfate I, degradation product 23


748
ksi_deg24
Lysosome
keratan sulfate I, degradation product 24


749
ksi_deg25
Lysosome
keratan sulfate I, degradation product 25


750
ksi_deg26
Lysosome
keratan sulfate I, degradation product 26


751
ksi_deg27
Lysosome
keratan sulfate I, degradation product 27


752
ksi_deg28
Lysosome
keratan sulfate I, degradation product 28


753
ksi_deg29
Lysosome
keratan sulfate I, degradation product 29


754
ksi_deg3
Lysosome
keratan sulfate I, degradation product 3


755
ksi_deg30
Lysosome
keratan sulfate I, degradation product 30


756
ksi_deg31
Lysosome
keratan sulfate I, degradation product 31


757
ksi_deg32
Lysosome
keratan sulfate I, degradation product 32


758
ksi_deg33
Lysosome
keratan sulfate I, degradation product 33


759
ksi_deg34
Lysosome
keratan sulfate I, degradation product 34


760
ksi_deg35
Lysosome
keratan sulfate I, degradation product 35


761
ksi_deg36
Lysosome
keratan sulfate I, degradation product 36


762
ksi_deg37
Lysosome
keratan sulfate I, degradation product 37


763
ksi_deg38
Lysosome
keratan sulfate I, degradation product 38


764
ksi_deg39
Lysosome
keratan sulfate I, degradation product 39


765
ksi_deg4
Lysosome
keratan sulfate I, degradation product 4


766
ksi_deg40
Lysosome
keratan sulfate I, degradation product 40


767
ksi_deg41
Lysosome
keratan sulfate I, degradation product 41


768
ksi_deg5
Lysosome
keratan sulfate I, degradation product 5


769
ksi_deg6
Lysosome
keratan sulfate I, degradation product 6


770
ksi_deg7
Lysosome
keratan sulfate I, degradation product 7


771
ksi_deg8
Lysosome
keratan sulfate I, degradation product 8


772
ksi_deg9
Lysosome
keratan sulfate I, degradation product 9


773
ksii_core2
Lysosome
keratan sulfate II (core 2-linked)


774
ksii_core2_deg1
Lysosome
keratan sulfate II (core 2-linked), degradation





product 1


775
ksii_core2_deg2
Lysosome
keratan sulfate II (core 2-linked), degradation





product 2


776
ksii_core2_deg3
Lysosome
keratan sulfate II (core 2-linked), degradation





product 3


777
ksii_core2_deg4
Lysosome
keratan sulfate II (core 2-linked), degradation





product 4


778
ksii_core2_deg5
Lysosome
keratan sulfate II (core 2-linked), degradation





product 5


779
ksii_core2_deg6
Lysosome
keratan sulfate II (core 2-linked), degradation





product 6


780
ksii_core2_deg7
Lysosome
keratan sulfate II (core 2-linked), degradation





product 7


781
ksii_core2_deg8
Lysosome
keratan sulfate II (core 2-linked), degradation





product 8


782
ksii_core2_deg9
Lysosome
keratan sulfate II (core 2-linked), degradation





product 9


783
ksii_core4
Lysosome
keratan sulfate II (core 4-linked)


784
ksii_core4_deg1
Lysosome
keratan sulfate II (core 4-linked), degradation





product 1


785
ksii_core4_deg2
Lysosome
keratan sulfate II (core 4-linked), degradation





product 2


786
ksii_core4_deg3
Lysosome
keratan sulfate II (core 4-linked), degradation





product 3


787
ksii_core4_deg4
Lysosome
keratan sulfate II (core 4-linked), degradation





product 4


788
kynr-L
Cytosol
L-Kynurenine


789
l2n2m2mn
Lysosome
de-Fuc, reducing GlcNAc removed, de-Sia form of





PA6 (w/o peptide linkage)


790
lac-D
Mitochondria
D-Lactate


791
lac-L
Cytosol
L-Lactate


792
lac-L
Extra-organism
L-Lactate


793
lac-L
Mitochondria
L-Lactate


794
lald-D
Cytosol
D-Lactaldehyde


795
lald-D
Mitochondria
D-Lactaldehyde


796
lald-L
Cytosol
L-Lactaldehyde


797
lald-L
Mitochondria
L-Lactaldehyde


798
lanost
Endoplasmic Reticulum
Lanosterol


799
lathost
Endoplasmic Reticulum
Lathosterol


800
lcts
Lysosome
Lactose


801
Lcyst
Cytosol
L-Cysteate


802
Lcyst
Mitochondria
L-Cysteate


803
leu-L
Cytosol
L-Leucine


804
leu-L
Extra-organism
L-Leucine


805
leu-L
Mitochondria
L-Leucine


806
Lfmkynr
Cytosol
L-Formylkynurenine


807
lgnccoa
Cytosol
lignocericyl coenzyme A


808
lgnccoa
Mitochondria
lignocericyl coenzyme A


809
lgnccoa
Peroxisome
lignocericyl coenzyme A


810
lgnccrn
Cytosol
lignoceryl carnitine


811
lgnccrn
Mitochondria
lignoceryl carnitine


812
lneldccoa
Mitochondria
linoelaidyl coenzyme A (C18:2CoA)


813
lnlccoa
Mitochondria
linoleic coenzyme A (C18:2CoA)


814
lnlecoa
Cytosol
Linolenoyl-CoA (C18:3CoA)


815
lnlecoa
Mitochondria
Linolenoyl-CoA (C18:3CoA)


816
lnlecrn
Cytosol
linolenoyl carnitine (C18:3Crn)


817
lnlecrn
Mitochondria
linolenoyl carnitine (C18:3Crn)


818
lnlncacoa
Mitochondria
alpha-Linolenoyl-CoA (C18:3CoA, n-3)


819
lnlncgcoa
Mitochondria
gamma-linolenoyl-CoA (C18:3CoA, n-6)


820
lnlncgcoa
Peroxisome
gamma-linolenoyl-CoA (C18:3CoA, n-6)


821
lnlne
Cytosol
Linolenic acid (C18:3)


822
lnlne
Extra-organism
Linolenic acid (C18:3)


823
lpam
Mitochondria
Lipoamide


824
lpro
Mitochondria
Lipoylprotein


825
Lsacchrp
Mitochondria
L-Saccharopine


826
lys-L
Cytosol
L-Lysine


827
lys-L
Extra-organism
L-Lysine


828
lys-L
Mitochondria
L-Lysine


829
m1mpdol
Cytosol
alpha-D-mannosyl-beta-D-mannosyl-





diacylchitobiosyldiphosphodolichol, mammals


830
m2mn
Cytosol
(alpha-D-mannosyl)2-beta-D-mannosyl-N-





acetylglucosamine


831
m2mn
Lysosome
(alpha-D-mannosyl)2-beta-D-mannosyl-N-





acetylglucosamine


832
m2mpdol
Cytosol
(alpha-D-mannosyl)2-beta-D-mannosyl-





diacetylchitobiosyldiphosphodolichol, mammals


833
m3mpdol
Cytosol
(alpha-D-mannosyl)3-beta-D-mannosyl-





diacetylchitodiphosphodolichol, mammals


834
m4m
Golgi Apparatus
(alpha-D-mannosyl)4-beta-D-mannosyl-





diacetylchitobiose


835
m4mpdol
Cytosol
(alpha-D-Mannosyl)4-beta-D-mannosyl-





diacetylchitobiosyldiphosphodolichol, mammals


836
m4mpdol
Endoplasmic Reticulum
(alpha-D-Mannosyl)4-beta-D-mannosyl-





diacetylchitobiosyldiphosphodolichol, mammals


837
m5m
Golgi Apparatus
(alpha-D-mannosyl)5-beta-D-mannosyl-





diacetylchitobiose


838
m5mpdol
Endoplasmic Reticulum
(alpha-D-Mannosyl)5-beta-D-mannosyl-





diacetylchitobiosyldiphosphodolichol, mammals


839
m6m
Golgi Apparatus
(alpha-D-mannosyl)6-beta-D-mannosyl-





diacetylchitobiose


840
m6mpdol
Endoplasmic Reticulum
(alpha-D-Mannosyl)6-beta-D-mannosyl-





diacetylchitobiosyldiphosphodolichol, mammals


841
m7m
Endoplasmic Reticulum
(alpha-D-mannosyl)7-beta-D-mannosyl-





diacetylchitobiose


842
m7m
Golgi Apparatus
(alpha-D-mannosyl)7-beta-D-mannosyl-





diacetylchitobiose


843
m7mpdol
Endoplasmic Reticulum
(alpha-D-Mannosyl)7-beta-D-mannosyl-





diacetylchitobiosyldiphosphodolichol, mammals


844
m8m
Endoplasmic Reticulum
(alpha-D-mannosyl)8-beta-D-mannosyl-





diacetylchitobiose


845
m8m
Golgi Apparatus
(alpha-D-mannosyl)8-beta-D-mannosyl-





diacetylchitobiose


846
m8mpdol
Endoplasmic Reticulum
(alpha-D-Mannosyl)8-beta-D-mannosyl-





diacetylchitobiosyldiphosphodolichol, mammals


847
mal-L
Cytosol
L-Malate


848
mal-L
Mitochondria
L-Malate


849
malACP
Cytosol
Malonyl-[acyl-carrier protein]


850
malACP
Mitochondria
Malonyl-[acyl-carrier protein]


851
malcoa
Cytosol
Malonyl-CoA


852
malcoa
Mitochondria
Malonyl-CoA


853
malt
Cytosol
Maltose


854
malt
Lysosome
Maltose


855
malttr
Cytosol
Maltotriose


856
malttr
Lysosome
Maltotriose


857
man
Cytosol
D-Mannose


858
man
Endoplasmic Reticulum
D-Mannose


859
man
Golgi Apparatus
D-Mannose


860
man
Lysosome
D-Mannose


861
man1p
Cytosol
D-Mannose 1-phosphate


862
man6p
Cytosol
D-Mannose 6-phosphate


863
meoh
Cytosol
Methanol


864
meoh
Endoplasmic Reticulum
Methanol


865
mercplac
Cytosol
3-Mercaptolactate


866
mercppyr
Cytosol
Mercaptopyruvate


867
mercppyr
Mitochondria
Mercaptopyruvate


868
mescoa
Mitochondria
Mesaconyl-CoA


869
mescon
Mitochondria
Mesaconate


870
met-L
Cytosol
L-Methionine


871
met-L
Extra-organism
L-Methionine


872
methf
Cytosol
5,10-Methenyltetrahydrofolate


873
methf
Mitochondria
5,10-Methenyltetrahydrofolate


874
mev-R
Cytosol
(R)-Mevalonate


875
mev-R
Endoplasmic Reticulum
(R)-Mevalonate


876
mev-R
Peroxisome
(R)-Mevalonate


877
mglyc_CHO
Cytosol
monoacylglycerol, CHO specific


878
mhpacd
Cytosol
3-Methoxy-4-hydroxyphenylacetaldehyde


879
mhpgald
Cytosol
3-Methoxy-4-hydroxyphenylglycolaldehyde


880
mi1p-D
Cytosol
1D-myo-Inositol 1-phosphate


881
mizoac
Cytosol
3-Methylimidazoleacetic acid


882
mizoacd
Cytosol
3-Methylimidazole acetaldehyde


883
mlthf
Cytosol
5,10-Methylenetetrahydrofolate


884
mlthf
Mitochondria
5,10-Methylenetetrahydrofolate


885
mma
Cytosol
Methylamine


886
mmal
Cytosol
Methylmalonate


887
mmal
Mitochondria
Methylmalonate


888
mmalsa-S
Cytosol
(S)-Methylmalonate semialdehyde


889
mmalsa-S
Mitochondria
(S)-Methylmalonate semialdehyde


890
mmcoa-R
Mitochondria
(R)-Methylmalonyl-CoA


891
mmcoa-S
Mitochondria
(S)-Methylmalonyl-CoA


892
mn
Cytosol
beta-1,4-mannose-N-acetylglucosamine


893
mn
Lysosome
beta-1,4-mannose-N-acetylglucosamine


894
mpdol
Cytosol
beta-D-





Mannosyldiacetylchitobiosyldiphosphodolichol,





mammals


895
mthgxl
Cytosol
Methylglyoxal


896
mxtyrm
Cytosol
3-Methoxytyramine


897
N-bi
Cytosol
Gal b1-4 GlcNAc b1-2 Man a1-3(Gal b1-





4 GlcNAc b1-2 Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


898
N-bi
Extra-organism
Gal b1-4 GlcNAc b1-2 Man a1-3(Gal b1-





4 GlcNAc b1-2 Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


899
N-bi
Golgi Apparatus
Gal b1-4 GlcNAc b1-2 Man a1-3(Gal b1-





4 GlcNAc b1-2 Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


900
N-biS1
Cytosol
Gal b1-4 GlcNAc b1-2 Man a1-3(NeuAc a2-3





Gal b1-4 GlcNAc b1-2 Man a1-6) Man b1-





4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


901
N-biS1
Extra-organism
Gal b1-4 GlcNAc b1-2 Man a1-3(NeuAc a2-3





Gal b1-4 GlcNAc b1-2 Man a1-6) Man b1-





4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


902
N-biS1
Golgi Apparatus
Gal b1-4 GlcNAc b1-2 Man a1-3(NeuAc a2-3





Gal b1-4 GlcNAc b1-2 Man a1-6) Man b1-





4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


903
N-tetra/N-triLac1
Cytosol
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-





4) Man a1-3(Gal b1-4 GlcNAc b1-2(Gal b1-





4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


904
N-tetra/N-triLac1
Extra-organism
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-





4) Man a1-3(Gal b1-4 GlcNAc b1-2(Gal b1-





4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


905
N-tetra/N-triLac1
Golgi Apparatus
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-





4) Man a1-3(Gal b1-4 GlcNAc b1-2(Gal b1-





4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


906
N-tetraLac1
Cytosol
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-





4) Man a1-3(Gal b1-4 GlcNAc b1-2(Gal b1-





4 GlcNAc b1-3 Gal b1-4 GlcNAc b1-6) Man a1-





6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


907
N-tetraLac1
Extra-organism
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-





4) Man a1-3(Gal b1-4 GlcNAc b1-2(Gal b1-





4 GlcNAc b1-3 Gal b1-4 GlcNAc b1-6) Man a1-





6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


908
N-tetraLac1
Golgi Apparatus
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-





4) Man a1-3(Gal b1-4 GlcNAc b1-2(Gal b1-





4 GlcNAc b1-3 Gal b1-4 GlcNAc b1-6) Man a1-





6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


909
N-tetraLac1S1
Cytosol
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-





4) Man a1-3(Gal b1-4 GlcNAc b1-2(NeuAc a2-





3 Gal b1-4 GlcNAc b1-3 Gal b1-4 GlcNAc b1-





6) Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-





6) GlcNAcOH


910
N-tetraLac1S1
Extra-organism
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-





4) Man a1-3(Gal b1-4 GlcNAc b1-2(NeuAc a2-





3 Gal b1-4 GlcNAc b1-3 Gal b1-4 GlcNAc b1-





6) Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-





6) GlcNAcOH


911
N-tetraLac1S1
Golgi Apparatus
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-





4) Man a1-3(Gal b1-4 GlcNAc b1-2(NeuAc a2-





3 Gal b1-4 GlcNAc b1-3 Gal b1-4 GlcNAc b1-





6) Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-





6) GlcNAcOH


912
N-tetraLac1S2
Cytosol
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-





4) Man a1-3(NeuAc a2-3 Gal b1-4 GlcNAc b1-





2(NeuAc a2-3 Gal b1-4 GlcNAc b1-3 Gal b1-





4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


913
N-tetraLac1S2
Extra-organism
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-





4) Man a1-3(NeuAc a2-3 Gal b1-4 GlcNAc b1-





2(NeuAc a2-3 Gal b1-4 GlcNAc b1-3 Gal b1-





4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


914
N-tetraLac1S2
Golgi Apparatus
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-





4) Man a1-3(NeuAc a2-3 Gal b1-4 GlcNAc b1-





2(NeuAc a2-3 Gal b1-4 GlcNAc b1-3 Gal b1-





4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


915
N-tetraLac1S3
Cytosol
Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-





4)Mana1-3(NeuAca2-3Galb1-4 GlcNAc b1-





2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





6)Mana1-6)Manb1-4GlcNAcb1-4(Fuc a1-





6)GlcNAcOH


916
N-tetraLac1S3
Extra-organism
Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-





4)Mana1-3(NeuAca2-3Galb1-4 GlcNAc b1-





2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





6)Mana1-6)Manb1-4GlcNAcb1-4(Fuc a1-





6)GlcNAcOH


917
N-tetraLac1S3
Golgi Apparatus
Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-





4)Mana1-3(NeuAca2-3Galb1-4 GlcNAc b1-





2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





6)Mana1-6)Manb1-4GlcNAcb1-4(Fuc a1-





6)GlcNAcOH


918
N-tetraLac1S4
Cytosol
NeuAca2-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-





4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-4 GlcNAc





b1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-





4(Fuc a1-6)GlcNAcOH


919
N-tetraLac1S4
Extra-organism
NeuAca2-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-





4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-4 GlcNAc





b1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-





4(Fuc a1-6)GlcNAcOH


920
N-tetraLac1S4
Golgi Apparatus
NeuAca2-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-





4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-4 GlcNAc





b1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-





4(Fuc a1-6)GlcNAcOH


921
N-tetraLac2
Cytosol
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-





3(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2(Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-





4GlcNAcb1-4(Fuca1-6)GlcNAcOH


922
N-tetraLac2
Extra-organism
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-





3(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2(Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-





4GlcNAcb1-4(Fuca1-6)GlcNAcOH


923
N-tetraLac2
Golgi Apparatus
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-





3(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2(Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-





4GlcNAcb1-4(Fuca1-6)GlcNAcOH


924
N-tetraLac2S1
Cytosol
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-





3(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-





6)GlcNAcOH


925
N-tetraLac2S1
Extra-organism
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-





3(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-





6)GlcNAcOH


926
N-tetraLac2S1
Golgi Apparatus
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-





3(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-





6)GlcNAcOH


927
N-tetraLac2S2
Cytosol
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-





3(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-





6)GlcNAcOH


928
N-tetraLac2S2
Extra-organism
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-





3(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-





6)GlcNAcOH


929
N-tetraLac2S2
Golgi Apparatus
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-





3(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-





6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-





6)GlcNAcOH


930
N-tetraLac2S3
Cytosol
Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-





4)Mana1-3(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-





6)GlcNAcOH


931
N-tetraLac2S3
Extra-organism
Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-





4)Mana1-3(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-





6)GlcNAcOH


932
N-tetraLac2S3
Golgi Apparatus
Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-





4)Mana1-3(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-





6)GlcNAcOH


933
N-tetraLac2S4
Cytosol
NeuAca2-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-





4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-





4GlcNAcb1-4(Fuca1-6)GlcNAcOH


934
N-tetraLac2S4
Extra-organism
NeuAca2-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-





4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-





4GlcNAcb1-4(Fuca1-6)GlcNAcOH


935
N-tetraLac2S4
Golgi Apparatus
NeuAca2-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-





4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-





4GlcNAcb1-4(Fuca1-6)GlcNAcOH


936
N-tetraLac3
Cytosol
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-4)Mana1-3(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-





6)GlcNAcOH


937
N-tetraLac3
Extra-organism
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-4)Mana1-3(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-





6)GlcNAcOH


938
N-tetraLac3
Golgi Apparatus
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-4)Mana1-3(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-





6)GlcNAcOH


939
N-tetraLac3S1
Cytosol
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-4)Mana1-3(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-





6)GlcNAcOH


940
N-tetraLac3S1
Extra-organism
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-4)Mana1-3(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-





6)GlcNAcOH


941
N-tetraLac3S1
Golgi Apparatus
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-4)Mana1-3(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-





6)GlcNAcOH


942
N-tetraLac3S2
Cytosol
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-





4GlcNAcb1-4(Fuca1-6)GlcNAcOH


943
N-tetraLac3S2
Extra-organism
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-





4GlcNAcb1-4(Fuca1-6)GlcNAcOH


944
N-tetraLac3S2
Golgi Apparatus
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-3Galb1-





4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-





4GlcNAcb1-4(Fuca1-6)GlcNAcOH


945
N-tetraLac3S3
Cytosol
Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-





3Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-





4GlcNAcb1-4(Fuca1-6)GlcNAcOH


946
N-tetraLac3S3
Extra-organism
Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-





3Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-





4GlcNAcb1-4(Fuca1-6)GlcNAcOH


947
N-tetraLac3S3
Golgi Apparatus
Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-4GlcNAcb1-





3Galb1-4GlcNAcb1-4)Mana1-3(NeuAca2-3Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-2(NeuAca2-3Galb1-





4GlcNAcb1-3Galb1-4GlcNAcb1-6)Mana1-6)Manb1-





4GlcNAcb1-4(Fuca1-6)GlcNAcOH


948
N-tetraS1/N-triLac1S1
Cytosol
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-





4) Man a1-3(NeuAc a2-3 Gal b1-4 GlcNAc b1-2





(Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-





4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


949
N-tetraS1/N-triLac1S1
Extra-organism
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-





4) Man a1-3(NeuAc a2-3 Gal b1-4 GlcNAc b1-2





(Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-





4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


950
N-tetraS1/N-triLac1S1
Golgi Apparatus
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-





4) Man a1-3(NeuAc a2-3 Gal b1-4 GlcNAc b1-2





(Gal b1-4 GlcNAc b1-6) Man a1-6) Man b1-





4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


951
N-tetraS2/N-triLac1S2
Cytosol
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-





4) Man a1-3(NeuAc a2-3 Gal b1-4 GlcNAc b1-





2(NeuAc a2-3 Gal b1-4 GlcNAc b1-6) Man a1-





6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


952
N-tetraS2/N-triLac1S2
Extra-organism
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-





4) Man a1-3(NeuAc a2-3 Gal b1-4 GlcNAc b1-





2(NeuAc a2-3 Gal b1-4 GlcNAc b1-6) Man a1-





6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


953
N-tetraS2/N-triLac1S2
Golgi Apparatus
Gal b1-4 GlcNAc b1-2(Gal b1-4 GlcNAc b1-





4) Man a1-3(NeuAc a2-3 Gal b1-4 GlcNAc b1-





2(NeuAc a2-3 Gal b1-4 GlcNAc b1-6) Man a1-





6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


954
N-tetraS3
Cytosol
Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-





4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-





4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-





6) Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-





6) GlcNAcOH


955
N-tetraS3
Extra-organism
Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-





4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-





4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-





6) Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-





6) GlcNAcOH


956
N-tetraS3
Golgi Apparatus
Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-





4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-





4 GlcNAc b1-2(NeuAc a2-3 Gal b1-4 GlcNAc b1-





6) Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-





6) GlcNAcOH


957
N-tetraS4
Cytosol
NeuAc a2-3 Gal b1-4 GlcNAc b1-2(NeuAc a2-





3 Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-





3 Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-





4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


958
N-tetraS4
Extra-organism
NeuAc a2-3 Gal b1-4 GlcNAc b1-2(NeuAc a2-





3 Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-





3 Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-





4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


959
N-tetraS4
Golgi Apparatus
NeuAc a2-3 Gal b1-4 GlcNAc b1-2(NeuAc a2-





3 Gal b1-4 GlcNAc b1-4) Man a1-3(NeuAc a2-





3 Gal b1-4 GlcNAc b1-2(NeuAc a2-3 Gal b1-





4 GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


960
N-tri
Cytosol
Gal b1-4 GlcNAc b1-2 (Gal b1-4 GlcNAc b1-4)





Man a1-3(Gal b1-4 GlcNAc b1-2 Man a1-6) Man b1-





4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


961
N-tri
Extra-organism
Gal b1-4 GlcNAc b1-2 (Gal b1-4 GlcNAc b1-4)





Man a1-3(Gal b1-4 GlcNAc b1-2 Man a1-6) Man b1-





4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


962
N-tri
Golgi Apparatus
Gal b1-4 GlcNAc b1-2 (Gal b1-4 GlcNAc b1-4)





Man a1-3(Gal b1-4 GlcNAc b1-2 Man a1-6) Man b1-





4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


963
N-triS1
Cytosol
Gal b1-4 GlcNAc b1-2 (Gal b1-4 GlcNAc b1-4)





Man a1-3(NeuAc a2-3 Gal b1-4 GlcNAc b1-





2 Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-





6) GlcNAcOH


964
N-triS1
Extra-organism
Gal b1-4 GlcNAc b1-2 (Gal b1-4 GlcNAc b1-4)





Man a1-3(NeuAc a2-3 Gal b1-4 GlcNAc b1-





2 Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-





6) GlcNAcOH


965
N-triS1
Golgi Apparatus
Gal b1-4 GlcNAc b1-2 (Gal b1-4 GlcNAc b1-4)





Man a1-3(NeuAc a2-3 Gal b1-4 GlcNAc b1-





2 Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-





6) GlcNAcOH


966
N-triS2
Cytosol
Gal b1-4 GlcNAc b1-2 (NeuAc a2-3 Gal b1-





4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-4





GlcNAc b1-2 Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


967
N-triS2
Extra-organism
Gal b1-4 GlcNAc b1-2 (NeuAc a2-3 Gal b1-





4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-4





GlcNAc b1-2 Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


968
N-triS2
Golgi Apparatus
Gal b1-4 GlcNAc b1-2 (NeuAc a2-3 Gal b1-





4 GlcNAc b1-4) Man a1-3(NeuAc a2-3 Gal b1-4





GlcNAc b1-2 Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


969
n2m2m
Golgi Apparatus
((N-acetyl-D-glucosaminyl)2-(alpha-D-mannosyl)2-





beta-D-mannosyl-diacetylchitobiose


970
n2m2mf
Golgi Apparatus
GlcNAc b1-2 Man a1-3(GlcNAc b1-2 Man a1-





6) Man b1-4 GlcNAc b1-4(Fuc a1-6) GlcNAcOH


971
n2m2mn
Lysosome
de-Fuc, reducing GlcNAc removed, de-Sia, de-Gal





form of PA6 (w/o peptide linkage)


972
n2m2nm
Lysosome
n2m2nmasn (w/o peptide linkage)


973
n2m2nmasn
Lysosome
N-Acetyl-beta-D-glucosaminyl-1,2-alpha-D-





mannosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,2-





alpha-D-mannosyl-1,6)-(N-acetyl-beta-D-





glucosaminyl-1,4)-beta-D-mannosyl-1,4-N-acetyl-





beta-D-glucosaminyl-R


974
n2m2nmn
Lysosome
reducing GlcNAc removed form of n2m2nmasn (w/o





peptide)


975
n3m2m
Golgi Apparatus
((N-acetyl-D-glucosaminyl)3-(alpha-D-mannosyl)2-





beta-D-mannosyl-diacetylchitobiose


976
n3m2mf
Golgi Apparatus
GlcNAc b1-2 (GlcNAc b1-4) Man a1-3(GlcNAc b1-





2 Man a1-6) Man b1-4 GlcNAc b1-4(Fuc a1-





6) GlcNAcOH


977
n4abutn
Cytosol
N4-Acetylaminobutanal


978
n4m2m
Golgi Apparatus
((N-acetyl-D-glucosaminyl)4-(alpha-D-mannosyl)2-





beta-D-mannosyl-diacetylchitobiose


979
n4m2mf
Golgi Apparatus
GlcNAc b1-2(GlcNAc b1-4) Man a1-3(GlcNAc b1-





2(GlcNAc b1-6) Man a1-6) Man b1-4 GlcNAc b1-





4(Fuc a1-6) GlcNAcOH


980
na1
Cytosol
Sodium


981
na1
Extra-organism
Sodium


982
na1
Golgi Apparatus
Sodium


983
nac
Cytosol
Nicotinate


984
nad
Cytosol
Nicotinamide adenine dinucleotide


985
nad
Endoplasmic Reticulum
Nicotinamide adenine dinucleotide


986
nad
Mitochondria
Nicotinamide adenine dinucleotide


987
nad
Nucleus
Nicotinamide adenine dinucleotide


988
nad
Peroxisome
Nicotinamide adenine dinucleotide


989
nadh
Cytosol
Nicotinamide adenine dinucleotide—reduced


990
nadh
Endoplasmic Reticulum
Nicotinamide adenine dinucleotide—reduced


991
nadh
Mitochondria
Nicotinamide adenine dinucleotide—reduced


992
nadh
Peroxisome
Nicotinamide adenine dinucleotide—reduced


993
nadp
Cytosol
Nicotinamide adenine dinucleotide phosphate


994
nadp
Endoplasmic Reticulum
Nicotinamide adenine dinucleotide phosphate


995
nadp
Mitochondria
Nicotinamide adenine dinucleotide phosphate


996
nadp
Peroxisome
Nicotinamide adenine dinucleotide phosphate


997
nadph
Cytosol
Nicotinamide adenine dinucleotide phosphate—





reduced


998
nadph
Endoplasmic Reticulum
Nicotinamide adenine dinucleotide phosphate—





reduced


999
nadph
Mitochondria
Nicotinamide adenine dinucleotide phosphate—





reduced


1000
nadph
Peroxisome
Nicotinamide adenine dinucleotide phosphate—





reduced


1001
naglc2p
Cytosol
N-Acetyl-D-glucosaminyldiphosphodolichol





(mammals)


1002
ncam
Cytosol
Nicotinamide


1003
nh4
Cytosol
Ammonium


1004
nh4
Extra-organism
Ammonium


1005
nh4
Mitochondria
Ammonium


1006
nicrns
Cytosol
Nicotinate D-ribonucleoside


1007
nicrnt
Cytosol
Nicotinate D-ribonucleotide


1008
nicrnt
Mitochondria
Nicotinate D-ribonucleotide


1009
nicrnt
Nucleus
Nicotinate D-ribonucleotide


1010
nm2m
Golgi Apparatus
(N-acetyl-D-glucosaminyl-(alpha-D-mannosyl)2-beta-





D-mannosyl-diacetylchitobiose


1011
nm4m
Golgi Apparatus
(alpha-D-mannosyl)4-beta-D-mannosyl-





diacetylchitobiose


1012
nmn
Cytosol
NMN


1013
nmn
Mitochondria
NMN


1014
nmn
Nucleus
NMN


1015
nmnphr
Cytosol
L-Normetanephrine


1016
nncoa
Mitochondria
nonanoyl-CoA (C9:0CoA)


1017
nrpphr
Cytosol
Norepinephrine


1018
nrvnc
Cytosol
nervonic acid


1019
nrvnc
Extra-organism
nervonic acid


1020
nrvnccoa
Cytosol
nervonyl coenzyme A


1021
nrvnccoa
Mitochondria
nervonyl coenzyme A


1022
nrvnccoa
Peroxisome
nervonyl coenzyme A


1023
nrvnccrn
Cytosol
Nervonyl carnitine


1024
nrvnccrn
Mitochondria
Nervonyl carnitine


1025
ntm2amep
Cytosol
N-Trimethyl-2-aminoethylphosphonate


1026
nwharg
Cytosol
N-(omega)-Hydroxyarginine


1027
o2
Cytosol
O2


1028
o2
Endoplasmic Reticulum
O2


1029
o2
Extra-organism
O2


1030
o2
Mitochondria
O2


1031
o2
Nucleus
O2


1032
o2
Peroxisome
O2


1033
o2−
Cytosol
Superoxide


1034
o2−
Mitochondria
Superoxide


1035
o2−
Nucleus
Superoxide


1036
o2−
Peroxisome
Superoxide


1037
oaa
Cytosol
Oxaloacetate


1038
oaa
Mitochondria
Oxaloacetate


1039
occoa
Cytosol
Octanoyl-CoA (C8:0CoA)


1040
occoa
Mitochondria
Octanoyl-CoA (C8:0CoA)


1041
occoa
Peroxisome
Octanoyl-CoA (C8:0CoA)


1042
ocdca
Cytosol
octadecanoate (n-C18:0)


1043
ocdca
Extra-organism
octadecanoate (n-C18:0)


1044
ocdcea
Cytosol
octadecenoate (n-C18:1)


1045
ocdcea
Extra-organism
octadecenoate (n-C18:1)


1046
ocdcea9
Cytosol
octadecenoate (C18:1, n-9)


1047
ocdctra3
Cytosol
octadecatrienoate (C18:3, n-3)


1048
ocdctra6
Cytosol
octadecatrienoate (C18:3, n-6)


1049
ocdcya
Cytosol
octadecdienoate (n-C18:2)


1050
ocdcya
Extra-organism
octadecdienoate (n-C18:2)


1051
ocddea6
Cytosol
octadecadienoate (C18:2, n-6)


1052
ocdycacoa
Cytosol
octadecadienoyl-CoA (n-C18:2CoA)


1053
ocdycacoa
Mitochondria
octadecadienoyl-CoA (n-C18:2CoA)


1054
ocdycacoa6
Cytosol
octadecadienoyl-CoA (C18:2CoA, n-6)


1055
ocdycacoa6
Mitochondria
octadecadienoyl-CoA (C18:2CoA, n-6)


1056
ocdycacrn
Cytosol
octadecadienoyl carnitine (C18:2Crn)


1057
ocdycacrn
Mitochondria
octadecadienoyl carnitine (C18:2Crn)


1058
ocsttea6
Cytosol
ocosatetraenoate (C22:4, n-6)


1059
ocsttea6
Extra-organism
ocosatetraenoate (C22:4, n-6)


1060
octa
Cytosol
octanoate


1061
od2coa
Cytosol
trans-Octadec-2-enoyl-CoA


1062
od2coa
Mitochondria
trans-Octadec-2-enoyl-CoA


1063
odcoa3
Cytosol
octadecatrienoyl-CoA (C18:3CoA, n-3)


1064
odcoa3
Mitochondria
octadecatrienoyl-CoA (C18:3CoA, n-3)


1065
odcoa6
Cytosol
octadecatrienoyl-CoA (C18:3CoA, n-6)


1066
odcoa6
Mitochondria
octadecatrienoyl-CoA (C18:3CoA, n-6)


1067
odecoa
Cytosol
Octadecenoyl-CoA (n-C18:1CoA)


1068
odecoa
Mitochondria
Octadecenoyl-CoA (n-C18:1CoA)


1069
odecoa
Peroxisome
Octadecenoyl-CoA (n-C18:1CoA)


1070
odecoa9
Cytosol
octadecenoyl-CoA (C18:1CoA, n-9)


1071
odecoa9
Mitochondria
octadecenoyl-CoA (C18:1CoA, n-9)


1072
odecrn
Cytosol
octadecenoyl carnitine


1073
odecrn
Mitochondria
octadecenoyl carnitine


1074
orn
Cytosol
Ornithine


1075
orn
Extra-organism
Ornithine


1076
orn-L
Cytosol
L-Ornithine


1077
orn-L
Extra-organism
L-Ornithine


1078
orn-L
Mitochondria
L-Ornithine


1079
orot
Cytosol
Orotate


1080
orot5p
Cytosol
Orotidine 5′-phosphate


1081
osttcoa6
Cytosol
ocosatetraenoyl-CoA (C22:4CoA, n-6)


1082
osttcoa6
Mitochondria
ocosatetraenoyl-CoA (C22:4CoA, n-6)


1083
oxa
Cytosol
Oxalate


1084
pa_CHO
Cytosol
Phosphatidate, CHO specific


1085
pa_CHO
Mitochondria
Phosphatidate, CHO specific


1086
pacald
Cytosol
Phenylacetaldehyde


1087
pan4p
Cytosol
Pantetheine 4′-phosphate


1088
pap
Cytosol
Adenosine 3′,5′-bisphosphate


1089
paps
Cytosol
3′-Phosphoadenylyl sulfate


1090
pc_CHO
Cytosol
phosphatidylcholine, CHO specific


1091
pdcoa
Cytosol
pentadecanoyl-CoA (C15:0CoA)


1092
pdcoa
Mitochondria
pentadecanoyl-CoA (C15:0CoA)


1093
pdx5p
Cytosol
Pyridoxine 5′-phosphate


1094
pe_CHO
Cytosol
phosphatidylethanolamine, CHO specific


1095
pep
Cytosol
Phosphoenolpyruvate


1096
pep
Mitochondria
Phosphoenolpyruvate


1097
pg_CHO
Mitochondria
phosphatidylglycerol, CHO specific


1098
pgp_CHO
Mitochondria
Phosphatidylglycerophosphate, CHO specific


1099
phe-L
Cytosol
L-Phenylalanine


1100
phe-L
Extra-organism
L-Phenylalanine


1101
phe-L
Mitochondria
L-Phenylalanine


1102
pheamn
Cytosol
Phenethylamine


1103
pheme
Cytosol
Protoheme


1104
pheme
Extra-organism
Protoheme


1105
pheme
Mitochondria
Protoheme


1106
phom
Cytosol
O-Phospho-L-homoserine


1107
phpyr
Cytosol
Phenylpyruvate


1108
phpyr
Mitochondria
Phenylpyruvate


1109
phyt
Cytosol
phytanic acid


1110
phytcoa
Cytosol
phytanyl coa


1111
phytcoa
Peroxisome
phytanyl coa


1112
pi
Cytosol
Phosphate


1113
pi
Endoplasmic Reticulum
Phosphate


1114
pi
Extra-organism
Phosphate


1115
pi
Golgi Apparatus
Phosphate


1116
pi
Mitochondria
Phosphate


1117
pi
Peroxisome
Phosphate


1118
pino_CHO
Cytosol
phosphatidyl-1D-myo-inositol, CHO specific


1119
pmtcoa
Cytosol
Palmitoyl-CoA (n-C16:0CoA)


1120
pmtcoa
Mitochondria
Palmitoyl-CoA (n-C16:0CoA)


1121
pmtcoa
Peroxisome
Palmitoyl-CoA (n-C16:0CoA)


1122
pmtcrn
Cytosol
L-Palmitoylcarnitine (C16:0Crn)


1123
pmtcrn
Mitochondria
L-Palmitoylcarnitine (C16:0Crn)


1124
pnto-R
Cytosol
(R)-Pantothenate


1125
pnto-R
Extra-organism
(R)-Pantothenate


1126
ppa
Cytosol
Propionate


1127
ppbng
Cytosol
Porphobilinogen


1128
ppcoa
Cytosol
Propanoyl-CoA (C3:0CoA)


1129
ppcoa
Mitochondria
Propanoyl-CoA (C3:0CoA)


1130
ppcoa
Peroxisome
Propanoyl-CoA (C3:0CoA)


1131
ppi
Cytosol
Diphosphate


1132
ppi
Endoplasmic Reticulum
Diphosphate


1133
ppi
Mitochondria
Diphosphate


1134
ppi
Nucleus
Diphosphate


1135
ppi
Peroxisome
Diphosphate


1136
ppp9
Cytosol
Protoporphyrin


1137
ppp9
Mitochondria
Protoporphyrin


1138
pppg9
Cytosol
Protoporphyrinogen IX


1139
pppg9
Mitochondria
Protoporphyrinogen IX


1140
pppi
Cytosol
Inorganic triphosphate


1141
pram
Cytosol
5-Phospho-beta-D-ribosylamine


1142
prgnlone
Cytosol
Pregnenolone


1143
prgstrn
Cytosol
Progesterone


1144
prist
Cytosol
pristanic acid


1145
pristcoa
Cytosol
pristanoyl coa


1146
pristcoa
Peroxisome
pristanoyl coa


1147
pro-L
Cytosol
L-Proline


1148
pro-L
Extra-organism
L-Proline


1149
pro-L
Mitochondria
L-Proline


1150
prpncoa
Mitochondria
Propenoyl-CoA


1151
prpp
Cytosol
5-Phospho-alpha-D-ribose 1-diphosphate


1152
ps_CHO
Cytosol
Phosphatidylserine, CHO specific


1153
pser-L
Cytosol
O-Phospho-L-serine


1154
ptcoa
Mitochondria
Pentanoyl-CoA (C5:0CoA)


1155
ptdca
Cytosol
pentadecanoate (C15:0)


1156
ptdcacoa
Mitochondria
pentadecanoyl Coenzyme A


1157
ptrc
Cytosol
Putrescine


1158
ptrc
Extra-organism
Putrescine


1159
ptrc
Mitochondria
Putrescine


1160
pyam5p
Cytosol
Pyridoxamine 5′-phosphate


1161
pydam
Cytosol
Pyridoxamine


1162
pydx
Cytosol
Pyridoxal


1163
pydx5p
Cytosol
Pyridoxal 5′-phosphate


1164
pydxn
Cytosol
Pyridoxine


1165
pyr
Cytosol
Pyruvate


1166
pyr
Extra-organism
Pyruvate


1167
pyr
Mitochondria
Pyruvate


1168
q10h2
Mitochondria
Ubiquinol-10


1169
r1p
Cytosol
alpha-D-Ribose 1-phosphate


1170
r5p
Cytosol
alpha-D-Ribose 5-phosphate


1171
retinal
Cytosol
Retinal


1172
ribflv
Cytosol
Riboflavin


1173
rnam
Cytosol
N-Ribosylnicotinamide


1174
Rtotalcoa
Cytosol
R total Coenzyme A


1175
Rtotalcoa
Mitochondria
R total Coenzyme A


1176
Rtotalcoa
Peroxisome
R total Coenzyme A


1177
ru5p-D
Cytosol
D-Ribulose 5-phosphate


1178
s2l2fn2m2masn
Lysosome
PA6


1179
s2l2n2m2m
Lysosome
de-Fuc form of PA6 (w/o peptide linkage)


1180
s2l2n2m2masn
Lysosome
de-Fuc form of PA6


1181
s2l2n2m2mn
Lysosome
de-Fuc, reducing GlcNAc removed form of PA6 (w/o





peptide linkage)


1182
s7p
Cytosol
Sedoheptulose 7-phosphate


1183
sarcs
Cytosol
Sarcosine


1184
sarcs
Mitochondria
Sarcosine


1185
sarcs
Peroxisome
Sarcosine


1186
seahcys
Cytosol
Se-Adenosylselenohomocysteine


1187
seasmet
Cytosol
Se-Adenosylselenomethionine


1188
sel
Cytosol
Selenate


1189
selcys
Cytosol
Selenocysteine


1190
selhcys
Cytosol
Selenohomocysteine


1191
selmeth
Cytosol
Selenomethionine


1192
seln
Cytosol
Selenide


1193
selnp
Cytosol
Selenophosphate


1194
ser-L
Cytosol
L-Serine


1195
ser-L
Extra-organism
L-Serine


1196
ser-L
Mitochondria
L-Serine


1197
sl-L
Mitochondria
L-sulfolactate


1198
so3
Cytosol
Sulfite


1199
so3
Extra-organism
Sulfite


1200
so4
Cytosol
Sulfate


1201
so4
Lysosome
Sulfate


1202
sopyr
Cytosol
3-Sulfopyruvate


1203
sopyr
Mitochondria
3-Sulfopyruvate


1204
sph1p
Endoplasmic Reticulum
Sphinganine 1-phosphate


1205
sphgmy_CHO
Cytosol
Sphingomyeline, CHO specific


1206
sphgn
Cytosol
Sphinganine


1207
sphs1p
Endoplasmic Reticulum
Sphingosine 1-phosphate


1208
spmd
Cytosol
Spermidine


1209
spmd
Extra-organism
Spermidine


1210
sprm
Cytosol
Spermine


1211
spyr
Cytosol
3-Sulfinylpyruvate


1212
spyr
Mitochondria
3-Sulfinylpyruvate


1213
sql
Endoplasmic Reticulum
Squalene


1214
srtn
Cytosol
Serotonin


1215
Ssq23epx
Endoplasmic Reticulum
(S)-Squalene-2,3-epoxide


1216
strcoa
Cytosol
Stearyl-CoA (n-C18:0CoA)


1217
strcoa
Mitochondria
Stearyl-CoA (n-C18:0CoA)


1218
strcoa
Peroxisome
Stearyl-CoA (n-C18:0CoA)


1219
strcrn
Cytosol
Stearoylcarnitine (C18:0Crn)


1220
strcrn
Mitochondria
Stearoylcarnitine (C18:0Crn)


1221
strdnccoa
Cytosol
stearidonyl coenzyme A (C18:4CoA)


1222
strdnccoa
Mitochondria
stearidonyl coenzyme A (C18:4CoA)


1223
strdnccoa
Peroxisome
stearidonyl coenzyme A (C18:4CoA)


1224
succ
Mitochondria
Succinate


1225
succoa
Mitochondria
Succinyl-CoA


1226
sucsal
Mitochondria
Succinic semialdehyde


1227
t2m26dcoa
Mitochondria
trans-2-Methyl-5-isopropylhexa-2,5-dienoyl-CoA


1228
t2m26dcoa
Peroxisome
trans-2-Methyl-5-isopropylhexa-2,5-dienoyl-CoA


1229
taur
Cytosol
Taurine


1230
tcggrpp
Cytosol
trans,trans,cis-Geranylgeranyl pyrophosphate


1231
tdcoa
Cytosol
Tetradecanoyl-CoA (n-C14:0CoA)


1232
tdcoa
Mitochondria
Tetradecanoyl-CoA (n-C14:0CoA)


1233
tdcoa
Peroxisome
Tetradecanoyl-CoA (n-C14:0CoA)


1234
tdcrn
Cytosol
tetradecanoylcarnitine (C14:0Crn)


1235
tdcrn
Mitochondria
tetradecanoylcarnitine (C14:0Crn)


1236
tdecoa7
Cytosol
tetradecenoyl-CoA (C14:1CoA, n-7)


1237
tdecoa7
Mitochondria
tetradecenoyl-CoA (C14:1CoA, n-7)


1238
tethex3coa
Peroxisome
tetracosahexaenoyl coenzyme A


1239
tetpent3coa
Peroxisome
tetracosapentaenoyl coenzyme A, n-3


1240
tetpent6coa
Peroxisome
tetracosapentaenoyl coenzyme A, n-6


1241
tettet6coa
Peroxisome
tetracosatetraenoyl coenzyme A


1242
thbpt
Cytosol
Tetrahydrobiopterin


1243
thcholstoic
Endoplasmic Reticulum
3alpha,7alpha,12alpha-Trihydroxy-5beta-





cholestanoate


1244
thcholstoic
Peroxisome
3alpha,7alpha,12alpha-Trihydroxy-5beta-





cholestanoate


1245
thf
Cytosol
5,6,7,8-Tetrahydrofolate


1246
thf
Mitochondria
5,6,7,8-Tetrahydrofolate


1247
thm
Cytosol
Thiamin


1248
thmpp
Cytosol
Thiamine diphosphate


1249
thr-L
Cytosol
L-Threonine


1250
thr-L
Extra-organism
L-Threonine


1251
thr-L
Mitochondria
L-Threonine


1252
thym
Cytosol
Thymine


1253
thymd
Cytosol
Thymidine


1254
thymd
Extra-organism
Thymidine


1255
trans-dd2coa
Mitochondria
trans-Dodec-2-enoyl-CoA


1256
trdcoa
Mitochondria
tridecanoyl-CoA (C13:0CoA)


1257
trdox
Cytosol
Oxidized thioredoxin


1258
trdox
Mitochondria
Oxidized thioredoxin


1259
trdrd
Cytosol
Reduced thioredoxin


1260
trdrd
Mitochondria
Reduced thioredoxin


1261
tre
Cytosol
Trehalose


1262
triglyc_CHO
Cytosol
Triglyceride, CHO specific


1263
trp-L
Cytosol
L-Tryptophan


1264
trp-L
Extra-organism
L-Tryptophan


1265
trypta
Cytosol
Tryptamine


1266
tsul
Cytosol
Thiosulfate


1267
ttc
Cytosol
tetracosanoate (n-C24:0)


1268
ttc
Extra-organism
tetracosanoate (n-C24:0)


1269
ttccoa
Peroxisome
tetracosanoyl-CoA (n-C24:0CoA)


1270
ttdca
Cytosol
tetradecanoate (C14:0)


1271
ttdca
Extra-organism
tetradecanoate (C14:0)


1272
ttdcea7
Cytosol
tetradecenoate (C14:1, n-7)


1273
Tyr-ggn
Cytosol
Tyr-194 of apo-glycogenin protein (primer for





glycogen synthesis)


1274
tyr-L
Cytosol
L-Tyrosine


1275
tyr-L
Extra-organism
L-Tyrosine


1276
tyr-L
Mitochondria
L-Tyrosine


1277
tyramine
Cytosol
Tyramine


1278
uacgam
Cytosol
UDP-N-acetyl-D-glucosamine


1279
uacgam
Golgi Apparatus
UDP-N-acetyl-D-glucosamine


1280
ubq10
Mitochondria
Ubiquinone-10


1281
udp
Cytosol
UDP


1282
udp
Golgi Apparatus
UDP


1283
udp
Nucleus
UDP


1284
udpacgal
Cytosol
UDP-N-acetyl-D-galactosamine


1285
udpg
Cytosol
UDPglucose


1286
udpgal
Cytosol
UDPgalactose


1287
udpgal
Golgi Apparatus
UDPgalactose


1288
udpglcur
Cytosol
UDP-D-glucuronate


1289
udpglcur
Golgi Apparatus
UDP-D-glucuronate


1290
udpxyl
Golgi Apparatus
UDP-D-xylose


1291
ump
Cytosol
UMP


1292
ump
Golgi Apparatus
UMP


1293
ump
Nucleus
UMP


1294
uppg3
Cytosol
Uroporphyrinogen III


1295
ura
Cytosol
Uracil


1296
urcan
Cytosol
Urocanate


1297
urea
Cytosol
Urea


1298
urea
Extra-organism
Urea


1299
urea
Mitochondria
Urea


1300
uri
Cytosol
Uridine


1301
utp
Cytosol
UTP


1302
utp
Nucleus
UTP


1303
vacccoa
Cytosol
vaccenyl coenzyme A (C18:1CoA)


1304
vacccoa
Mitochondria
vaccenyl coenzyme A (C18:1CoA)


1305
val-L
Cytosol
L-Valine


1306
val-L
Extra-organism
L-Valine


1307
val-L
Mitochondria
L-Valine


1308
xan
Cytosol
Xanthine


1309
xmp
Cytosol
Xanthosine 5′-phosphate


1310
xol7a
Endoplasmic Reticulum
7 alpha-Hydroxycholesterol


1311
xol7aone
Endoplasmic Reticulum
7alpha-Hydroxycholest-4-en-3-one


1312
xtp
Cytosol
XTP


1313
xtsn
Cytosol
Xanthosine


1314
xu5p-D
Cytosol
D-Xylulose 5-phosphate


1315
zym_int2
Endoplasmic Reticulum
zymosterone


1316
zymst
Endoplasmic Reticulum
Zymosterol


1317
zymstnl
Endoplasmic Reticulum
Zymostenol








Claims
  • 1. A computer readable medium or media having stored thereon computer-implemented instructions suitably programmed to cause a processor to perform the computer executable steps of: (a) providing a data structure relating a plurality of reactants to a plurality of reactions, wherein said plurality of reactants and said plurality of reactions are a selection of reactants and reactions as shown in Tables 1, 3 and 4 for a Chinese hamster ovary (CHO) cell, and wherein said data structure relates a plurality of reactants and a plurality of reactions selected from the reactants and reactions as shown in Tables 1 and 2 for a CHO cell transcriptome, orproviding a data structure relating a plurality of reactants to a plurality of reactions, wherein said plurality of reactants and said plurality of reactions are a selection of reactants and reactions as shown in Tables 5, 8 and 9 for a Chinese hamster ovary (CHO) cell, and wherein said data structure relates a plurality of reactants and a plurality of reactions selected from the reactants and reactions as shown in Tables 5, 6 and 7 for a CHO cell transcriptome;(b) providing a constraint set for said plurality of reactions for said data structure;(c) determining at least one flux distribution that minimizes or maximizes an objective function when said constraint set is applied to said data structure, wherein said at least one flux distribution is predictive of a physiological function of said CHO cell or a culture condition for said CHO cell; and(d) providing output to a user of said at least one flux distribution determined in step (c).
  • 2. The computer readable medium or media of claim 1, wherein said objective function is uptake rate of two or more nutrients, wherein said two or more nutrients are carbon sources; wherein said objective function comprises product formation, energy synthesis, biomass production, or a combination thereof; orwherein said objective function comprises decreasing byproduct formation.
  • 3-4. (canceled)
  • 5. The computer readable medium or media of claim 1, wherein said culture condition is selected from the group consisting of optimized culture medium for said cell, optimized cell culture process, optimized cell productivity, and metabolic engineering of said cell.
  • 6. The computer readable medium or media of claim 5, wherein optimized cell productivity is selected from the group consisting of increased biomass production and increased product yield.
  • 7. The computer readable medium or media of claim 1, wherein said culture condition is selected from the group consisting of reduced scale up variability, reduced batch to batch variability, reduced clonal variability, improved cell growth, viable cell density and cell productivity in exponential growth phase or stationary phase.
  • 8-10. (canceled)
  • 11. The computer readable medium or media of claim 1, wherein said physiological function is selected from the group consisting of growth, energy production, redox equivalent production, biomass production, production of biomass precursors, production of a protein, production of an amino acid, production of a purine, production of a pyrimidine, production of a lipid, production of a fatty acid, production of a cofactor, transport of a metabolite, and consumption of carbon, nitrogen, sulfur, phosphate, hydrogen or oxygen.
  • 12. The computer readable medium or media of claim 1, wherein said plurality of reactions comprises at least one reaction from peripheral metabolic pathway.
  • 13. The computer readable medium or media of claim 12, wherein said peripheral metabolic pathway is selected from the group consisting of amino acid biosynthesis, amino acid degradation, purine biosynthesis, pyrimidine biosynthesis, lipid biosynthesis, fatty acid metabolism, cofactor biosynthesis and transport processes.
  • 14-18. (canceled)
  • 19. The computer readable medium or media of claim 1, wherein at least one reactant in said plurality of reactants or at least one reaction in said plurality of reactions is annotated with an assignment to a subsystem or compartment.
  • 20. The computer readable medium or media of claim 19, wherein at least a first substrate or product in said plurality of reactions is assigned to a first compartment and at least a second substrate or product in said plurality of reactions is assigned to a second compartment.
  • 21. A method for predicting a culture condition for a CHO cell, comprising: (a) providing a data structure relating a plurality of reactants to a plurality of reactions from a CHO cell, wherein said plurality of reactants and said plurality of reactions are a selection of reactants and reactions as shown in Table 1, 3 and 4 for a Chinese hamster ovary (CHO) cell, and wherein said data structure relates a plurality of reactants and a plurality of reactions selected from the reactants and reactions as shown in Tables 1 and 2 for a CHO cell transcriptome, each of said reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating said substrate and said product, wherein said plurality of reactions comprises one or more extracellular exchange reactions, orproviding a data structure relating a plurality of reactants to a plurality of reactions from a CHO cell, wherein said plurality of reactants and said plurality of reactions are a selection of reactants and reactions as shown in Tables 5, 8 and 9 for a Chinese hamster ovary (CHO) cell, and wherein said data structure relates a plurality of reactants and a plurality of reactions selected from the reactants and reactions as shown in Tables 5, 6 and 7 for a CHO cell transcriptome, each of said reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating said substrate and said product, wherein said plurality of reactions comprises one or more extracellular exchange reactions;(b) providing a constraint set for said plurality of reactions for said data structure;(c) providing an objective function, wherein said objective function is uptake rate of two or more nutrients, wherein said two or more nutrients are carbon sources;(d) determining at least one flux distribution that minimizes or maximizes the objective function when said constraint set is applied to said data structure, wherein said at least one flux distribution is predictive of a culture condition for said eukaryotic cell; and(e) providing output to a user of said at least one flux distribution determined in step (d).
  • 22. The method of claim 21, wherein said objective function further comprises product formation, energy synthesis, biomass production, decreasing byproduct formation or a combination thereof.
  • 23. (canceled)
  • 24. The method of claim 21, wherein said culture condition is selected from optimized culture medium for said cell, optimized cell culture process, optimized cell productivity, and metabolic engineering of said cell.
  • 25. The method of claim 24, wherein optimized cell productivity is selected from the group consisting of increased biomass production and increased product yield.
  • 26. The method of claim 21, wherein said culture condition is selected from the group consisting of reduced scale up variability, reduced batch to batch variability, reduced clonal variability, improved cell growth, viable cell density and cell productivity in exponential growth phase or stationary phase.
  • 27-33. (canceled)
  • 34. The method of claim 21, wherein at least one reactant in said plurality of reactants or at least one reaction in said plurality of reactions is annotated with an assignment to a subsystem or compartment.
  • 35. The method of claim 34, wherein at least a first substrate or product in said plurality of reactions is assigned to a first compartment and at least a second substrate or product in said plurality of reactions is assigned to a second compartment.
  • 36. A method for optimizing a Chinese hamster ovary (CHO) cell to produce a product comprising: (a) providing a data structure relating a plurality of reactants to a plurality of reactions, wherein said plurality of reactants and said plurality of reactions are a selection of reactants and reactions as shown in Tables 1, 3, and 4 for a CHO cell, and wherein said data structure relates a plurality of reactants and a plurality of reactions selected from the reactants and reactions as shown in Tables 1 and 2 for a CHO cell transcriptome, orproviding a data structure relating a plurality of reactants to a plurality of reactions, wherein said plurality of reactants and said plurality of reactions are a selection of reactants and reactions as shown in Tables 5, 8 and 9 for a Chinese hamster ovary (CHO) cell, and wherein said data structure relates a plurality of reactants and a plurality of reactions selected from the reactants and reactions as shown in Tables 5, 6 and 7 for a CHO cell transcriptome;(b) providing a constraint set for said plurality of reactions for said data structure;(c) determining at least one flux distribution that minimizes or maximizes an objective function when said constraint set is applied to said data structure, wherein said at least one flux distribution is predictive of producing a product in said CHO cell; and(d) modifying said CHO cell as determined in step (c).
  • 37. (canceled)
  • 38. The method of claim 36, wherein said objective function comprises product formation, energy synthesis, biomass production, decreasing byproduct formation, production of said product or a combination thereof.
  • 39. (canceled)
  • 40. The method of claim 36, wherein said culture condition is selected from the group consisting of optimized culture medium for said cell, optimized cell culture process, optimized cell productivity, and metabolic engineering of said cell.
  • 41-84. (canceled)
Parent Case Info

This application claims the benefit of priority of U.S. Provisional application Ser. No. 61/402,273, filed Aug. 25, 2010, and U.S. Provisional application Ser. No. 61/379,366, filed Sep. 1, 2010, the entire contents of each application are incorporated herein by reference.

Provisional Applications (2)
Number Date Country
61402273 Aug 2010 US
61379366 Sep 2010 US